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UNIDO United Nations Industrial Development Organization 
WHO World Health Organization 
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INTRODUCTION 
During the past decade the economic situation in many of the sub-Saharan African 
countries has been deteriorating. Most of their governments have not been able to 
meet the basic health needs of the growing population. There is unequal distribution 
of the limited health resources between the urban and the rural areas and, within urban 
agglomerations, between the priviliged and the poor. The funds available for the pur­
chase of drugs and medical materials are both inadequate and badly spent. Asa result 
most essential drugs are unavailable to the majority of the rural population. 
If the basic needs of the African sub-Saharan countries are ever to be met a meticu­
lous use of limited resources is essential. In Africa, about half of the health budget is 
spent on drugs, compared to less than 7 % in Europe ' and, in Africa, up to three quar-
tersof thedrugbudgetis spent on drugswhich are expensive, useless or even harmful24. 
An important step in the rationalization of expenditure on drugs is the formulation 
of a list of essential drugs. Many of these lists have been published but very little has 
been written on the quantities in which the essential drugs are necessary. Yet this in­
formation is important when essential drugs programmes are to be started. 
In 1980 the supply of drugs in Ghana had stagnated to such an extent that foreign 
aid was offered. The church-related health institutions, associated in the Christian 
Health Association of Ghana (CHAG), constituted a Drug Committee that in the fol­
lowing years advised on the selection, the quantities necessary and the distribution of 
essential drugs, and also supervised the carrying out of several drug relief programmes 
to all 66 CHAG hospitals and clinics by means of the distribution of prepacked stand­
ard packages of essential drugs. 
During the implementation of these drug relief programmes the need was felt to 
evaluate the methods and the results of the selection of essential drugs, the quantific­
ation of drug needs and the system of distribution. This book describes the studies, re­
ports on the advice of the CHAG Drug Committee and gives an evaluation of its acti­
vities. 
In Chapter I a review of the literature on essential drugs is given. 
Chapter II describes the country and population of Ghana and its health facilities. 
Chapter III describes the studies and activities of the CHAG Drug Committee and 
the resultant advice. 
In Chapter IV the methodology and results of a drug utilization study involving sev­
enteen CHAG institutions over the years 1981-82 are presented and discussed. 
In Chapter V the activities of the Drug Committee are evaluated. The method of 
drug selection is evaluated by comparing the CHAG list of essential drugs with a quan­
tified consensus of 38 lists of essential drugs made in or for African countries. Each de­
cision made to select the drugs for the CHAG list is analyzed. 
The quantified drug needs as expressed in the CHAG estimates are compared with 
results of the few available studies, and with the results of the drug utilization study 
presented in Chapter Г . The present CHAG methodology of quantifying drug needs 
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is compared with two other methods known from literature. 
The system of distribution using standard packages is evaluated by comparing for 
several individual health institutions the actual volume of drugs allocated with the ac­
tual consumption data derived from the drug utilization study. Further the use of sta­
tistical parameters in quantifying the drug needs of health institutions is discussed. 
In Chapter VI is discussed the extent to which the conclusions of this present study 
could be used by health planners in other sub-Saharan countries. 
I have been a member of the Drug Committee from its inception in 1980 and have 
been involved in all studies and activities. Chapters II, III and Г have been written 
from this point of view. After returning from Ghana in September 19831 have tried to 
take distance and to evaluate the work done there by carrying out a study of the litera­
ture on essential drugs and the analysis, partly by computer, of all available data. This 
critical evaluation is contained in Chapter V. 
In view of my involvement in the activities of the CHAG Drug Committee and the 
fact that I am the author of this study, it should be realized that my personal role is du­
alistic as I am both actor and critic. 
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Chapter One 
LITERATURE ON ESSENTIAL DRUGS 
1.1 Introduction 
In this chapter a review of the literature on essential drugs is given. The following 
subjects are discussed: the general concept of essential drugs (1.2), the selection of es-
sential drugs (1.3), the quantification of drug needs (1.4), policies on the supply of es-
sential drugs (1.5) and the distribution of essential drugs (1.6). 
1.2 Essential Drugs 
1.2.1 Definition of essential drugs 
The World Health Organization (WHO) defines "drugs", "medicines", "pharma-
ceutical products" and "medicinal products" as "the substances and/or the products 
used in man for prophylactic, diagnostic and therapeutic purposes, including sub-
stances of synthetic or natural origin, biologicals such as vaccines and sera and in some 
cases, blood and its derivatives"5. Although not specifically stated we can assume that 
dressings, X-ray material and various plastic disposables as syringes, gloves and cathe-
ters are not included. 
In the 1983 WHO list of essential drugs a definition of essential drugs is given6: "Es-
sential drugs are those that satisfy the health care needs of the majority of the popula-
tion". Parallel to the definition of drugs per se, this will include vaccines, sera and 
products for diagnostic procedures. 
Not all authors and certainly not all essential drugs programmes use this definition. 
Most publications describing programmes supplying a number of health institutions 
with a set of essential drugs are faced with the problem that some basic items that are 
not "essential drugs" according to the definition are in fact nearly as essential. In actual 
programmes these items are then usually supplied together with the essential drugs 
and for practical purposes they are sometimes added to the list. Examples are dressing 
material7 and soap, envelopes and exercise books8. On many larger lists pharmaceuti-
cal raw materials (used to formulate e.g. mixtures or ointments), laboratory materials 
and diagnostic chemicals for X-ray examinations are included. Although these sub-
stances are considered as drugs in the WHO definition and although for larger health 
institutions they can be considered essential, the fact that they are sometimes included 
and sometimes not makes comparison between lists difficult. Within the scope of this 
study therefore these items will not be considered. 
The same applies to vaccines. According to the two WHO definitions vaccines can 
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certainly be called essential drugs. Many authors have even stressed that they might be 
more essential than most drugs9·10. Yet vaccines are not included in most of the short 
lists of essential drugs. The main reason is probably a practical one: vaccines require a 
cold chain and the supply therefore will nearly always be separate from that of essen-
tial drugs. Within the WHO there is a separate programme for vaccination, the Ex-
tended Programme on Immunization. In this study vaccines will not be considered. 
We will limit ourselves to essential drugs, excluding products for diagnostic proce-
dures, pharmaceutical raw materials and vaccines except when otherwise stated. 
1.2.2 History of the essential drugs concept 
The concept of essential drugs has emerged simultaneously from many countries. 
In 1963 Cuba was probably the first country to publish a National Formulary by gen-
eric names ' '. Maurice Kings revolutionary book "Medical Care in Developing Coun-
tries" (1966) published the first check-list of basic drugs12. Tanzania followed in 1970 
with the first national list divided for different levels of health care13. In 1972 Peru 
published a comprehensive list "Medicamentos Básicos"14 based on a clear national 
policy accompanied by adapted legislation. 
The early nineteenseventies brought the insight that economic growth could not be 
unlimited '* and that it would not automatically supply the needs of all the people on 
earth. New concepts in meeting global needs on a scheduled basis were developed16. 
In line with this trend of economizing on resources and meeting basic needs on a global 
scale, the first WHO list of essential drugs was published in 1977, listing 212 active in-
gredients17. It was reviewed in 197918 and 19836. At first, reactions were mixed. An 
editorial in The Lancet in 1978 reacted positively to the concept and even considered 
applying a similar approach to developed countries, yet called the selection "desert is-
land drugs"19. In general however, many positive critiques were published20,21 and ex-
tra suggestions were made22. The pharmaceutical industry criticised the idea20·21, 
claiming that drugs not on the list would be considered inessential and that a list res-
tricting a free choice of drugs would lead to a deterioration in health care19. Lasagna 
made various comments on what he called "ex cathedra judgements"23 and concluded 
that "clearly suboptimal care for patients would result from restriction to these WHO 
drugs"24. Together with others he called for differentiating the list according to level of 
existing health care and available resources23. In Ghana the 1979 version of the list 
was received with the comment: "As a starting point it is good, as an end a disaster"25. 
In later years acceptance of the WHO concept of essential drugs became more or 
less universal and now "underlies any approach to a rational and cost-effective 
pharmaceutical policy"26. It has become obvious that the first WHO list made an enor-
mous impact. 
In 1978 the Executive Board of the WHO approved the Action Programme on Es-
sential Drugs27·28 which was ratified by the World Health Assembly in 1978 and 
197929,30 ¡ n thjs Drug Action Programme (DAP) the WHO played an even more ac-
tive role. The objective was formulated as "to ensure the regular supply to all people of 
safe and effective drugs of acceptable quality at lowest possible cost, in order to reach 
the overall objective of health for all by the year 2000 through health systems based on 
primary health care"31. In 1978 the African Regional Expert Committee on Drugs 
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underlined the concept of essential drugs32, advised countries to work on a rational 
drug policy33 and in 1981 published a regional list of essential drugs34. However, in 
1982 WHO Director-General Mahler warned the committee that "action at the inter-
national level can be useful for generating important concepts; action at the national 
level is all important for putting them into effect"35. By that time some African coun-
tries had already gone a long way to ensure a regular supply of essential drugs at af-
fordable cost, e.g. Mozambique26,36"40 and Lesotho41"43, or were struggling to do so as 
in the case of Kenya7·44"46 and Tanzania8,47"49. In other countries Voluntary Agencies 
were trying to organise a coordinated supply for their health institutions, e.g. in Ruan-
da43·50"52, Southern Sudan5356 and Ghana57"62. Outside Africa, Cuba ' ', Peru14, Bang-
ladesh43·6367 and Sri Lanka68·69 have set examples in rational drug supply and adapted 
legislation. 
1.2.3 Criteria for essential drugs 
The criteria to determine which drugs are essential were formulated by the WHO at 
the presentation of the first list in 197717 and were later slightly adapted6. 
a) essential drugs should offer the widest possible coverage of the population; the se-
lection is dependant on pattern of diseases, experience and training of health per-
sonnel, financial resources and genetic, demographic and environmental factors; 
b) only drugs for which sound scientific data on efficacy and safety are available 
should be selected; 
c) adequate standards of quality, bioavailability and stability under expected local 
conditions should be assured; 
d) whenever available, the international non-proprietary (generic) name should be 
used; 
e) when two or more drugs seem similar, the choice should be made on a basis of care-
ful evaluation of their relative efficacy, safety, quality, price and availability; in 
some cases pharmacokinetic properties or the possibility of local manufacture may 
influence the choice; 
f) fixed combinations are only acceptable when the combination provides a proven 
advantage over the single compounds in therapeutic effect, safety or compliance. 
1.2.4 Advantages and disadvantages of the concept of essential 
drugs 
Many authors have mentioned the advantages of an essential drugs list. They can be 
summarised as follows:40·70 
a) reducing the number of drugs to be purchased, stored, analyzed and distributed, 
resulting in easier and more effective management and facilitating quality control; 
b) stimulating national production of essential drugs; 
c) facilitating bulk purchasing with consequent reduction of costs; 
d) making cost-effective use of limited resources; 
e) facilitating medical and therapeutical training of health care workers at all levels; 
f) facilitating objective drug information; 
g) facilitating the monitoring of drug use. 
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Further it can be stated that without essential drugs, Primary Health Care is impos-
sible7 '7 2 . Korn73 advocates the use of a list of essential drugs on a more microenviron-
mental basis: the supposed improved availability will increase the faith of patients in 
the health station and will also increase the status and job-satisfaction of the health-
worker; moreover, a more precise diagnosis will be necessary as compared with the 
situation where drugs are not available anyway. Moore44 adds to this that when people 
have gained the confidence to come more regularly they will also have more access to 
family-planning and preventive activities; that the unnecessary self-referral to higher 
levels of health care will diminish and that, as a consequence, health care will become 
cheaper. In Kenya this seems to be the case74. Bygberg75 mentions that costs will be re-
duced as no more expensive drugs will be given out unnecessarily when cheaper alt-
ernatives are available. 
The disadvantages as brought up by the pharmaceutical industry and some authors 
when the first WHO list was published can be summarised as follows: 
a) to restrict the choice of drugs limits the doctor in prescribing the best drug for each 
patient; 
b) drugs not on the list will be considered inessential; 
c) some drugs are widely used although their efficacy has not been scientifically 
proved; it would be unjust to ban them as many patients and doctors prefer to use 
them; 
d) the quality of generic products is less guaranteed than that of brandnamed drugs; 
e) when buying generic products, no funds will be generated for research and the 
development of new drugs24. 
Few of these arguments have stood the test of time. By 1984 the concept of essential 
drugs had been taken over by more than 80 countries74. The deteriorating economic 
situation in most of the poorer countries has made a costeffective use of their limited 
resources more and more of a necessity. 
1.2.5 Ethical aspects of medical choices 
Whenever resources are insufficient to meet the needs of all, making a choice is in-
evitable. This necessity to choose underlies the concept of essential drugs. 
Doctors, however, are not very well equiped for such an economical choice. This 
aspect is hardly ever incorporated in the curriculum of their medical studies; more-
over, the Hippocratic oath76·77 is based on the concept of the doctor doing his utmost 
for each individual patient and therefore does not include the possibility of making a 
choice. The oath fails to guide him in respect to the wider context of his responsibility 
to the health needs of a whole community78·79. This means, in fact, that any amount of 
money or effort spent on individual patients can be defended by citing the oath or the 
concept behind it. This confuses the issue of injustices in the allocation of health care 
resources and is often misused to justify expensive urban health care in countries that 
cannot afford it. 
McDermott80 has written a fine chapter on what Waddington81 called "statistical 
morality". This is the idea that some action we may take, influencing the frequency of a 
phenomenon, can be morally good even without our knowing just who may be affect-
ed, which makes it possible to shift the criterium of the "moral good" from the known 
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individual, as in the thought behind the Hippocratic oath, to a less identifiable groupof 
individuals. He cites the example that when efforts to improve the statistical indices of 
child nutrition or infant mortality are taken as morally good, for the population as a 
whole the individual relationships cease to be the essence of the matter and that this 
"moral good" can then hardly be expressed except in statistical parameters80. This ex-
ample shows that the "moral good" is not restricted to individuals or to decisions mor-
ally good for individuals, and brings to light the possibility that an ethical choice which 
has to be made between an individual and the (statistical) masses does not necessar-
ily have to be in favor of the individual. 
This choice is a basic problem in most African countries in which 80-90% of the al-
ready limited health budget is spent on curative care for a minority of the people living 
in urban areas. Among others, Yudkin is a passionate advocate of reallocation of these 
health resources by means of their transfer from the overspending urban elite to de-
prived rural areas82"84 and by reducing expenses on luxurious drugs37,48. As WHO Di-
rector-General Mahler put it: "Wisdom demands that health measures be applied 
where they are most needed, most effective and least costly"85. Speaking about expen-
sive Western medical technologies he said: "These technologies are appropriate only 
if they are effective and can be applied for the benefit of the whole of a society in a 
manner it can accept and at a cost it can afford"85. 
When resources are limited, and in Africa they are, priorities have to be set. This 
means, in fact, that resources for meeting basic health needs will, at least partly, have 
to be generating by cutting down on expensive health actions. As these actions might 
in principle be defended by the Hippocratic oath this oath is then seen to be in conflict 
with the "statistical good" as mentioned above. 
Apart from this, Christian-ethical implications should be included as the Bible also 
has stressed the depth and responsibilities of interpersonal relations. The church-re-
lated health institutions in Africa, usually ahead of other organisations in implement-
ing a policy of fair allocation of limited health resources, face a similar ethical dilemma 
when one doctor's salary could pay for ten health workers, or when an elective opera-
tion takes as much time as a health talk to twenty women about their sixty children. In 
their Primary Health Care programmes these institutions try to provide basic, accept-
able health care which is effective in respect to 90-95 % of the diseases of poverty and 
within the existing limits of resources this is often the best they can do. Yet this statisti-
cal choice leaves a certain number of fellow-men unserved, fellow-men that the Bible 
tells one not to disregard. In a note from the Board of Missions of the Netherlands Re-
formed Church, this problem is very well formulated as "whom do we choose to igno-
re?"86 
The answer could be to change the compassion of coping with the problem of one 
patient at a time into a different one, an indirect, statistical compassion to those "we 
never get to see"80. The WHO has clearly made this choice. In a paper from 1977 
Mahler stated: "Social justice demands that all citizens of the world should reach an 
acceptable level of health that permits them to lead socially and economically produc-
tive lives, before sophisticated measures for individual health care are provided be-
yond what can be afforded for the population as a whole"87. 
The WHO list of essential drugs was meant as a first step in setting priorities for 
health care. It can certainly be used as an instrument to ban the most obvious examples 
of expensive, useless or even harmful drugs and if used as such, the advocates or users 
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of such drugs have something to fear. However, the main goal is to offer a tool to those 
who, with limited resources, face ethical choices for the benefit of the majority of the 
people. 
1.3 The selection of essential drugs 
1.3.1 Introduction 
In this section a number of essential drugs lists is reviewed. After having selected the 
lists within given parameters, the question is considered as to whether it is possible to 
reach a certain consensus as to which drugs are considered essential. The occurence of 
drugs on 38 lists is quantified. 
1.3.2 Selection of essential drugs lists 
There are far too many essential drugs lists to be able to enumerate them all and by 
no means all of them have been published. It is therefore impossible to present a com­
prehensive study of all these lists up to the end of 1983 and an attempt only can be 
made. Apart from general lists intended for no specific area, attention is focused on 
lists made in or for sub-Saharan countries. Lists of individual health institutions are 
not taken into account and only one list from the district level is included"8. In the case 
where later or reviewed editions of a list are available the latest available version has 
been taken. However, when an extensive time lapse between editions has occurred, or 
when the lists grossly differentiate they have been included separately. In such cases 
the intellectual effort behind each of the lists is considered to be different, meriting 
separate inclusion)*. 
1.3.3 Description of selected essential drugs lists 
1) Source 
In this study 30 different essential drugs lists are reviewed. Of these, 17 are intended 
for twelve individual countries in Africa: Tanzania8·1370, Lesotho42·89, Ruanda90·91, 
Ghana88·92, Cap Verde93, Zaire94, Sierra Leone95, Chad96, Sudan54, Uganda97, Ken­
ya7 and Cameroon98. Six of these have been produced by Voluntary Agencies, eleven 
by local governments. Of thirteen lists not limited to one particular country, seven 
have originated from international organisations WHO6·17·99, Red Cross100, FAO101, 
РАНО
102
 and UNIDO103, three have come from Voluntary Agencies102·104·105 and 
three are scientific publications12·106·107. 
)* For this reason the first list of the WHO from 197717 as well as the 1983 revision6 are in­
cluded and the 1979 review18 is not. For Tanzania the list of 1970 '3, the official Government 
list of 198170 and the basic list for the drug supply plan of 198 38 are considered separately. 
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2) Dating 
The lists can be divided into three groups: seven early lists from before 1978, the 
WHO list of 1977 with later editions, and 21 later lists, published after 1980. 
3) Description 
Of the seven early lists, the list of King '2 and the 1970 Tanzania lists13 are by far the 
most useful. Other ones include proprietary names98100, many obsolete prepar-
ations94 or both106. One is too short to be effective93. As to the lists published after the 
WHO list of 197717 it is not easy to compare the quality. Criteria used are: whether the 
WHO list has been of influence; whether the order of presentation is the same as that 
of the WHO list; whether solely generic names have been used; whether drugs of very 
limited use are included or drugs of very common use have been left out; and whether 
many obsolete drugs are on the list. When compared according to these criteria, eight 
lists are of outstanding quality. Three of these have been published using the WHO 
system of classification: the official list of Tanzania70, the list of Simmonds and Walker 
published in The Lancet in 1982107 and the proposed list for a large drug project in Su-
dan54 . Five other lists that did not use the WHO classification are: a 1981 list from the 
Church Hospital Association of Sierra Leone95, one from the Christian Medical Com-
mission of the World Council of Churches102, one from a 1983 drugs logistics 
educational paper from the WHO99 and the lists for the drug relief plans for Kenya7 
and Tanzania8. 
Four other lists carry no visible relation to the WHO list. They are the proposed list 
for a project in Chad96, the list for the Ashanti Akim district in Ghana88 and the lists of 
the Lesotho Dispensary Association89 and of BUFMAR in Ruanda90. The remaining 
lists are of limited value: six of them because of inconsistent choices or omissions and 
three that are long, comprehensive lists of the Health Ministries of Lesotho42, Ghana92 
and Ruanda91 which are intended to exclude drugs rather than to indicate priorities. 
The WHO lists617 are a group in themselves. Their impact has been enormous and, 
as mentioned before, they now form the basis of many essential drugs programmes. 
Their value lies in the world-wide discussion and change in thought they have brought 
about. 
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Figure 1. Frequency distribution of number of items on 38 essential drugs lists. Number of 
items is given as number of chemical preparations and not as number of drugs, 
which would be higher. 
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4) Number of items on the lists 
Of 30 lists, five are differentiated for use at different levels of health 
c a r e 13,54,70.105,106 w^gn ga^j of these differentiations are considered as separate lists, 
the total number of lists rises to 38)*. The frequency distribution according to number 
of items on each list is visualized in Figure 1. It can be seen that the majority of essential 
drugs lists contains less than 75 items. 
Three different groups will be analyzed separately: short lists (0-50 items), medium 
lists (51-100 items) and long lists (over 100 items). In Table 1 these groups are differ-
entiated for early, WHO, and later lists. The short lists are usually meant for dispensa-
ries and health centres, the longer lists for hospital care. 
Table 1. 38 lists of essential drugs differentiated for early, WHO and later lists with indica-
tion of the number of items. 
Number of items" 
Early lists (- 1978) 
WHO lists** (1977, 1983) 
Later lists (1981 -) 
Total 
0-50 
5 
17 
22 
51-100 
3 
6 
9 
101-
2 
2 
3 
7 
Total 
10 
2 
26 
38 
* In accordance with general practice the number of items is given as the number of chemical 
preparations and not as number of dosage forms, which would be higher 
** The 1979 WHO list is not reviewed separately 
1.3.4 Quantitative analysis of consensus on the selection of essential 
drugs for Africa 
1) Methods 
Drugs from all 38 lists were tabulated and for each drug the total number of lists on 
which it appeared was marked. Excluding pharmaceutical preparations and diagnos-
tic agents, 368 different drugs were included in the lists. A selection of the results is 
presented in Appendix 1 in which 107 drugs that were included seven times or more 
(7/38 = 18%) are listed. Data are presented according to the groups as used in Table 
1. 
Frequency of appearance on the lists in the different groups was quantified by 
counting the number of lists in which the drug was included. The result was expressed 
as a percentage of the maximum possible. The maximum score for a drug was there-
fore 38/38 ( 100%). For certain drugs closely related alternatives were in use. In these 
cases the total score for the therapeutic category was counted, e.g. ferrous sulphate 
and ferrous fumarate were taken together as "iron tablets". 
)* A leveled list with 20 basic drugs and 40 supplementary drugs is scheduled as one list of 20 
and another of 60 drugs. 
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2) Results 
The 29 drugs that were included in 50% or more of all lists are presented in Table 2. 
This first selection of "most essential drugs" includes all 26 highest scoring drugs with-
in the group of the 22 short lists, being drugs that were included in this group of lists 
eight times or more (36%). From the group of 9 medium lists it includes the upper 16 
drugs, being all drugs mentioned seven times or more (78%). 
Table 2. 29 "most essential drugs", included in 20 or more of 38 different lists of essential 
drugs. Frequency expressed as percentage. 
Drug 
aspirin tab. 
chloroquine tab. 
iron tab. 
sulfa tab. 
tetracycline cap. 
antibiotic eye oint. 
broad anthelmintic 
oral rehydration salt 
antacid 
antiasthmatic 
benzyl benzoate 
piperazine 
procain pencillin inj. 
ergomctrine 
phénobarbital 
disinfectans 
chloroquine inj. 
vitamin (multi/BCo) 
phenox.meth.penicill.t. 
folic acid tab. 
lidocain 1-2% inj. 
metronidazole tab. 
benzath.benz.penic.inj. 
chloroquine syrup 
laxans 
paracetamol tab. 
chloramphenicol cap. 
epinephrine inj. 
gentian violet paint 
Frequency 
in 38 lists 
(%) 
100 
95 
89 
84 
79 
76 
74 
74 
71 
68 
66 
66 
66 
63 
63 
61 
61 
61 
58 
58 
53 
53 
53 
53 
53 
50 
50 
50 
50 
Remarks 
sulphate: 84% ftimarate: 13% 
dimidine: 71% other: 16% 
tetracycline: 45% other AB: 39% 
meb.: 37% tiab.: 34% beph.: 24% 
leva.: 21% 
especially after 1977 
alum.hy.: 45% magn.tr/hy.: 47% 
am.ph.: 45% salb.: 21% 
ephedr.: 42% 
tabs/syrup 
inj.: 53% tab.: 37% 
chlorhex.: 39% iodine: 50% 
multiv.: 47% BCo.: 39% 
especially after 1977 
senna: 34% other: 26% 
only after 1977 
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No more information can be gained from the dugs mentioned in less than 36% of 
the short lists. However, only drugs mentioned seven times or more (78%) in the 
group of 9 medium lists have been included in the list of most essential drugs. For that 
reason all drugs that appeared on at least five of the medium lists (over 50%) have 
been taken to indicate a second level priority, insofar as the drugs had not yet been in-
cluded in the first list of most essential drugs. These 15 drugs are presented in Table 3. 
Table 3: 21 essential drags not mentioned inTable 2 which appear in 5 or more of 9 medium 
size (51-100 item) lists of essential drugs. Frequency expressed as percentage. 
Drug 
promethazine tab/syr. 
niclosamide 
antitussivum 
diuretic tab. 
aminophylline inj. 
papaverine/atropine tab. 
antischistosomiasis tab. 
water for inj. 
retinol cap. 
benzoic ac.comp.oint. 
chlorpromazine tab. 
diazepam inj. 
atropine inj. 
morfia/pethidine inj. 
quinine inj. 
Frequency 
in 38 lists 
(%) 
47 
45 
45 
42 
39 
29 
45 
45 
47 
42 
45 
37 
39 
37 
29 
Remarks 
codeine: 26% other: 24% 
furosemide: 26% hydr.chl.th: 26% 
niridazole: 34% metrif: 16% 
Appearing mainly on lists after 1977: 
co-trimoxazole tab. 
vaccines: tetanus* 
DTP 
polio 
BCG 
measles 
chlorphenamine tab. 
diethylcarbamazine tab. 
diazepam tab. 
antihypertensivum 
29 
29 
26 
24 
24 
21 
29 
34 
32 
29 res: 24% hydr.c.th: 16% meth.d: 13% 
* Vaccines have a low score because they do not appear on some lists at all; of 31 lists of less 
than 100 items vaccines are included in 9 lists only, mainly from after 1977 
A third level of priority was indicated by listing all drugs that appeared six or seven 
times in the group of seven long lists, insofar as they had not been included in the previ-
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ous selections. This group of long lists is not very selective and this is the reason why 
only a score of 6/7 or more is taken into consideration. This selection of 18 drugs is 
presented in Table 4. 
Table 4. 18 essential drugs not mentioned in tables 2 and 3 which appear on at least 6 long 
(over 100 item) lists of essential drugs. Frequency expressed as percentage. 
Drug 
benzyl penicil.inj. 
streptomycin inj. 
INH/Thiacetazone tab. 
hydrocortisone inj. 
chlorpromazine inj. 
digoxin tab. 
digoxin inj. 
sodium chloride inf. 
glucose 5% inf. 
emetine inj. 
iron dextran inj. 
prednisolone tab. 
oxytocin inj. 
insulin inj. 
ether 
snake antivenom 
thiopentone inj. 
tetanus antitoxin 
Frequency 
in 38 lists 
(%) 
47 
45 
37 
29 
39 
29 
29 
29 
26 
26 
26 
26 
26 
21 
18 
18 
24 
24 
One more selective criterium had to be used as, for some drugs, the situation since 
the early seventies has changed, negatively influencing their opportunity to be in-
cluded in the early lists. The reason for this could be either the introduction of the drug 
after that time, changes in indications for use, or reduction in price e.g. after the patent 
expired. To correct for these possible changes the same criteria for selection had to be 
applied in respect to the later lists only. This application had no effect on the first list of 
"most essential drugs" as all high scoring drugs had already been included; six more 
drugs qualified on the second list and these have been added to the list in Table 3. The 
subgroup of late long lists was too small to be of use. 
1.3.5 Discussion 
Including a drug in a short list of essential drugs is a much stronger indication of its 
being considered essential than including it in a long list. For this reason the short lists 
are more discriminating and supply, in fact, much more valuable information. 
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There are two reasons as to why the list of "most essential drugs" is interesting and 
might be of value. The first is that its contents more particularly express the consensus 
within the group of short lists, being the more discriminating group. This is illustrated 
by the fact that the list of 29 "most essential drugs" contains all 26 highest scoring 
drugs of this group. The second reason is that this list will be especially useful in choos-
ing essential drugs for dispensaries and health centres which is the level of health care 
on which most essential drug programmes are concentrating. 
Although this "core" list, a term used by a WHO working group on essential drugs, 
can never be considered as complete or ready-made for a given situation, it can serve 
very well as a check-list for sub-Saharan countries to ensure that no essential drugs 
have been forgotten. In some situations a few more drugs for specific conditions pre-
valent in the area will have to be added. In section V.2 of this study this core list of 
"most essential drugs", based on consensus in literature on essential drugs, will be 
used as a yardstick to evaluate other lists of essential drugs. 
The second and third selection indicate the extra priorities as prevalent in the me-
dium and long lists of essential drugs, which can be rougly attributed to health care at 
hospital level. What should be realized is that the method of recording implies that in 
the second selection are included only drugs that have a score of less than 36% in the 
short lists; these were drugs that rarely appeared on short lists. This implies also to the 
third selection in which are included only drugs that had a low score in both short as 
well as medium lists, and that therefore appeared mainly in the lists of over 100 items. 
Again the results can not be considered as fully comprehensive. The number of medi-
um and long lists the data are based on is rather small and the lists, being long, are rath-
er undiscriminating. In general there is much less agreement on the drugs to be used at 
hospital level. Yet the quantified consensus can indicate drugs that are generally con-
sidered essential. The lists might be used as check-list and have to be adapted to local 
situations. 
When scores in early and late lists are compared, some drugs can be seen to be en-
tering the scene: e.g. oral rehydration salts (early lists 30%, later lists 887o), paraceta-
mol (early 0 %, later 65 % ) and mebendazole (0 %, later 46 % ). Other drugs are disap-
pearing, e.g. tetrachlorethylene (60%, later 8%) and emetine (50%, later 12%). 
These changes could perhaps be attributed partly to the publishing of the WHO list of 
1977. 
Some drugs have unexpectedly low scores, e.g. ampicillin (39%) and antihyperten-
siva (29%). Apparently these are rarely selected as essential drugs. 
1.4 Quantification of drug needs 
1.4.1 Drug utilization studies 
Drug utilization has been defined by a WHO expert committee as "the marketing, 
distribution, prescription and use of drugs in a society with a special emphasis on the 
resulting medical, social and economic consequences"1()8. The objectives of drug utili-
zation studies are to quantify the state, the developmental trends and the time course 
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profiles of drug usage. The data are of value in the planning of drug supply and distrib-
ution and for estimating drug needs in a society,preferably after considering the over-
all morbidity pattern within the actual country or region109. 
Not many drug utilization studies have been carried out '10. Moreover, the results of 
these are difficult to compare ' ' '. Rabin and Busch ' n mention three reasons for this. 
The first is that there is no single unit that is satisfactory as a basis for international 
comparison either at one point in time or over a period of time. The monetary unit is 
neither constant in time nor comparable between countries'13. However, since 1979 
the use of the Defined Daily Dose (DDD) has been advocated as a technical unit of 
measurement of comparison109114. Whenever possible, this daily dosage should be 
given in weight of active substance109. 
The second reason for the scarcity of drug utilization studies is that data on drug use 
are often not available or that their source is uncertain. The third is that if attempts are 
made to compare countries with respect to changes in their consumption over time, 
additional problems arise e.g. in inflation, population growth, exchange rates and so-
cial changes. 
1.4.2 Drug need quantification in Africa 
In developing countries hardly any drug utilization studies have been carried out al-
though there is a great need for reliable information on marketing, distribution and 
use of drugs in those countries "where progress in health care depends largely on im-
provements in the provision and use of drugs" 'l4. This observation was made by Frie-
bel who measured drug consumption in two African countries. His data were derived 
from 1977 purchasing orders from Central Medical Stores in the one and 1974 nation-
al estimates for drug supply for Primary Health Care in the other. He compared these 
data, expressed in DDD, with figures from Norway and concluded that the availability 
of drug utilization figures is a precondition of any improvement in drug supply n4. 
As mentioned above, one of the problems is the difficulty of obtaining reliable data. 
Even official estimates as used in Friebels study can be grossly inaccurate. Hamel'l5 
sums up the possible reasons for these inaccuracies: hospitals requesting more than 
necessary, knowing that amounts will be cut anyhow; hospitals requesting unsuitable 
(cost/therapeutic) or unnecessary drugs through personal preferences or the influ-
ence of the drug companies; and less than optimal prescribing practices (polypharma-
cy, over-prescribing and unnecessary prescribing). 
A1979 WHO publication differentiates between three stages at which real drug ut-
ilization can be measured: drugs prescribed by the doctor, drugs acquired by the pa-
tient and drugs actually consumed by the patient. Information on this last stage can on-
ly be obtained with great difficulty by very exhaustive interviews of the patients113 
which can be very inaccurate ' '6. Yet measurements of drug consumption by means of 
analysis of expenditure, prescriptions issued or hospital pharmacy files are also liable 
to many biases, especially in developing countries. Van der Geest has published sever-
al papers on the unofficial and illegal ways of distributing drugs '17" '19 and for Camer-
oon cautiously estimates that in rural health institutions about one third of drugs are 
withdrawn from the system "7. Whenever utilization is measured at an early stage in 
the drug flow, e.g. in hospital pharmacy files or central hospital stores, this loss cannot 
be differentiated from the actual drug consumption by the patient. 
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1.4.3 Methods of drug need quantification 
Three different methods of drug need quantification can be distinguished: the pop-
ulation-based method, the service-based method (or demand-morbidity method) and 
the consumption-based method120. In this section a short description of each will be 
given. In section V.3.3 and in chapter VI the merits of each method will be discussed. 
1) The population-based method 
The method is based on the surveyed or estimated prevalence of various illnesses in 
the population. To estimate drug needs these data are combined with coverage of the 
population by existing health services and with generally accepted or devised treat-
ment norms. In the book "Managing Drug Supply"120 an example is given for Haiti. I 
know of no example from Africa. 
The advantage of the method is its clear scientific approach. One of the disadvan-
tages is that the result can never be more accurate than the underlying epidemiological 
data which are usually lacking or fragmentary in developing countries. A second dis-
advantage is that the coverage by existing health institutions is often difficult to assess. 
A third disadvantage is that it does not take into account the differences between cal-
culated minimal requirements and the practical rate of consumption which includes 
all kinds of losses, spoiling, and less than optimal prescribing patterns. 
2) The service-based or demand-morbidity method 
This method uses the morbidity pattern among patients visiting health institutions 
as derived from patient statistics. These "demand-morbidity" data are combined with 
a chosen standard therapy regime and total drug needs are calculated. The best re-
corded example is given by Simmonds and Walker1(l7 who calculated the drug require-
ments for a hypothetical population of 10.000 in a refugee camp. The results were la-
ter used by the WHO/UN High Commission for Refugees. Moore7 used the method 
to calculate the contents of standardised kits of essential drugs for dispensaries and ru-
ral health centres in Kenya. Of late the WHO has used the same method in a training 
paper on drug supplies and logistics99·121. Moore and Walker used it in Ethiopia122. 
The advantage of this method is that it is much more practical than the population-
based method, as the problem of collecting epidemiological data and data on coverage 
are avoided. Moreover, it estimates drug needs for a system with a standardised opti-
mal prescription pattern. This is at the same time a disadvantage as no such optimal 
prescription pattern is practised and as estimates tend to be too low. A second disad-
vantage is that reliable data on morbidity pattern from hospital- or health centre statis-
tics might be difficult to obtain, for two reasons. The first is that in a fair proportion of 
patients no strict diagnosis is made and only the symptoms are treated. The method of 
translating symptoms into recordable diagnoses should be uniform for the statistics to 
be reliable but this is often not the case. The second reason is that many patients pres-
ent with more than one diagnosis. Here again the method of recording should be uni-
form but often is not. 
3) The consumption-based method 
A third method of estimating drug requirements is to study the pattern of drug con-
sumption in a number of health institutions in a given area over a given period. These 
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consumption figures can be related to the number of patients treated. The average 
drug consumption per number of patients treated can be used as a model for other in-
stitutions or for the region as a whole. The essential drugs programme of the Christian 
Health Association of Ghana60 is an example of this method and will be discussed and 
evaluated in this study. 
The advantage of the method is that only one parameter is used, bypassing epidem-
iology, coverage, and standard therapy, measuring actual drug consumption only. 
Losses and actual (mostly less than optimal) prescribing practices are incorporated in 
the result. The advantage here is at the same time the disadvantage: these losses cannot 
be differentiated from the actual drug requirements of the patient. 
1.5 Policies on the supply of essential drugs 
1.5.1 Introduction 
Improving the availability and quality of essential drugs in developing countries at 
affordable cost involves many factors. Experience has shown that adequate results 
have been achieved only when a coherent and strong national drug policy exists, 
backed by adequate legislation. The literature on this subject is vast. In this section a 
review will be presented of some different elements in national drug policies insofar as 
they have been of historical interest or can be of practical consequence. 
1.5.2 National drug policies 
In the introduction to the first WHO list of essential drugsI7 clear advise is given on 
formulating a national drug policy. More publications followed ^3 2 ·1 2 3"1 2 5 . The most 
comprehensive description of necessary steps in establishing a national drug policy is 
given by Lionel and Herxheimer126·127. To summarise: a national drug policy usually 
starts with the formation of a national committee of experts to advise the government 
on reduction of costs, increase in effectivity, and on necessary legislation. The policy 
itself usually includes the following elements: the formulation of a national list of es-
sential drugs using generic names; bulk purchase by international tender; local pro-
duction of some basic items; quality control; drug information and health education, 
both for health workers and the general public; and the regulation of advertising and 
sales promotion. 
In 1978 the African Regional WHO Expert Committee on Drugs confirmed the 
WHO recommendations33. Outside Africa, sound examples of national drug policies 
are to be found in Cuba", Peru14, Sri Lanka68 and Bangladesh128130. In Africa, Mo-
zambique has been the most succesful26·38·40·131 in that the number of drugs on the na-
tional list is now less than 300, all prescribing is by generic names and sales promotion 
has virtually disappeared40,48. The cornerstone of Mozambique's policy has been the 
establishment of strict drug registration, an effective national formulary and an exclu-
sive state system of drug procurement through international tenders40, all within the 
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context of a national struggle to create a socialist and democratic society48. 
Each of the elements mentioned above will be discussed briefly. 
1) Reduction of costs 
The reduction of costs is a most urgent problem for most developing countries. In 
Africa, in 1981, 46.4% of total health expenditure was spent on pharmaceuticals as 
compared to 6.1 % in North America and 6.8% in Europe '. Drug expenditure in Afri-
ca has been increasing much faster than the BNP: in the period 1971-75 drug expendi-
ture in 32 African countries rose by 21.1 % per year while the BNP rose by 4.7% only 
per year132. Yudkin estimated the increase for one African country at one third per 
year throughout a period of five consecutive years79·83. 
Patel1 gives the best available summary of five different ways to reduce drug ex-
penditure and tries to quantify the estimated effects of each. The two most effective 
measures are a national selection of drugs, and bulk purchase, which together could 
account for a 40% reduction in costs; other measures which can be taken are a public 
system of distribution, the use of generic names, and domestic production; the three 
together to account for another 20% reduction. 
Many other authors also indicate measures which can be taken to reduce the costs. 
Silverman '^ emphatically states that the formulation of national drug formularies will 
have the strongest effect. Not only the reduction of the use of unnecessary brand-
named drugs but also reduction in the use of expensive dosage forms such as syrups 
and injections can represent a considerable saving38,78. Studies in Ghana2 and Zaire3 
show that cost reductions of 70-75% can be achieved by a rational, generic prescrib-
ing of essential drugs in the simplest dosage form. 
It should be realized that no real savings in an absolute sense can be expected from 
national drug policies as a whole. As the impact of the policy increases, more people 
will have access to essential drugs and the cost of the total system will be likely to rise44. 
In any case the savings made by a more efficient drug supply will be necessary in order 
to pay for the supply to that part of the population that previously had no access to es-
sential drugs. 
2) Legislation 
Effective legislation is the backbone of any drug policy. Detailed descriptions of the 
necessary elements have been given by the WHO134 which has expressed willingness 
to advise member states124, and by Lionel and Herxheimer126,127: the laws and reg-
ulations must "specify the standards required and the categories of persons to be per-
mitted to manufacture, sell, prescribe and dispense drugs; they must also set out the 
means to be used to ensure that provisions are met and the penalties for contravention 
or non-compliance"126. The authors mention that voluntary regulation is far more re-
liable, effective and cheaper than external regulation but observe that many efforts at 
self-policing are exceedingly disappointing. 
Most West-African countries have obsolete and inadequate drug laws135. 
3) Use of generic names 
The WHO has from the beginning17 advocated the use of generic names as laid 
down in the International Nonproprietary Names for Pharmaceutical Substances 
(INN)136. This advise is also given by nearly all authors writing on the reduction of 
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costs1·78. The advantages are well summed up in theTanzanian list of essential drugs70: 
The use of generic names is less confusing than when there are many dissimilar brand-
names for one drug; the generic name drugs are usually cheaper and give the pharma-
cists flexibility in the dispensing of drugs, and facilitate the teaching of healthworkers 
as they will have to learn one name only. The cost reduction achieved by using generic 
products is estimated at between 10%1·137 and 30%4M3. The pharmaceutical industry 
is not happy with the idea and claims that it will be harmful to innovation137138. This is-
sue will be discussed in section 1.5.4. 
4) Essential drugs lists: restrictive and selective 
Essential drugs lists have at least two different functions. The first is to ban unneces-
sary, mostly brand-named, drugs which usually consume a fair proportion of the na-
tional drug budget. This function could be called restrictive. Restrictive essential drugs 
lists, intended to exclude drugs, usually contain several hundred items. Examples of 
restrictive essential drugs lists are the lists of the Ministries of Health of Lesotho42, 
Ghana92 and Ruanda91. Mozambique has probably been the most successful in actu-
ally banning any drug not on the national list26·38. This is the most essential step neces-
sary to reduce expenses on many unnecessary brand-named drugs that are generally 
propagated with vehemence by pharmaceutical companies. 
The second function of essential drugs lists is to select a limited number of drugs for 
the different levels of health care and to serve as a basis for the supply of drugs by local 
production or bulk import by the government. A notable example is the five-tier list of 
Tanzania70. These selective essential drugs lists are much shorter. 
5) Import 
Although many developing countries already economize on the purchase of drugs 
as compared with richer countries114 considerable saving can still be achieved by a 
more rational import policy on essential drugs. The system of governmental bulk pur-
chase by international tender has been advocated by many authors17'139-141. As it does 
not require a big governmental body but only a small motivated expert committee, this 
system does not involve a big investment5. Although officially practised in many Afri-
can countries, in reality the bulk purchasing by tender system is often disrupted by the 
agressive marketing policies of pharmaceutical companies which many officials can-
not resist. 
WHO and UNICEF have offered assistance and advice to individual coun-
tries32·124·142. The possible savings have been estimated at 20%1 or even more in indi-
vidual cases79. Up till now Mozambique26 and Tanzania143 seem to be the most suc-
cessful in implementing a rational import policy. 
6) Local production 
The advantages of local production of essential drugs have been summarized by Li-
onel and Herxheimer126: increased self-reliance, a reliable flow of supply, the saving 
of foreign exchange and the provision of local employment. To this can be added a 
better utilization of local resources144, transfer of technology, manpower training and 
industrialization '4 '. The view has been expressed that the whole process of increasing 
local production could be financed from savings made on the rational supply of essen-
tial drugs as a whole1. 
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The counter arguments are many, the most important of these being that drugs 
domestically produced are generally more expensive than generic products bought by 
international tender. The price difference has been estimated at 60-80% but could be 
much higher145. The reasons for this are usually linked to small scale production per 
jei23 : depreciation of investment, maintenance, spareparts
I46
 and quality control123 
are more expensive for small industries than for the big drug companies. Even produc­
tion by a subsidiary of a multinational company can be expensive because of patent 
restrictions and because of systems of tied purchases and transfer-pricing (when raw 
materials are sold from the multinational firm to the local subsidiary for fixed, exorbit­
ant prices)79. Greater self-reliance and savings in foreign exchange might prove illuso­
ry when dependence on expensive spare parts and servicing still exist5. Specific Afri­
can problems exist in the absence of a chemical industry, the unreliability of public 
services such as water and electricity and because of the lack of qualified personnel33. 
Problems involved in marketing fall outside the scope of this study. 
The UNIDO has differentiated between five levels of pharmaceutical industrializa­
tion63·103·147 which can be summarized as follows: 
Phase 0: no pharmaceutical industry in any form; 
Phase 1: repacking and packaging; production of packaging material; 
Phase 2: formulation of tablets, capsules, syrups and ointments from bulk drugs; 
production of plant extracts and some organic and anorganic intermediates; 
Phase 3: formulation of parenterals, biologicals, immunologicals, single-step syn­
thetic drugs and fine organic intermediates; 
Phase 4: multi-step synthetic drugs, fermentation products (e.g. antibiotics)147. 
In 1976 Ghana was in Phase 2 and this is still the case. 
The conditions necessary to start local production are: a finished feasibility-study32 
for which WHO help has been offered '2 4, and a strict adherence to a national list of es­
sential drugs5·41. One very interesting point to be considered is that before local pro­
duction is started, a quality control laboratory should be operating, as quality control 
is a prerequisite for both local production and generic bulk purchase138·148"150. 
7) The choice between bulk purchase and local production 
Most authors agree that local production is usually more expensive than bulk pur­
chase. However, it should be realized that the price of the products of a new industry 
can never be low114. For example Tanzania accepts that locally produced drugs are 
25 % more expensive than imported ones49. Another point which requires mentioning 
is that it is claimed that starting national production is inevitable. As an UNIDO offi­
cial put it: "the course of local production of pharmaceuticals in order to cut down im­
ports in a situation where collaboration from transnational cooperations and develop­
ing countries and decentralized economies is not forthcoming, becomes the only pos­
sible way out of a dire situation"103. 
It is questionable as to whether a pharmaceutical industry is the best sector in which 
to start industrialization ' '4. The goals of industrialization and those of providing inex­
pensive drugs to the poor are not always compatable as local manufacture does not ne­
cessarily produce cheap drugs146. It could be a more desirable option for poor coun­
tries to build up systems for the purchasing of drugs as efficiently as possible as "in this 
way investment risks are minimized and production is centred in the most competitive 
plants"б3. This is what Taylor wrote in a publication for the Office of Health Econom-
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ics, which was founded in 1962 by the Association of the British Pharmaceutical In-
dustry. 
It is difficult to see why a first stage of repacking and formulating simple mixtures 
and ointments should not be profitable in view of the price and transportation costs of 
imported finished products. In the case of more sophisticated processes a careful study 
should be made of the foreign currency involved and the capital investment necessary 
should be compared with that involved in starting other industries, before any steps 
are taken. Feasibility and acceptability in view of the available manpower should be 
assessed as well. 
An interesting view is expressed by the Christian Medical Commission of the World 
Council of Churches149: one could consider starting local production in a decentral-
ised way, e.g. expanding facilities for the production of eye-drops in a hospital pharm-
acy that is already making them for domestic use. In this manner the existing expertise 
can be carefully expanded. Small-scale projects are typical of Voluntary Agencies, 
which have started several43·97·151. 
8) Quality control 
As has been mentioned above, both in the case of local production149·150 and in that 
of generic bulk purchase138 quality control is a prerequisite; in regard to the latter be-
cause examples are known of substandard products 138'14(). Furthermore, quality con-
trol is essential in order to check on the disintegration of drugs under tropical condi-
tions 152 and control the quality of raw materials124·150. A final reason is that effective 
quality control could be necessary to convince the medical profession of the accepta-
bility of imported or locally produced generic products. 
In 1975 the WHO in resolution WHA 28.65 adopted the "Certification Scheme on 
the Quality of Drugs moving in International Commerce"153. This scheme requires 
certification of three essential aspects: that the product is authorised for sale and for 
distribution in the exporting country; that the batch conforms to specifications; and 
that the manufacturing plant is regularly inspected for proper manufacturing stand-
ards and quality control measures '54. Another WHO publication defines the different 
responsibilities of government and producer: the government to be responsible for the 
inspection of the manufacturing plant, for sampling and for quality analysis, for verify-
ing analytical specifications and for the use of the Certification Scheme; the manufac-
turers' responsibility includes self-inspection at all stages of production, maintaining 
adequate analytical facilities and the keeping of records on all analytical tests per-
formed. Moreover, the WHO states clearly that in the case of the importing country 
not being able to guarantee sufficient quality control the exporting country should 
then supply documents according to the Certification Scheme17. This Scheme was, 
however, up to the present ( 1984) not been endorsed by all member states, including 
some important drug exporting countries such as Germany and Switzerland153. 
Setting up regional quality control laboratories has been considered33·155. Recently 
the WHO published data indicating that even a small national one-analist laboratory 
could undertake 200-300 analyses per year, could detect substandard and mislabeled 
drugs and could perform the full analysis of more than 75% of the drugs on WHO's 
model list of essential drugs ' n · '56. It is obvious that when the means available are limit-
ed, quality control is only possible in the case of a restricted number of drugs139. This 
justification for the use of a list of essential drugs has been mentioned before. 
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9) Education and information 
In order to be able to form a policy that will be successful in improving the supply of 
essential drugs it is essential to educate both health workers on all levels and the gener-
al public5·7·17·49·148. 
Malcolm Segali139 distinguished three levels at which the necessary education can 
take place: during the basic training of health workers, during their post-basic training 
by a governmental information service on drugs emphasising sound prescribing prac-
tices, and health education of the general public. 
Many authors mention the enormous consequence of some basic shortcomings on 
the training of health workers. Concentrating on university medical studies, Yudkin79 
observes that their general set-up is Western and that training is mostly carried out by 
teachers who received their own training in developed countries. He describes the de-
sire to establish an "international reputation" for the medical school, which is neces-
sary for the international mobility of graduates and concludes that "health care comes 
to be synonymous with curative medicine, and this in tum is reduced to hospital tech-
nology and the latest drugs"48. The Christian Medical Commission speaks of "profes-
sional elitism"157 and Gunaratne states: "medical education seems to be patterned to 
give professional satisfaction to the teachers rather than education and training to 
their students" '5,t. There is an urgent need for the establishment of a different curricu-
lum for doctors and other health workers; they should be taught to place clinical deci-
sions about the individual patient within the context of the health needs of the popula-
tion and to make a more discriminating use of the scarce resources available in their di-
agnosis and treatment9. Another necessity is the careful re-training of health workers 
in the field, e.g. with diagnostic flow-charts and standard therapy regimes2·7. 
It is usually seen as a governmental responsibility to supply objective information 
on drugs ^ 26. Examples are the 1972 "Vademécum Oficial de Medicamentos Básicos" 
of Peru14 and the 1981 Lesotho formulary42. However, the main problem in develop-
ing countries with regard to post-basic training is the fact that the multinational 
pharmaceutical firms have a virtual monopoly on information on drugs, as medical 
journals and objective publications on drug efficacy and costs are usually lacking83. 
The well-known MIMS Africa159 is more often than not the only desk reference avail-
able. Moreover, the pharmaceutical firms put enormous pressure on doctors with, for 
example, one sales representative per four doctors in Tanzania, compared to one in 
twenty in Britain83. 
A recent example of a welcome initiative is the wall-chart with indications and dos-
age of some forty essential drugs in the Kenyan drug distribution plan16ü, which is use-
ful both to health workers in the field and to the public. A similar chart is in use in Tan-
zania. This is of course only possible in the case of a limited range of drugs. It is ex-
tremely useful for making all parties involved acquainted with the national policy on 
essential drugs. 
10) Advertising 
Examples of incomplete or wrong information in advertisements161163 or, more 
specifically, the presentation of more indications for use and the omission of certain 
contra-indications164 are well documented. Mellrose165·166 and Silverman133·167 have 
effectivily focused public attention on many examples of what they call "drug dump-
ing" in the Third World. 
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Effective control on advertising is usually lacking48,83 although the WHO called for 
it from 1977 onwards17. An interesting phenomenon, however, may be observed in 
Mozambique where rigid governmental bulk purchasing linked to a national list of es-
sential drugs brought about, as a spontaneous side-effect: the virtual disapparance of 
drug advertising and company salesmen, without the need for direct administrative 
and legislative measures on promotional activities40. This could perhaps serve as a 
model for other countries. 
1.5.3 International action 
In the 1975 WHO Certification Scheme on the quality of drugs153, regulations for 
labelling and drug information have been laid down. The International Federation of 
Pharmaceutical Manufacturers Associations (IFPMA) admits that drug information 
should in principle be uniform all over the world168 and in 1981 published a Code of 
Pharmaceutical Marketing Practices169. This code, however, was received by Health 
Action International (HAI) as being grossly insufficient. HAI is an informal cooperat-
ing network of some 50 consumers, development action and other public interest 
groups, established in 1981170. Anwar Fazal, president of the International Order of 
Consumer Unions (IOCU) even suggested that the industry proposed the code "not 
to put its house to order, but simply to forestall external regulation of the industry, not-
ably by the WHO"64. A serious flaw in the IFPMA code is the absence of any form of 
sanction. As a reaction the HAI published its own Draft International Code of Pharm-
aceutical Marketing Practices171. 
The offer of several IFPMA member firms to supply essential drugs at reduced 
prices is a recent issue31·63·172. HAI reacted strongly, calling this a threat to the objec-
tivity of the WHO because it would be very difficult to both cooperate with the pharm-
aceutical industry and at the same time regulate its behavior. "Industry priorities and 
world health priorities inherently conflict"l73. In the same paper the Chairman of the 
WHO Ad-hoc Committee on Drug Policies was cited as saying "the question at issue 
was whether industry would give priority to health or profit if it is considered that to be 
its option. The question was one which the WHO Executive Board should consider 
very carefully before deciding what ground rules should be laid down for the industry 
participation in and contribution to the Organizations Action Programme on Essen-
tial Drugs"173)*. 
1.5.4 Research and development 
The WHO has listed the present goals of research into health problems of the third 
world as: clinical and epidemiological studies on the efficacy and the safety of essential 
drugs used in local conditions; the development of appropriate technology for pack-
aging and formulating the most essential drugs in these countries; and studies on the 
)* Figures show that this is not illusory. Six countries (USA, Japan, W-Germany, Switzerland, 
Britain and France) control 70-75% of all world drug production1·64; these countries also 
contribute about 50% of the total budget of the WHO64. 
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stability of the products under tropical conditions33. In the introduction to the 1983 
revised list of essential drugs6 is also mentioned: the investigation of the benefits and 
safety of some traditionally used herbal remedies; the value of non-medicinal forms of 
treatment; the effects of genetic, nutritional and environmental factors on the therap-
eutic response; and operational research to improve procurement procedures and to 
evaluate and improve distribution systems. 
Paul Janssen174 of the Belgian pharmaceutical firm of the same name made a com-
plete inventory of the state of affairs in 90 infectious diseases of the developing world 
and concluded that excellent mass immunisation is possible against 10, that excellent 
chemotherapy exist against 24 and satisfactory chemotherapy against another 23. 
This leves 33 diseases against which either no, or unsatisfactory chemotherapy is avail-
able. Simon175 is very optimistic about the prospects for new vaccines and rationally 
developed effective drugs. We can conclude that there is a need for research on the 
treatment or prevention of tropical diseases and that good prospects for research in his 
field exist. This research should be aimed at both generating new knowledge and at ap-
plying existing knowledge87. 
This subject is linked to the concept of essential drugs by the fact that, in reaction to 
the policy of using generic drugs instead of brand-named preparations, the pharma-
ceutical industry has warned that this would hamper innovation137·138. The fundamen-
tal problem is that whilst 5-20% of the price of drugs is spent on research and develop-
ment (R&D)5 and whilst 15-20% of world drug consumption takes place in the devel-
oping world3163·168 only about 1% of the total budget of R&D is spent on research in 
drugs against tropical diseases.)* 
Apart from this budget from the pharmaceutical industry, there is the much smaller 
budget for the WHO Special Programme on Research and Training in Tropical Dis-
eases176. As the estimated cost of developing one single drug is estimated at between 
US $ 40-55 million123 the possibilities of developing new drugs are limited. For Diana 
Mellrose this settles the argument: as such a small proportion is spent on research on 
drugs for developing countries there is no need for them to contribute to this budget by 
buying brand-named drugs177. Or, as Herxheimer put it, if the consumer contributes 
to the cost of drug development he should have some say in the direction such devel-
opment should take138. The pharmaceutical industry's response was to state that in 
many cases the health problems of the North and South overlap, that the Third World, 
after having completed the demografie transition, will have the same pattern of dis-
eases as the developed world and will then need the same drugs, and that in general the 
outcome of research can never be predicted63. Yudkin, however, states that the 
pharmaceutical companies feel that it is more profitable to create in an underdeveb 
oped country a market for drugs produced mainly for developed countries, than to 
create a drug especially for underdeveloped countries where resources are limited and 
profits may therefore be low48. As the WHO has explicitly stated that it is very urgent 
to ensure thorough application of existing knowledge within the health system as well 
)* These are the figures: total expenditure on R&D is estimated at US $ 8.000 million annual-
ly ,46 of which only US $ 60 million is spent on drugs intended for use in developing coun-
tries l0; this is about the same as one fighter bomber or a few kilometers of motorway 12'\ or 
about 2% of all R&D on cancer48. 
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as to immediately apply new knowledge as soon as it has proved its worth87, the fear of 
the pharmaceutical industry might not be completely unjustified that, immediately af-
ter launching a successful drug, the patent will be ignored by some countries. On the 
other hand, the high prices for new drugs such as praziquantel178, a new and promising 
anti-schistosomiasis drug, prohibit their use in the areas where they are most needed. 
These factors would constitute an argument in favour of international financial sup-
port of R&D in drugs against tropical diseases, as in fact has been propagated as prob-
ably the most effective form of help the North could offer the South10·63. In any case 
the grossly inadequate budget for R&D on tropical diseases should be increased. 
1.6 Distribution 
1.6.1 General aspects 
Fair and regular distribution is "a vital link"179 in the supply of essential drugs. "A 
just distribution of health resources is as important as their quality and quantity" said 
Mahler85. The need for a functioning distribution system will even become greater as 
more areas are reached by Primary Health Care systems179. 
The present distribution of health resources shows differences as big within devel-
oping countries as those that exist between the rich and the poor world. In 1977 even 
in Tanzania 79% of drug funds went into hospitals, 7% to health centres and 14% to 
dispensaries48. 
The problems are many and nearly insurmountable; they mostly are related to a 
combination of bad transport facilities lacking maintenance and fuel, bad communic-
ations179 and long distances139, resulting in inadequate supply, the inadequate flow of 
information, a lack of supervision and feelings of neglect and isolation on the part of 
the health workers179. Of all the factors mentioned, transport is usually the most capi-
tal intensive. The problem is a vicious circle: as there is no proper distribution system 
no drugs are supplied, and as there are no drugs there is no need to improve the sys-
tem148. The combined introduction of a system of bulk import, repackaging and dis-
tribution of a limited set of essential drugs would be ideal. This would involve provid-
ing facilities for storage and inventory control, transportation and maintenance, re-
packaging and labelling, quality control and education and motivation at all levels of 
staff. This last element is often considered to be the most essential5·44. 
There has been much discussion on the desirability of the system existing in many 
countries whereby drugs are distributed free of charge as part of an over-ambitious 
National Health Service. The system has many disadvantages33, of which the resulting 
passive attitude of the patient and the inability of the state to pay for it have to be espe-
cially mentioned. Another disadvantage is that under such a system drugs do not ap-
pear to have any financial value and this might lead to a situation where the necessary 
administrative structure is inadequate or even non-existent. A workshop in Ruanda 
advised against it and propagated a governmental subsidy on essential drugs in-
stead141. A system of this sort exists in Mozambique36. 
No clear advise emerges on distribution plans. We have to limit ourselves to looking 
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to some recorded examples. In the Tanzanian drug relief plan49 existing transport to 
regional centres and into the district is considered sufficient. In the Kenyan pro­
gramme to supply dispensaries with essential drugs, sealed boxes are distributed 
throughout regional and district centres7. In a drug supply plan for Southern Sudan 
the transport of the drugs is up to the "consumers", i.e. the local community or health 
committee55. As will be discussed later, the same applies to the drug distribution sys­
tem of the Christian Health Association of Ghana, where health institutions from all 
over Ghana have to collect their allocation from two distribution centres60. In the case 
of these last two examples "collection" has replaced "distribution". 
1.6.2 Distribution by means of standard packages 
The first publication on the distribution of essential drugs by means of prepacked 
standard packages was Simmonds and Walker's paper107 that was published in The 
Lancet of Februari 1982 at a moment when the first five hundred prepacked boxes for 
all church related health institutions in Ghana had already been shipped. It was a short 
paper on the estimated drug needs of an imaginary population of 10.000 in a refugee 
camp. At that time in certain areas of Kenya a pilot project was in progress to test the 
system of a monthly supply of essential drugs to dispensaries and rural health centres 
by standard kits of essential drugs. Moore reported on this project later in 19827·180. In 
the years 1982 and 1983 similar plans were prepared for Tanzania and Southern-Su­
dan. No official publications appeared untili the present (1984), therefore working 
papers only are available8·49,54"56·143. 
Table 5. Summary of publications on standard packages of essential drugs. 
1982 Simmonds 
& Walker107 
1982 Moore, 
Kenya7·46 
1982-83 
Tanzania" 
1982-83 
S.Sudan54 
Number of 
items 
on the list 
28 D 
30 D 
38 D 
17 
31 D 
35 D 
15 
21 
Meant for: 
Number of 
patients * 
10.000 
2.000 
3.000 
1.000 
1.000 
2.000 
? 
Time 
period 
3m 
1m 
1m 
1m 
1m 
1m 
3m 
6 m 
Type of health 
institution 
(refugee camp) 
dispensary 
health centre 
dispensary В 
dispensary A 
health centre 
PHC unit 
dispensary 
D These lists have been used for a comparative study (section V.2) 
* New patients, consultations, or treatment episodes 
34 
In all programmes the general idea is the same: calculated amounts of several differ-
ent essential drugs are packed together in a standard kit, intended for a certain type of 
health institution for a given period of time, or for a given number of treatment ep-
isodes.)* In Table 5 a summary of these publications is given. 
The assumption is, in the concept of standard packages, that needs within the var-
ious health institutions are more or less the same. Objectives are to provide drug quan-
tities that are sufficient but not excessive, and to encourage a more careful diagnosis 
and treatment49. The advantages are: safe and intact delivery; easy handling, storage 
and inventory control; increased confidence in the Health Service; new interest and 
motivation among health workers; less self-referral to higher echelons; and working 
within clear budgetary limits49. 
In Chapter V the choice of essential drugs and quantification of drug needs as re-
ported in these publications will be discussed in detail. 
)* See section V.4.3.3 
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Chapter Two 
GHANA 
II. 1 Land and people 
In 195 7 Ghana, formerly the British Colony of the Gold Coast, was the first African 
country to gain independence from colonial rule. In 1966 the president of this rich and 
promising country, dr. Kwame Nkrumah, was ousted by the first of, by 1984, five suc­
cessful military coups. Since 1981 the country has been governed by a Provisional Na­
tional Defence Council under the leadership of Fl. Luitenant Jerry Rawlings. 
Ghana is situated on the Gulf of Guinea in West Africa, and is roughly rectangular 
in shape with a north-south distance of 750 km and a coast line of 540 km along which 
more than forty forts and castles were once situated to protect the gold and slave trades 
(see figure 2). Three climatological areas can be distinguished: a narrow coastal strip 
G H A N A 
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Figure 2. Map of Ghana with administrative regions and main roads. 
O CHAG distribution centre 
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of dry savanna land, a broad tropical forest belt covering about one third of the total 
surface, and the northern savanna area. The Volta Lake, which was formed after con-
struction of the Akosombo dam, is one of the largest man-made lakes in the world and 
virtually cuts the country in two. Rainfall varies from 2000 mm per year in the humid 
South to 1000 mm per year in the North. 
In 1980 the total population was 11.679.000 according to a World Bank estim-
ate181. Compared with data from the last census of 1970 this would imply an annual 
growth of 3.1% over 1970-79. With 47 inhabitants per km2 in 1980 Ghana is, after 
Nigeria, the second most densily populated country of sub-Saharan Africa. Popula-
tion is concentrated in the mid-southern part of the country, where in the four most 
densely populated regions, 52% of the population lives on 24% of the total surface 
(115 inh/km2) (see figure 3). Of the total population, more than one third live in corn-
Figure 3. Four administrative regions in Ghana constituting 24% of the total surface, in 
which more than half of the total population lives. 
munities of over 5000, which makes Ghana one of the most urbanized countries in 
Africa. Annual growth of the cities was 5.1% over the period 1970-79, which is more 
than the population growth in general '8 '. However, 48 %. of the urban population lives 
either in the agglomerations Greater Accra (one million inhabitants in 1982) or Rum-
asi (400.000 in 1982)182, and it should be realized that many Ghanaian towns are still 
purely agrarian and are in fact large rural settlements rather than organized citieslfi3. In 
1978 71 % of children were enrolled in primary school, and 32% in secondary school. 
Like all public services, schools suffer greatly from lack of resources caused by the 
continuing political and economical crises. 
More than 60% of the population has maintained adherence to the traditional reli-
gions, with 20% Christians (mainly in the South) and 12% islamic influences (in the 
North). Tribal distinctions have a rather limited effect on national policy. English is 
the official language. The country has been divided in nine administrative regions. 
The Gross National Product (GNP) was estimated at US S 420 per capita per year 
in 1980 (Netherlands: US $ 10.230) which being over US $ 370, places Ghana nar-
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rowly within the World Bank group of Middle Income Countries63. However, in this 
group the average GNP is US $ 1420, while in the Lower Income group it is only US $ 
240. In view of the fact that the average annual growth over the period 1960-79 in 
Ghana has been minus 0.8%, it would be more realistic to include Ghana in this Lower 
Income group, as is also suggested by health indicators which are discussed below. In 
1979 agriculture and fishing accounted for 54% of employment; mines, industry and 
public works for another 20% and services and government for 26% 1 8 1 . Because of 
the continuing economic crisis a large proportion of the professional population has 
left the country for Nigeria, European countries or the USA. 
II.2 Health indicators in Ghana 
Some vital health statistics of Ghana are represented in Table 6 with corresponding 
data of low, middle and high income (industrialized) countries as reference. Most in­
dicators show that Ghana is in a situation comparable with lower income countries, or 
worse. Some of the goals to be achieved by these countries have been formulated as: 
an infant mortality of less than 50 per 1000, a life expectancy of 65 years or more, and 
Table 6. Health indicators in Ghana, compared with those for low, middle and high income 
countries9·181'183. 
Gross National Product 
per capita, in US $ (1980) 
Crude birth rate in births 
per 1000 population 
Crude death rate in deaths 
per 1000 population 
Life expectancy at birth in 
in years 
Infant mortality rate in 
deaths per 1000 live births 
Child mortality rate in 
deaths per 1000 children 1-4 yr 
Ghana" 
400 
48-50 
17-19 
49-50 
130 
(63-235)" 
22 
34 
Low 
Income 
Countries 
240 
42 
16 
51 
49-237<: 
18 
60 
Middle 
Income 
Countries 
1420 
34 
10 
61 
12-157c 
10 
18 
High 
Income 
Countries 
9440 
15 
10 
74 
13 
1 
a Figures for 1980 and 1982 
b Figures for the urbanized South and the rural North 
с Variation between countries 
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a literacy rate of at least 75%1 6. As can be seen from the table, Ghana still has a long 
way to go. 
No reliable statistics on incidence and prevalence of the most common diseases are 
available. However, the Ghana Health Assessment Team has described a method for 
assessing quantitatively the relative importance of different disease problems on the 
health of the population by measuring the impact of a disease by the number of healthy 
days of life lost through illness, disability and death. According to this method, the first 
ranking ten for Ghana are : malaria, measles, child pneumonia, sickle cell disease, mal­
nutrition, prematurity, birth injury, accidents, gastroenteritis and tuberculosis; to­
gether they cause 57.4% of all lost days of healthy life184. This list however does not 
completely correspond with the most frequent complaints or most frequent diagnoses 
in health institutions, as many common conditions (e.g. worm infections) are not con­
sidered to cause a great loss of healthy life. On the other hand these extensive studies 
have contributed to the development of the idea of selective primary health care9, 
which is the process of choosing the most cost-effective approaches to meeting health 
needs. 
II.3 Health facilities in Ghana 
In the seventies Ghana allocated 7-9% of the annual budget to health care185, of 
this amount more than one third was spent in Accra where only ten percent of the pop­
ulation lives 1 8 6 · , Κ 7 . In 1975 15% was spent on primary health care, 45% on secundary 
(district) hospital care, and 40%) on tertiary (specialized) services, mainly concentrat­
ed in Korle-Bu teaching hospital188. This disparity of distribution of resources is fur­
ther illustrated by the fact that 70% of the population lives in rural areas where only 
24% of the national health personnel and only 14% of doctors are stationed189. In 
1976 75.9% of the budget was reserved for curative care, and 9.7% for preven­
tion189·190. Reliable data for the period after 1976 are not available because of the de­
teriorating economic situation and political instability. 
Existing health facilities, according to 1983 Ministry of Health data182 are present­
ed in Table 7. The total number of hospitals is 106, of which 35 are church-related 
(33%). It can be seen that (para)govemmental hospitals, pharmaceutical manufac­
turing plants and retail shops are concentrated in the four most densily populated re­
gions, while church-related hospitals are not. The total number of beds was 12.973 in 
1975 "" .It is unlikely that this number has increased in subsequent years. The total 
number of out-patient attendances in 1981 was 5.267.996 according to a Ministry of 
Health estimate182. The accuracy of this figure cannot be established. Government 
health care is free. The services however suffer from nearly unsurmountable difficult­
ies caused by the exodus of trained personnel and lack of resources and materials. Vol­
untary Agency facilities are partially financed by the Government and charge moder­
ate fees. 
The total number of doctors in Ghana was 1.031 in 1975 (1 per 9.625 inh.) but this 
was reduced to a mere 600 in 1983, with less than half of these working in rural areas. 
This resulted for 1983 in an estimated de facto ratio of 1 per 7000 inh. in urban ag­
glomerations, and 1 per 35.000 in rural areas. Since 1979 the government has com-
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Table 7. Health facilities in Ghana. 
Government hospitals 
Para-govemment & 
mines hospitals 
Church-related hospitals 
Health centres 
Health posts 
Dressing stations 
Pharmaceutical factories 
Pharmaceutical shops 
Total 
51 
20 
35 
69 
119 
67 
21 
197 
In four most densely 
populated regions* 
28 (55%) 
13 (65%) 
11 (31%) 
30 (43%) 
50 (42%) 
41 (61%) 
21 (100%) 
175 (89%)** 
* Greater Accra, Central, Eastern and Ashanti Region, where 52% of the population lives 
(see figure 3) 
** 118 in Greater Accra alone 
mitted itself to the primary Health Care Strategy192. Pilot district projects have been 
started in each region, which were in some cases closely related to existing church-re­
lated hospitals. The projects suffer from the same problems as the governmental 
health services as a whole and, in fact, only those projects with some external resources 
(mostly from Voluntary Agencies) have survived. 
Π.4 CHAG and CHAG Drug Committee 
In september 1967 about forty church-related "mission-"hospitals and clinics in 
Ghana founded a voluntary association with the name "Church Hospital Association 
of Ghana" (CHAG) that was later changed into "Christian Health Association of 
Ghana" with the initials remaining the same. Its objectives were defined as: to encour­
age and promote the highest standards of Christian Medical Care; to facilitate and co­
ordinate the relationship of its members with the Ministry of Health; and to assist its 
members in employment of staff, in procurement of supplies, in planning and the co­
ordination of training programmes and also any other medical work or services re­
quested193. It is not a legislative or policy-making body, and does not infringe on the 
authority of any church, diocese, or governing board. 
In 1968 the combined CHAG institutions had about 2800 hospital beds, which was 
by then about 25 % of the national total1 9 4. In 1982 the number of member institutions 
had increased to 66, with 4386 beds, which was 34% of the total (see figure 4). In 1979 
the total number of out-patient consultations was 2.998.211, while in 1982 it was 
3.995.198 ^ (see Appendix 2). This increase of 33.2% over 3 years was partly caused 
by an increase in the number of participating institutions (10.9%) but mainly by an in­
crease in patient attendances in existing CHAG institutions (22.3%). Apart from an 
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Figure 4. CHAG health institutions in Ghana. 
L. Clinic 
* Hospital 
о Institution in drug utilization study 
increasing coverage of the rural population, this last figure is more likely to illustrate a 
shift in attendance from government- to church-related institutions, which could have 
been caused by the deterioration of the former and survival of the latter. The availabil­
ity of medical supplies and other materials through their own overseas relations has 
been an essential element in this survival of the CHAG institutions. Yet it should be 
realized that many church-related health institutions can only continue their services 
by the continuous government subvention which is usually enough to cover salary 
costs. 
As all governmental services suffer greatly from an absolute lack of nearly every­
thing, especially drugs and medical materials, and as many patients are therefore 
forced to supply their own from the free market outside, at present a much more in­
tense use is made of CHAG institutions than of governmental facilities. For this rea­
son one can safely assume that the 34% CHAG beds stand for a 40-50% CHAG pro­
portion in actual effective public health services, excluding of course traditional prac­
titioners and private clinics for which no figures are available. 
In 1980 the economic situation had deteriorated so much that the Ghana govern­
ment could no longer guarantee a regular supply of essential drugs and medical mate­
rials, of which the CHAG institutions also regularly received a share. As national 
funds to import drugs and raw materials were strained as well local production stag­
nated and a serious shortage of essential drugs and materials followed. In june 1980 
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the CHAG Executive Board appointed a CHAG Drug Committee to assess the need 
of essential drugs, to coordinate overseas drug donations and to set out a long term 
policy on the supply of essential drugs and materials. The committee consisted of two 
pharmacists (Dutch and Philippine), two doctors (Ghanaian and Dutch) and the 
CHAG Executive Secretary (Ghanaian). The author was appointed secretary, and, as 
from 1982, chairman. 
In the years 1980-83 the committee was engaged in many activities in the field of 
data-collecting and of planning, coordinating and supervising the distribution of 
many overseas drug donations and assisting in several relief operations57"59. In total 
over DFl 3.5 million (US $ 1.2 million) worth of drugs and medical supplies were dis-
tributed through CHAG, of which DFl 1.5 million was donated by overseas churches 
and over DFl 2 million by the government of the Netherlands. These activities will be 
discussed and evaluated in the following chapters. 
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Chapter Three 
CHAG DRUG COMMITTEE ACTIVITIES 
ULI Introduction 
To identify the problems and to pave the way to future solutions, the Drug Commit-
tee (hereafter the committee) started its activities by formulating a number of basic 
questions. These questions were: 
a) How many CHAG institutions have to be served? How many patients do they 
treat? 
b) Which drugs are to be considered essential? 
c) In what quantities are these drugs needed? 
d) How could the drugs be allocated and distributed with the means currently avail-
able? 
e) What would the cost of a reliefoperation amount to? 
It was decided to find the answers to the first two questions by conducting an inquiry 
among all member institutions. The remaining questions were to be answered by ad-
ministrative research carried out by the committee itself. 
In this chapter are discussed: the methods and results of the 1980 Inquiry (III.2); 
the quantification of drug needs (III.3); allocation and distribution of drugs (III.4); the 
1981-83 CHAG drugs programmes (III.5); and the 1983 revision of the CHAG list of 
essential drugs (III.6). An evaluation of the above activities is described in Chapter V. 
The material from section III.2-4 has been published elsewhere60. 
III.2 The 1980 Inquiry 
III.2.1 Materials and Methods 
An inquiry form was distributed to the, by then, 52 CHAG institutions)* at the an-
nual conference in August 1980. Within one month 39 forms had been returned 
(75%). 
The inquiry consisted of three parts. In the first, statistical data over 1979 had to be 
given (number of beds, admissions, out-patient attendances, ante-natal controls, de-
liveries, and major surgery). In the second part 80, by that time common, drugs in 
)* By then 30 hospitals, 21 clinics and rural health programmes (RHP) and 1 maternity home. 
It is difficult to differentiate exactly between a clinic and a hospital, although consensus exist-
ed within CHAG as to which was what. In general a clinic or RHP had no doctor and no em-
phasis was put on in-patient care although usually a few beds were available for maternity 
and emergency cases. 
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93 dosage forms were listed and respondents were asked to mark only 25 needed for 
their immediate relief. It was thought that this would indicate the most acute needs at 
that moment, and was also intended as a practice exercise for the respondent. In the 
third part the same list was presented, and the respondents were again requested to 
mark 25 only, but this time to indicate the drugs that were considered to be indispens-
able in general, regardless of shortages at that particular time, and to indicate the esti-
mated annual consumption of each. In the choice offered in both lists topical prepar-
ations, mixtures and vaccines were deliberately omitted. The reasons for the omissions 
were that mixtures and topical preparations are bulky and expensive to import ready-
made, and should preferably be produced locally from raw materials; and secondly, as 
both budget and available logistics could afford only a bar minimum of essential drugs, 
these preparations were considered to be of less vital importance60. Vaccines were left 
out because a separate governmental organisation, the "Medical Field Unit" was tak-
ing care of that. 
Statistical data from the inquiry were condensed into a "Complete List of Member 
Institutions of the Church Hospital Association of Ghana"58. The missing figures 
from the non-responding institutions were compiled from annual reports that were 
available from the CHAG Secretariat, derived from careful estimates based on the 
number of beds which was usually known from previous lists and was not likely to have 
changed, and from any other information available to the committee. 
The choices indicated in the two drug lists were worked out separately. The number 
of times a particular drug had been marked was counted and this result was in a later 
stage differentiated for hospitals and clinics. The number of times each drug had been 
marked was expressed as a percentage of the number of respondents and called "pri-
ority-score". 
III.2.2 Results 
The response of 75% to the inquiry is satisfactory, as in general most biases seem to 
disappear when a response rate of 70% or more is achieved195. 
1) Statistical data 
It does not fit within the scope of this paper to present the full 1979 data of all 
CHAG institutions. Instead, the 1979 totals are given in Table 8. The data have been 
used for defining categories of size of the institutions, and for allocating supplies (see 
section III.4). 
Table 8. 1979 Annual figures for 52 CHAG institutions. 
Beds 
Admissions 
Out-patient consultations 
Ante natal controls 
Deliveries 
Major surgery 
3.858 
127.773 
2.555.500 
442.700 
39.000 
12.000 
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Table 9. Results of the 1980 inquiry. 
Number of times drugs were marked as "indispensable" by 39 CHAG institutions, 
differentiated for hospitals and clinics. Priority score expressed as percentage of the 
number of respondents. Drugs not on the WHO list of essential drugs6 in brackets. 
1983 
WHO 
class. 
1.1 
1.2 
2.1 
2.2 
4.2 
5 
6.1 
6.2 
6.3.1 
6.3.2 
Drug 
ether 
thiopentone inj. 
lidocain inj. 2% 
(5% heavy) 
(ketamine inj.) 
aspirin 
paracetamol tab. 
(syr.) 
(APC) 
(phenylbutazone) 
(pentazocine) 
(novamin sulphone inj.) 
morfia/pethidine inj. 
atropine inj. 
diazepam inj. 
phénobarbital tab. 
inj. 
mebendazole 
piperazine tab./syr. 
tiabendazole 
any broad anthelmintic 
metronidazole 
(clioquinol) 
ampicillin cap. 
syr. 
inj. 
bcnz.pen.cr. inj. 
phenoxymeth.pen. tab. 
syr. 
proc.pen. inj. 
chloramphenicol cap. 
(syr.) 
inj. 
sulfadimidine 
(triple sulfa) 
any sulfa 
co-trimoxazole 
tetracycline cap. 
syr. 
inj. 
Absolute score 
(39) 
Total 
14 
11 
8 
11 
11 
23 
18 
12 
4 
4 
— 
18 
25 
9 
18 
24 
3 
17 
14 
15 
27 
17 
6 
28 
14 
7 
21 
15 
11 
29 
20 
18 
7 
11 
16 
21 
8 
27 
11 
(23) 
Hosp. 
13 
11 
8 
11 
11 
10 
7 
2 
2 
1 
— 
10 
22 
9 
12 
14 
— 
12 
6 
7 
18 
10 
2 
18 
5 
6 
16 
8 
4 
14 
12 
9 
7 
3 
9 
11 
5 
14 
2 
(16) 
Clin. 
1 
— 
— 
— 
— 
13 
11 
10 
2 
3 
— 
8 
3 
— 
6 
10 
3 
5 
8 
8 
9 
7 
4 
10 
9 
1 
5 
7 
7 
15 
8 
9 
— 
8 
7 
10 
3 
13 
9 
— 
Priority score 
Total 
36 
28 
21 
28 
28 
59 
46 
31 
10 
10 
— 
46 
64 
23 
46 
62 
8 
44 
36 
38 
69 
44 
15 
72 
36 
18 
54 
38 
28 
74 
51 
46 
18 
28 
41 
54 
21 
69 
28 
(%) 
Hosp. 
56 
48 
35 
48 
48 
43 
30 
9 
9 
4 
— 
43 
96 
39 
52 
61 
— 
51 
26 
30 
78 
43 
9 
78 
22 
26 
70 
35 
17 
61 
52 
39 
30 
13 
39 
48 
22 
61 
9 
Clin. 
6 
— 
— 
— 
— 
81 
69 
62 
12 
19 
— 
50 
19 
— 
37 
62 
19 
32 
50 
50 
56 
44 
25 
62 
56 
6 
31 
44 
44 
94 
50 
56 
— 
50 
44 
62 
19 
81 
56 
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1983 
WHO 
class. 
6.3.4 
6.4 
6.5 
6.7 
6.8 
10.1 
10.2 
12.4 
12.5 
16 
17.1 
17.2 
17.3 
17.5 
18.1 
22 
24 
25.1 
25.2 
26.1 
26.2 
Drug 
nitrofurantoin 
streptomycin inj. 
INH/thiacetazone 
diethylcarbamazine 
griseofulvine 
chloroquine tab. 
syr. 
(inj.) 
(pyrimethamine) 
(niridazolc) 
(stibophen inj.) 
ferrous sulphate 
folic acid 
iron dextran inj. 
Phytomenadion inj. 
methyldopa 
reserpine 
any antihypertensivum 
digoxin tab. 
inj. 
epinephrine inj. 
furosemide tab. 
inj. 
alum.hydrox. tab. 
promethazine tab. 
inj. 
spasmolytic tab. 
antihaemorrhoid supp. 
(laxans supp) 
hydrocortisone inj. 
prednisolone 
crgometrine tab. 
inj. 
either 
oxytocin inj. 
amitryptiline 
chlorpromazine tab. 
inj. 
diazepam tab. 
aminophylline tab. 
inj. 
codeine 
potxhloride 
dextrose 5% inf. 
saline 0.9% inf. 
five other inf. 
Absolute score 
(39) 
Total 
6 
14 
8 
10 
3 
35 
22 
20 
10 
22 
3 
24 
24 
4 
8 
4 
5 
8 
3 
7 
8 
8 
12 
8 
20 
15 
9 
5 
2 
11 
6 
12 
27 
31 
5 
— 
8 
12 
11 
6 
6 
8 
3 
7 
7 
— 
(23) 
Hasp. 
4 
14 
8 
7 
2 
20 
9 
9 
2 
13 
— 
10 
11 
2 
4 
3 
3 
6 
3 
7 
7 
6 
11 
5 
11 
12 
3 
1 
— 
10 
6 
7 
17 
19 
2 
— 
3 
5 
5 
2 
5 
5 
3 
5 
5 
— 
(16) 
Clin. 
2 
— 
— 
3 
1 
15 
13 
11 
8 
9 
3 
14 
13 
2 
4 
1 
2 
2 
— 
— 
1 
2 
1 
3 
9 
3 
6 
4 
2 
1 
— 
5 
10 
12 
3 
— 
5 
7 
6 
4 
1 
3 
— 
2 
2 
— 
Priority score 
Total 
15 
36 
21 
26 
8 
90 
56 
51 
26 
56 
8 
62 
62 
10 
21 
10 
13 
21 
8 
18 
21 
21 
31 
21 
51 
38 
23 
13 
5 
28 
15 
31 
69 
79 
13 
— 
21 
31 
28 
15 
15 
21 
8 
18 
18 
— 
(%) 
Hasp. 
17 
61 
35 
30 
9 
87 
39 
39 
9 
56 
— 
43 
48 
9 
17 
13 
13 
26 
13 
30 
30 
26 
48 
22 
48 
52 
13 
4 
— 
43 
26 
30 
74 
83 
9 
— 
13 
22 
22 
9 
22 
22 
13 
22 
22 
Clin. 
12 
— 
— 
19 
6 
94 
81 
69 
50 
56 
19 
87 
81 
12 
25 
6 
12 
12 
— 
— 
6 
12 
6 
19 
56 
19 
37 
25 
12 
6 
— 
31 
62 
75 
19 
— 
31 
44 
37 
25 
6 
19 
— 
12 
12 
— 
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1983 
WHO 
class. 
27 
Drug 
ascorbic acid tab. 
(inj.) 
retinol 
(multivitamin) 
(vit. B-complex) 
either multiv./BCo 
multivitamin syr. 
vit. B-complex inj. 
Absolute score 
(39) 
Total 
11 
4 
4 
21 
15 
23 
14 
13 
(23) 
Hosp. 
2 
2 
1 
9 
6 
11 
2 
7 
(16) 
Clin. 
9 
2 
3 
12 
9 
12 
12 
6 
Priority score 
(%) 
Total Hosp. 
28 9 
10 9 
10 4 
54 39 
38 26 
59 48 
36 9 
33 30 
Clin. 
56 
12 
19 
75 
56 
75 
75 
37 
2) Drugs for immediate relief 
The list of drugs with priority-scores for "immediate relief' was used as a basis for 
an emergency eight-drug relief plan carried out in 1981-82 with financial support 
from the Netherlands Reformed Church and other donor agencies. As this relief plan 
was strongly innuenced by drug needs at that particular time, it will not be included in 
further discussions. 
3) Indispensable drugs in general 
Results of the inquiry on "indispensable drugs" and the calculated priority scores 
for hospitals and clinics are presented in Table 9. 
These results could not be indiscriminately used to establish a CHAG list of essen-
tial drugs because they were in fact only a reflection of what were felt to be needs that 
were in themselves strongly related to prescription habits. As an essential drugs list 
should be a harmonious entity offering a reasonable compromise between therapeutic 
range, safety, quality and cost, the committee had to "edit" the results of the question-
aire into a useful range of essential drugs. A fine example of a dubious result from the 
inquiry is the fact that Multivitamin syrup had a priority score of 75% in clinics; de-
spite this, it was not included in the final list because of its limited therapeutic value 
and because of cheaper alternatives being available. 
Differentiating the priority scores for hospitals and clinics raised the theoretical 
possibility of three lists of essential drugs: one for hospitals only, one for clinics only, 
and one for both. In practice, hardly any drug emerged exclusively required by clinics 
only so that a two-step essential drugs list could be compiled: 24 drugs for hospitals 
and clinics alike, and an extra 10 for hospitals only. Both lists are presented in Table 
10, in order of total priority score; scores differentiated for hospitals and clinics are in-
cluded. 
III.2.3 Remarks on the choice of drugs 
In this section a rough indication is given of the reasons why certain drugs have been 
choosen by the committee, especially in cases in which choices have been different 
from preferences as expressed by priority scores. 
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Table 10. CH AG essential drugs list, 1981, in order of total priority score. Scores differen-
tiated for hospitals and clinics. Drugs that are not on the WHO list of essential 
drugs6 in brackets. 
WHO 
class. 
6.7 
6.3.1 
6.3.1 
22 
6.3.2 
6.3.2 
5 
10.1 
10.1 
27 
2.1 
6.8 
17.2 
6.7 
2.1 
6.3.2 
6.1 
6.2 
6.3.1 
6.1 
24 
6.3.1 
6.4 
6.7 
2.2 
6.3.1 
6.3.2 
5 
6.3.4 
1.1 
16 
1.1 
6.3.4 
1.2 
Drug 
Standard list (hospitals and clinics) 
chloroquine phosphate tab. 150 mg base 
procain penicillin inj. 4 MU 
ampicillin cap. 250 mg 
ergometrine inj. 0.5 mg/ml 
tetracycline cap. 250 mg 
nitrofurantoin tab. 100 mg* 
phénobarbital tab. 100 mg 
folic acid tab. 5 mg 
ferrous sulphate tab. 200 mg 
(multivitamin/vitamin B-Co tab.) 
aspirin tab. 300 mg 
metrifonate tab. 100 mg** 
promethazine tab. 25 mg 
chloroquine phosphate inj. 200 mg/5 ml 
(novamin sulphone inj.) 
(chloramphenicol syr. 125 mg/5 ml) 
mebendazole tab. 100 mg 
metronidazole tab. 250 mg 
phenoxymeth. penicillin tab. 250 mg 
piperazine tab./syr. 
diazepam tab. 5 mg 
phenoxymeth. penicillin syr. 125 mg/5 ml 
diethylcarbamazine tab. 100 mg 
(pyrimethamine tab. 25 mg) 
Extra hospital list 
pethidine inj. 100 mg/2 ml 
benzyl penicillin er. inj. 1 MU 
chloramphenicol cap. 250 mg 
diazepam inj. 10 mg/2 ml 
streptomycin inj. 1000 mg 
anaesthetic ether 500 ml 
furosemide inj. 20 mg/2 ml 
thiopentone sodium inj. 1000 mg 
INH/thiacetazone tab. 300/150 mg 
lidocain inj. 2% 50 ml 
Priority score 
Total 
90 
74 
72 
69 
69 
65 
62 
62 
62 
59 
59 
56 
51 
51 
46 
46 
44 
44 
38 
36 
28 
28 
26 
26 
64 
54 
51 
46 
36 
36 
31 
28 
21 
21 
Hasp. 
87 
61 
78 
74 
61 
61 
61 
48 
43 
48 
43 
56 
48 
39 
43 
39 
51 
43 
35 
26 
22 
17 
30 
9 
96 
70 
52 
52 
61 
56 
48 
48 
35 
35 
(%) 
Clin. 
94 
94 
62 
62 
81 
69 
62 
81 
87 
75 
81 
56 
56 
69 
50 
56 
31 
44 
44 
50 
37 
44 
19 
50 
19 
31 
50 
37 
— 
6 
6 
— 
— 
— 
* Score for sulfa plus nitrofurantoin 
** Score for niridazole 
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Anaesthetics 
The choice fell on ether and thiopentone sodium, as ketamine was considered to be 
too expensive while quantities needed were very divergent. 
Analgesics 
Aspirin, by far the cheapest, was preferred to paracetamol (four times the price) 
and brand-named preparations (ten times). As injectable analgesic besides pethidine, 
novamin sulphone had to be included in spite of its side effects196 as no reasonable alt-
ernative was available. 
Anthelmintics 
Piperazine for ascariasis and mebendazole for all other worms were chosen. Al-
though not included in the inquiry and by that time hardly known, the committee pre-
ferred metrifonate above niridazole, it being easier to administer and cheaper. 
Antibiotics 
Benzyl penicillin was considered not practical for clinics, requiring six-hourly injec-
tions. Procain penicillin was chosen instead, together with Phenoxymethylpenicillin 
tablets, tetracyclin capsules and a limited quantity of the more expensive ampicillin for 
selected cases. For children penicillin and chloramphenicol syrups were included. For 
hospitals chloramphenicol capsules, streptomycin and benzyl penicillin injections 
were added. 
Chemotherapeuticals 
It was assumed that sulfa was mainly used for urinary tract infections, therefore nit-
rofurantoin was preferred, being cheaper. Basic anti-tuberculosis drugs were included 
despite a rather low priority score; the reason was that the committee was afraid to let 
many on-going therapy schedules be interrupted by a shortage of these drugs. 
Antimalarials 
Nearly all cases of malaria in Ghana could still be treated by chloroquine tabletsI97. 
For cerebral malaria a limited quantity of chloroquine injections was included; the 
quantity recommended was purposely not big enough to give each patient a "strong 
injection". Cloroquine syrup, bitter, bulky and expensive, was left out. Pyrimetha-
mine was included because it was widely used as a prophylactic agent. 
Placebo 
The need for a placebo is universal. Each patient claims a right to medicine and can 
not easily be sent away without it. To prevent the more expensive drugs being given 
out without sufficient indication, multivitamin or vitamin B-Complex tablets were 
considered indispensable as well and included in generous quantities. 
Other drugs 
In a meeting with all pharmacists of CHAG hospitals to discuss the results of the in-
quiry, certain extra suggestions were made; based on these, diazepam tablets and die-
thylcarbamazine tablets were included although their priority score was not very high. 
49 
Drugs left out 
Some of the drugs with high priority scores were left out because they were of limit-
ed therapeutic value or because cheaper and/or safer alternatives were available. All 
drugs left out while priority scores were above 40% for either hospitals or clinics are 
listed in Table 11, together with reason for exclusion. 
Table 11. Drugs with priority scores of over 40% in either hospitals or clinics in the 1980 in-
quiry, which were not included in the CHAG essential drugs list of 1981, in order 
of total priority score. Drugs that are not on the WHO list of essential drugs6 be-
tween brackets. 
WHO 
class. 
6.7 
6.3.2 
2.1 
17.2 
6.1 
6.3.1 
27 
24 
2.1 
1.2 
1.1 
18.1 
6.3.2 
27 
Drug 
chloroquine phosphate syr. 
sulfa tab. 
paracetamol tab. 
promethazine inj. 
tiabendazole tab. 
ampicillin syr. 
(multivitamin syr.) 
chlorpromazine inj. 
(paracetamol syr.) 
(lidocain 5% inj. heavy) 
(ketamine inj.) 
hydrocortisone inj. 
(tetracycline syr.) 
ascorbic acid tab. 
Priority score 
Total 
56 
54 
46 
38 
38 
36 
36 
31 
31 
28 
28 
28 
28 
28 
Hosp. 
39 
48 
30 
52 
30 
22 
9 
22 
9 
48 
48 
43 
9 
9 
(%) 
Clin. 
81 
62 
69 
19 
50 
56 
75 
44 
62 
— 
— 
6 
56 
56 
Reasons why 
excluded 
3 
i) 
2) 
1)2) 
1) 
1) 
2) 
1) 
2) 
1)2) 
2) 
1)2) 
1)2) 
1) Cheaper or safer alternative provided 
2) Limited use 
III.3 Quantification of drug needs 
As funds were promised for a six-month stock of essential drugs f or all CHAG insti-
tutions, it became necessary to quantify drug needs in order to be able to estimate costs 
and to place orders. 
One problem was that the estimated needs of drugs as expressed by respondents to 
the inquiry proved to be very divergent and the accuracy of the information could by 
no means be assessed. In fact the figures were useless. However, in two CHAG hospi-
tals, Agogo and Dormaa-Ahenkro, detailed records were available on patient attend-
ance and drug use. As time was pressing, data from these two hospitals were used to 
estimate drug needs for all CHAG institutions. As this later proved to be an important 
policy decision, a short description of these two institutions should be given. 
Agogo hospital is a 200-bed hospital in the Ashanti hills. It was founded in 1928, is 
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well-equiped and has around eight, in the majority expatriate, doctors of which four 
are specialists. It serves as a referral and training hospital. The author was a member of 
the staff and had in the previous year rationalized procurement and registration of es-
sential drugs so that both a permanent supply and sound book-keeping were guaran-
teed. Dormaa-Ahenkro was, in 1980, a middle-size, 89-bed hospital with three expa-
triate doctors; the hospital was well administered and had a permanent stock of drugs. 
Drug utilization data over the first half of 1980 in Agogo were linked with patient 
attendance over the same period and average drug use per number of out-patient con-
sultations was calculated. These data were later combined with 1980 data from Dor-
maa hospital. 
For several reasons it was decided to link drug use to the number of sick out-patient 
consultations only)*. The first reason was, that the sick out-patient department (sick 
OPD) was considered to be the department where most of the drugs are used, while 
the range of drugs in specialized departments such as CWC and ANC)* is limited, ren-
dering their number useless for purposes of calculating general drug use. A second 
reason was, that it was assumed by the committee that the number of in-patient admis-
sions, ante natal controls and child welfare clinic attendances would be a more or less 
constant fraction of the total OPD. The third reason was that the definition of "admis-
sion" was different in various CHAG hospitals, resulting in such a variation of figures 
in inquiry and annual reports, that data on number on admissions became useless for 
planning purposes)**. The last reason came into being because of a practical problem. 
Drug use in both hospitals was, at central drug store level where it was recorded, not 
differentiated for in and out-patient use as drugs were issued to the pharmacy only, 
from where they were given out to wards or individual patients. Registration of drug 
use at pharmacy or ward level was too incomplete to expect reliable results. 
Results of the 1980 estimates of necessary quantities are presented in Table 14 
which will be discussed in section II1.4. 
III.4 Allocation and distribution 
The committee decided to distribute the six-month stock of essential drugs to all 
CHAG institutions by using prepacked standard kits. The idea was that a certain 
amount of each of the 24 essential drugs be packed together as one " standard unit", in-
tended for both hospitals and clinics; and that another calculated amount of the ten 
extra hospital drugs be packed as an "extra hospital unit" for hospitals only. This 
would differentiate between the drug needs of hospitals and clinics, leaving only the 
size of the institutions to be taken into account. For this purpose all institutions were 
)* The total number of Out-Patient Department consultations (total OPD) consists of sick 
OPD plus Child Welfare Clinic (CWC) and Ante Natal Controls (ANC). Visits for dress-
ings or injections alone are not counted as consultations. 
)* * It was hardly ever recorded in hospital statistics whether patients admitted for a few hours in 
the emergency room were counted as admissions or not; the same applied for short-time 
maternity admissions and hospital-bom babies. 
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divided into four categories of size. These categories were based upon three parame­
ters: number of beds, annual number of deliveries, and annual number of sick out-pa­
tient consultations (sick OPD). The number of beds was chosen because this was a 
constant and therefore a reasonably reliable figure, usually well-documented. This 
figure, however, was not very revealing as to the amount of activity within the institu­
tion: some six-bed clinics treated more patients than some very large hospitals. For 
that reason, two parameters indicating activity had to be included: the number of de­
liveries, because that was usually well-documented, and the number of sick OPD be­
cause of the reasons stated in the previous section which can be summarized by the 
statement that the committee was of the opinion that the number of sick OPD consult­
ations was the most accurate single figure related to drug use.)* 
The parameters ио/used were: number of admissions (see previous section), num­
ber of ante natal controls (of little influence on drug use) and number of major oper­
ations (because of the uncertain definition of "major" and of the unclear relation to 
drug needs, while strongly related to skill and motivation of available manpower and 
therefore liable to fluctuation with time). Definition of the four categories of size 
based on the three parameters is presented in Table 12. 
Table 12. Categories of size for CHAG institutions. 
Cat. 
A 
В 
С 
D 
Beds 
over 150 
100-150 
50-100 
0-50 
OPD per year 
over 100.000 
50-100.000 
20-50.000 
0-20.000 
Deliveries per year 
over 1250 
750-1250 
250-750 
0-250 
The limits between the four categories for each of the three parameters were chosen 
by first taking the median value and then the median of the two resulting sub-groups. 
By this method four more or less equal groups were formed. These limits have not 
been changed since, although in the course of time some individual institutions 
changed category, based on new statistical data. In case of conflicting data (e.g. a clinic 
with few beds but many out-patients) the number of out-patients was the most influ­
ential parameter in defining the final category. 
The ratio of estimated general drug use between the four categories was calculated 
a s A : B : C : D = 1 0 : 6 : 3 : l . This ratio was a working compromise between the ratios 
of the three different parameters)**. 
The 1981 categorisation of the, by then, 54 CHAG institutions is given in Table 13, 
)* It should be noted that in the 1980 inquiry sick OPD attendance had not been separated 
from CWC figures; this was specifically corrected later. 
)** In some cases this ratio was, for practical purposes, changed into 9:6: 3:1. As there were 
no category D hospitals this simplified the ratio between hospitals to 3 :2:1 which is very 
useful for distribution purposes. 
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Table 13. Categorisation of 54 CHAG institutions (1981). 
Total number of distribution units between brackets. 
Hospitals 
Clinics 
Total 
Cat. A. 
(10 units) 
8 (80) 
8 (80) 
Cat. B. 
(6 units) 
15 (90) 
1 ( 6) 
16 (96) 
Cat. С 
(3 units) 
7(21) 
8(24) 
15 (45) 
Cat. D. 
(1 unit) 
15 (15) 
15 (15) 
Total 
units 
(191) 
( 45) 
(236) 
Table 14. CHAG distribution unit, per six months (1981). 
WHO 
class. 
2.1 
5 
6.1 
6.1 
6.2 
6.3.1 
6.3.2 
6.4 
6.7 
6.8 
10.1 
17.2 
22 
24 
27 
1.1 
1.2 
2.2 
5 
6.3.1 
6.3.2 
6.3.4 
16 
Drug 
Standard kit 
aspirin tab. 300 mg 
novamin sulphone inj. 
phénobarbital tab. 100 mg 
piperazine syr. 750 mg/5 ml, litre 
mebendazole tab. 100 mg 
metronidazole tab. 250 mg 
ampicillin cap. 250 mg 
phenoxymeth. penicillin tab. 250 mg 
phenoxymeth. penicillin syr. 60 ml bottle 
procain penicillin inj. 4 MU 
chloramphenicol syr. 125 mg/5 ml, litre 
tetracycline cap. 250 mg 
nitrofurantoin tab. 100 mg 
diethylcarbamazine tab. 100 mg 
chloroquine phosphate tab. 150 mg base 
chloroquine phosphate inj. 200 mg/5 ml 
pyrimethamine tab. 25 mg 
metrifonate tab. 100 mg 
ferrous sulphate tab. 200 mg 
folic acid tab. 5 mg 
promethazine tab. 25 mg 
ergometrine inj. 0.5 mg/ml 
diazepam tab. 5 mg 
multivitamin or vit.B-Co tab. 
Extra hospital kit 
anaesthetic ether, 500 ml 
thiopentone sodium inj. 1000 mg 
lidocain inj. 2%, 50 ml 
pethidine inj. 100 mg/2 ml 
diazepam inj. 10 mg/2 ml 
benzyl penicillin inj. 1 MU 
chloramphenicol cap. 250 mg 
streptomycin inj. 1000 mg 
INH/thiacctazone tab. 300/150 mg 
furosemide inj. 20 mg/2 ml 
Distribution unit 
for six months 
40.000 
500 
3.000 
10 
1.000 
1.000 
2.000 
2.000 
100 
400 
10 
3.000 
5.000 
10.000 
15.000 
300 
10.000 
1.000 
20.000 
10.000 
1.000 
200 
4.000 
50.000 
20 
100 
25 
200 
200 
500 
4.000 
800 
6.000 
100 
with the final allocation of distribution units. The schedule was as follows: a standard 
kit of 24 essential drugs was prepared in such a way that it could serve as a distribution 
unit. A category A institution would receive ten units, a category В six, С would re­
ceive three and D one. 
In total 236 standard units and 191 extra hospital units were necessary. The quan­
tities of drugs used for these standard kits to cover six-month's use in each of the insti­
tutions are presented in Table 14. A certain reserve had been incorporated. These are 
the final quantities that were used for planning all subsequent drug donations up till 
1983. 
III.5 CHAG essential drugs programmes 1981-1983 
Because of various misunderstandings and political problems it was not until the 
end of 1982 that the West German donating agency M1SEREOR gave the final ap­
proval for the six-month's supply of essential drugs. Drugs were ordered according to 
existing plans and supplied and prepacked by the International Dispensary Associa­
tion (IDA) in Amsterdam, The Netherlands. Including a certain reserve, 250 standard 
units and 200 extra units were sent, for a total value of DPI 770.000 (US $ 260.000) 
including packing, transport and insurance. The standard unit was packed in four car­
tons (116 kg), the extra unit in two (52 kg) (see figure 5). The total of 39.400 kg was 
shipped in four containers which arrived two by two in April and June 1983. The car­
tons were stored in the CHAG warehouse in Accra, from where member institutions 
had been requested to collect their share. Within three weeks nearly three quarters of 
the total had been collected. 
Figure 5. The first part of one standard distribution unit in the MISEREOR drug relief plan 
(April 1983). 
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Other donor agencies had, in the meantime, also shown interest in the plans and, by 
november 1982, Christoffel Blind Mission from West-Germany (CBM) had ap-
proved DF1 550.000 (US $ 185.000) for a similar operation. The committee then 
made a clear policy decision: that a six-months stock of drugs was the minimum that 
was worth the effort of prepacking and distribution, and preferred to spend the avail-
able funds on a six-month's supply of less than 34 drugs rather than on an estimated 
four-month's supply of the full 34. For that reason 19 basic drugs were selected from 
the CHAG list to which CBM, being especially committed to ophthalmological care, 
requested that atropine- and tetracycline eye-ointment be added. The committee of 
course agreed to this request to its own advantage as would become evident later. One 
type of kit with these basic drugs was ordered for hospitals and clinics the like. In May 
1983 the 250 units, packed again by IDA and each consisting of three cartons, arrived 
and were distributed through the CHAG warehouse in Accra and through the Dioces-
an Hospital Pharmacy in Kumasi, serving as distribution depot for Ashanti, Brong-
Ahafo, Northern and Upper Regions. By that time the committee and IDA had 
gained considerable experience in packing and handling procedures. Instead of con-
tainers being opened in the CHAG warehouse in Accra and part of the contents sent 
separately to the second distribution depot in Kumasi, separate containers for Kumasi 
alone were prepared by IDA and sent to Kumasi straight from the harbor. 
Special attention should be given here to an elegant and generous operation by the 
Government of the Netherlands in March 1983, when a half a million to a million 
Ghanaians were expelled from Nigeria and flooded all health institutions in Ghana. 
Based on available drug need estimates it was possible, within a matter of hours, to 
draw up a DF1260.000 (US $ 87.000) plan which would supply all CHAG institutions 
with a six-months stock of aspirin, chloroquine, tetracycline and procain penicillin in-
jections. The plan was immediately approved by the Directorate-General for Devel-
opment Cooperation of the Ministry of Foreign Affairs in The Hague and the drugs 
supplied by IDA were quickly flown in. Only a few weeks after the big migration most 
of the institutions had collected their share. 
In the summer of 1983 a big consignment of drugs and other medical materials, 
worth DF11.045.000 (US $ 345.000), was again distributed in the same way. Apart 
from drugs, pharmaceutical materials were distributed to all CHAG institutions with a 
formulating pharmacy, to enable these to prepare a number of essential pharmaceuti-
cal preparations themselves. As well as this, a six-month's supply of dressing materi-
als, X-ray films and -chemicals and plaster of paris was allocated and distributed. 
Of course not all materials could be prepacked. However, the allocation system 
could also be used by dividing a bulk quantity into 250 identical portions, and then 
calling such a portion a "unit". This way a large number of items could be allocated at a 
same time, as the unit size for each item could be calculated. When these unit quantit-
ies were put on a list, institutions could receive or collect a ten, six, three or one-fold is-
sue of these quantities, whether prepacked or not. 
A summary of CHAG Drug Committee activities is given in Table 15. 
Some remarks should be made on the system of "distribution by collection". Ghana 
is administratively very much centralized. In practice this means that nearly all CHAG 
institutions have, at regular intervals, to send staff-members to Accra for reasons of 
administrative procedures, purchases or meetings. It was therefore not a big strain to 
request members to collect their share from Accra where CHAG warehouse, head-
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Table 15. CHAG Drug Committee activities 1980-83. 
1980 
1981 
1982 
1983 
CHAG Drug Committee Activities 
Inquiry hospital statistics; 
Inquiry essential drugs. 
Quantification of drug needs, based 
on data from Agogo and Dormaa; 
Categorization of institutions. 
Inquiry pharmaceutical preparations; 
Inquiry laboratory-techniques/data; 
Second inquiry essential drugs. 
Drug Utilization Study 
Essential drugs 
list in use 
24 standard drugs 
10 extra drugs 
for hospitals 
34 standard drugs 
17 extra drugs 
for hospitals 
Drug donations 
planned 
8 drugs ($ 85.000) 
Netherlands Churches 
34 drugs ($ 260.000) 
Misereor 
21 drugs ($ 185.000) 
CBM; 
34 drugs & med.mat. 
($ 345.000) 
Netherl.govt. 
4 drugs ($ 87.000) 
Netherl.govt. 
Arri-
ved 
Apr 
82 
Apr 
83 
May 
83 
Jul 
83 
Mar 
83 
quarters and resthouse are situated in one compound. From the moment the distribu-
tion depot in Kumasi could be used it was logical to have institutions from the Ashanti, 
Brongh-Ahafo, Northern and Upper Regions collect their share from there, as these 
regions are only to be reached from Accra by means of a road around the Volta lake, 
through Kumasi (see Figure 2). The remaining Western, Central, Eastern and Volta 
Regions are administratively and transport-wise completely orientated towards Ac-
cra. It was only when serious fuel shortages occurred that collection was temporarily 
hampered. In several cases institutions pooled transport. 
III.6 Revision of the CHAG list of essential drugs 
Following further discussions on the essential drugs programme the need arose to 
revise the CHAG list of essential drugs. Some items were considered to be superfluous 
and others missing. In 1982 the committee decided to conduct a second inquiry. This 
time the open method was chosen: all members received a form on which the CHAG 
1981 list of 34 drugs was presented and were requested to comment on the chosen 
items and to suggest drugs they felt were missing. Of the by then 60 member institu-
tions, 38 (63%) returned the form. 
In total 252 suggestions had been made, for 82 new drug dosage forms. All sugges-
tions were marked and counted and drugs mentioned three times or more were con-
sidered for inclusion on the new list. Suggestions were compared with other data: the 
results of the 1980 inquiry ("priority-score", see Table 9); the results of a preliminary 
survey of twelve essential drugs lists from other countries, by then in Ghana available 
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to the committee, and the 1979 WHO list of essential drugs. As a result, 20 drug dos­
age forms were added to the CHAG list, two that had been limited to the extra list for 
hospitals only were moved to the standard list, and three were removed. 
The 22 new drugs are listed in Table 16. In most cases all parameters indicated that 
inclusion was justified. Only two drugs were included that were ио/оп the WHO list of 
essential drugs: ketamine and lidocaine 5% for spinal anaesthesia, having been sug­
gested by many respondents. Two drugs were strongly suggested by respondents, but 
were not included in many other lists: chloramphenicol injection and ampicillin syrup. 
Some drugs were included because they were frequently found on other lists (ergome-
Table 16. Drugs included in the 1983 revision of the CHAG list with reasons for inclusion. 
Drugs not on WHO list6 between brachets. 
WHO 
class. 
1.1 
1.2 
2.1 
4 
6.3.1 
6.3.2 
12.4 
16 
17.1 
18.1 
22 
24 
25.1 
26.1 
27 
Drug 
(ketamine inj.) 
(lidocaine 5% 
heavy inj.) 
paracetamol tab. 
atropine inj. 
ampicillin syr. 
benzath.benz.penic.inj. 
chloramphenicol inj. 
sulfadimidine tab. 
digoxine tab. 
hydrochl.thiazide tab. 
aluminium 
hydroxyde tab. 
prednisolone tab. 
ergometrine tab. 
Oxytocine inj. 
chlorpromazine inj. 
aminophylline tab. 
inj. 
oral rehydr. salts 
retinol (vit.A) 
Sugges­
ted 
in 1982 
inquiry 
7x 
4x 
6x 
3x 
7x 
3x 
8x 
8x 
6x 
5x 
7x 
8x 
7x 
6x 
6x 
3x 
3x 
1980 
hosp/clin. 
prior. 
score 
4 8 / 0 
4 8 / 0 
46/30 
3 9 / 0 
22/56 
3 0 / 0 
48 / 62c 
1 3 / 0 
22/ 19 
26/ 0 
3 0 / 3 1 
9/19 
22/44 
9 / 2 5 
2 2 / 6 
4 / 1 9 
High 
in 
lit." 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On 
1979 
WHO 
list 
For 
hospl 
clin.b 
H 
H 
HC 
H 
HC 
HC 
H 
HC 
H 
HC 
HC 
H 
HC 
H 
H 
HC 
H 
HC 
HC 
To be included in standard list:" 
1.2 
5 
lidocain 2% inj. 
diazepam inj. 
5x 
7x 
3 5 / 0 
52/37 
• 
• 
m 
и 
HC 
HC 
a By that time around twelve essential drugs lists were known to the committee 
b H: for hospitals only; HC: for hospitals and clinics 
с Score for "sulfa tablets" 
d These drugs were already on the list, but for hospitals only 
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trine tablets and retinol). In some cases the 1982 result expressed the need of a drug 
while the 1980 priority score was low (reserpine, digoxin, prednisolone, aminophyl-
line). The committee thought the inclusion of these drugs justified to complete the 
therapeutic range for hospitals. 
The three drugs removed from the list were phénobarbital tablets and chloram-
phenicol- and penicillin syrup. The first was considered superfluous as diazepam was 
on the list; and the two syrups were replaced by ampicillin syrup. Drugs that were not 
included in the new list despite the fact that they were suggested three times or more, 
are listed in Table 17, with reasons stated. 
The new CHAG list of essential drugs was published in August 1983 s9 and is pre-
sented in Appendix 3. It consists of 34 drugs for hospitals and clinics (standard) and 
17 extra for hospitals only (extra). The list has been limited to tablets and injections, 
apart from oral rehydration sachets, excluding vaccines, mixtures, topical prepar-
ations and infusions. The reasons have been stated before (section III.2.1). For these 
items a separate list was used. In 1981 a list of 15 essential pharmaceutical prepar-
ations was drafted by the committee. In the large scale relief programma of the Gov-
ernment of the Netherlands in 1982 funds were allocated to import 31 pharmaceutical 
raw materials necessary for these preparations, which were to be distributed to all 
Table 17. Drugs suggestes three times or more in the 1982 inquiry that were not taken for the 
1983 CHAG essential drugs list, with reasons for exclusion. Drugs not on the 1983 
WHO list6 between brachets. 
WHO 
class. 
2.1 
6.1 
6.3.1 
6.3.2 
6.5 
10.2 
12.3 
16 
18.1 
18.4 
19.1 
Drug 
(phenylbutazone tabs.) 
tiabendazole tabs. 
ampicillin inj. 
cloxaxillin cap. 
co-trimoxazole tab. 
(sulfathalazole tab.) 
griseofulvin cap. 
nystatin tab. 
Phytomenadion inj. 
methyldopa tab. 
propranolol tab. 
furosemide tab. 
hydrocortisone inj. 
oral antidiabetic tab. 
antivenom serum 
Suggested 
on 1982 
inquiry 
3x 
3x 
6x 
3x 
3x 
3x 
3x 
3x 
3x 
5x 
5x 
4x 
6x 
3x 
3x 
Low in 
1980 
inquiry 
• 
• 
• 
• 
• 
• 
• 
• 
Low 
in 
lit.* 
• 
Not on 
1979 
WHO list 
m 
• 
Other 
1) 
1) 
1) 
1) 
1) 
2) 
1) 
3) 
2) 
1) (Cheaper) alternative provided. 
2) Limited therapeutic calue. 
3) Hydrochlorthiazide tablets were preferred because of their antihypertensive effect, being 
cheaper as well. 
* By then around twelve lists were known to the committee. 
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CHAG formulating pharmacies. In 1983 the committee extended this list to 21 items, 
based on data of a separate inquiry. Some items that are usually found on essential 
drugs lists are included in this list instead of in the CHAG essential drugs list. Exam-
ples are iodine tincture, gentian violet, and benzyl benzoate. The list of essential for-
mulations is included in Appendix 4, although discussion of the distribution of pharm-
aceutical raw materials to CHAG institutions falls outside the scope of this study. Oral 
rehydration salts and aluminium hydroxyde tablets have in a later stage been moved to 
the 1983 CHAG list of essential drugs, because these are not bulky and do not need 
preparation. In fact the need for preparation is the distinguishing factor between the 
list of essential drugs and the list of essential pharmaceutical preparations. It should be 
realized that the CHAG lists have been made for practical purposes and that they are 
closely related to the means and possibilities of supply. Infusions have not been in-
cluded because a large and well-organized infusions manufacturing plant is operating 
in Ghana (which has separately been supported by the 1982 Netherlands Govern-
ment relief plan). Moreover, the possibilities to produce infusions in hospital pharma-
cies were too divergent to justify standardised distribution of raw materials. 
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Chapter Four 
DRUG UTILIZATION STUDY 
Г .1 Introduction 
In 1980 the CHAG Drug Committee realized the narrow basis of the drug con­
sumption figures on which all subsequent drug programmes were to be based but had 
to accept it as neither opportunity nor time were available to extend it. However, the 
need for evaluating the accuracy of these estimates was felt and it was later decided to 
perform a country-wide survey to measure actual drug use in as many CHAG institu­
tions as possible. This survey was performed between January and April 1983, before 
the actual relief operations took effect. The combination of the original 1981 esti­
mates based upon material from two hospitals and the 1983 country-wide survey on 
actual drug use can be considered as a prospective study in which a working hypothesis 
(the 1981 estimates) is applied (the 1981-82 relief plans) and results evaluated (the 
1983 survey). It should be stressed that actual drug use was measured during a period 
after the original estimates had been used for ordering the drugs, but before the big 
drug donations arrived in the country. This had been done because drug use could be 
influenced by choice and quantity of the donated drugs. 
Г .2 Materials and Methods 
Г .2.1 Selection 
In 1983 the CHAG had 66 member institutions, which are listed in Appendix 2. Of 
these, 29 were hospitals, 30 were clinics and 5 were Rural Health Programmes)*. 
Clinics and Rural Health Programmes are hereafter taken together as "Clinics". Giv­
en the limitations in time and availibility of petrol 34 institutions could be visited by the 
author and screened if it were possible to use them for administrative research. 
Screening criteria were: a reliable state of records on patient attendance over the pre­
vious years and a reasonably well kept system of stock-keeping in the central drug 
store. Of 34 institutions screened 17 could be admitted to the drug utilization study, of 
which 15 were hospitals and 2 clinics. 
In table 18 this selected group is compared with the total of 64 CHAG institutions 
according to certain criteria. The difference between a hospital and a clinic has been 
)* The two remaining institutions were a babies' home and an orthopaedic centre which are left 
out of consideration. 
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mentioned before)*. The limit between small and large institutions is set at 50.000 
Sick OPD consultations per year)** over the period studied. Data on presence of ex­
patriate (western) staff (for clinics: nurse in charge, for hospitals: doctor) were ob­
tained from the CHAG personnel officer)***. Relation to church (catholic or other) 
was recorded from the CHAG secretariat. 
Tabel 18. Selected group of 17 institutions compared with total group of 64 CHAG institu­
tions with ρ values indicating the probability that the distribution could be attribut­
ed to chance. 
Clinics / RHPa 
Hospitals 
Small" 
Large' 
Ghanaian 
Expatriate 
Catholic 
Other 
Total 
group 
35 
29 
46 
18 
20 
44 
40 
24 
Selected (%) 
2 6% 
15 52% 
9 20% 
8 44% 
6 30% 
11 25% 
13 32% 
4 18% 
Ρ 
0.0001 
0.09 
0.91 
0.27 
a Rural Health programme 
b Less than 50.000 sick OPD consultations per year 
с More than 50.000 sick OPD consultations per year 
As can be seen in the table, for all criteria except one ρ is more than 0.05 which 
indicates that the sample may be treated as a random sample with respect to these cri­
teria. For one criterium however ρ is very small. This indicates that in our sample clin­
ics are under-represented; this is hardly surprising in view of the data. 
Selection of clinics is shown in table 19. Apart from the 15 clinics visited extensive 
information was obtained on seven more, which information made the presence of a 
good administration too unlikely even to merit a screening visit. In total only two out 
of 22 clinics therefore had an administration reliable enough to be included in the drug 
utilization study. The conclusion is therefore that clinics are, by force, under-repre­
sented in this study. 
)* See note page 43 
)** See note page 51 
)*** When a hospital had both Ghanaian and western staff the choice was made by determining 
whose influence was likely to be the strongest on pattern of prescription in the out-patient 
department. 
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Table 19. Seleclion of clinics. 
Ghanaian 
Expatriate 
Total 
CHA G clinics 
13 
22 
35 
Clinics visited 
5 
10 
15 
Clinics selected 
0 
2 
2 
The selection of hospitals according to the two most important criteria has been 
summarized in table 20. The group of hospitals can be considered as a random sample 
of the total (χ2 = 0.811, p>0.3). In the selection 12 in 15 hospitals are Catholic (80%) 
while in the total group this is 23 in 29 (79%). 
Table 20. Selection of hospitals. 
Ghanaian 
Expatriate 
Total 
29 CHAG hospitals 
small* 
5 
11 
16 
large** 
5 
8 
13 
total 
10 
19 
29 
19hosp. visited 
small* 
4 
5 
9 
large** 
4 
6 
10 
total 
8 
11 
19 
75 hosp. selected 
small* 
3 
4 
7 
large** 
3 
5 
8 
total 
6 
9 
15 
* Less than 50.000 sick OPD consultations per year 
** More than 50.000 sick OPD consultations per year 
The conclusion is that the group of 15 hospitals is representative for the total of 29 
CHAG hospitals for the mentioned criteria; it is in particular not so that hospitals se­
lected on the presence of a reliable administration are only found in the group of large 
and/or expatriate doctor hospitals. 
Г .2.2 Institutions and periods studied 
Characteristics of and some statistical data for the selected institutions, according 
to data supplied by the institutions themselves, are presented in table 21. The total 
number of sick OPD consultations in the period studied was 1.593.768; the total num­
ber of OPD consultations was 2.499.613. Some of the hospitals and clinics had out-
stations in which patients were treated by staff with supplies from the institutions; 
these numbers have been added to their respective statistics. 
In principle, drug use in each institution was measured over the administrative years 
1981 and 1982. In two cases the period was extended to early 1983 because adminis­
trative registration of drug use had only started in the course of 1982. In all cases the 
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Table 21. Relevant Statistical data for and characteristics of 17 CHAG institutions selected 
for the Drug Utilization Study. 
Name 
Kpandu 
Adidome 
Akwatia 
Nkawkaw 
Koforidua 
Asikuma 
Agogo 
Maase-Ofinso 
Agroyesum 
Pramso 
Berekum 
Dormaa-Ahenkro 
Duayaw-Nkwanta 
Hwidiem 
Techiman 
Nsawam 
Bolgatanga 
Study 
Period 
81-82 
81-82 
8.82-4.83 
9.81-82 
81-82 
82 
81-82 
9.82-4.83 
81-82 
10.81-3.82 
81-82 
81-82 
81-82 
81-82 
81-82 
81-82 
81-82 
Mths 
24 
24 
9 
16 
24 
12 
24 
8 
24 
6 
24 
24 
24 
24 
24 
24 
24 
Sick 
OPD* 
93.400 
52.125 
94.810 
208.067 
157.893 
51.580 
219.367 
24.883 
49.493 
21.001 
199.127 
117.309 
63.032 
80.204 
107.812 
43.938 
9.728 
cwc* 
30.000" 
18.103 
8.487 
40.463 
50.484 
20.575 
81.592 
3.726 
86.634 
7.501 
53.513 
28.000 
28.683 
62.983 
47.973 
9.831 
43.093 
ΑΝσ 
4.940 
10.092 
15.862 
36.638 
19.377 
21.327 
3.984 
20.669 
3.953 
34.214 
26.203 
14.474 
24.924 
29.483 
11.363 
6.701 
Characteristics 
1 2 3 4 5 
H S G С В 
H S G Ρ С 
H L G С А 
H L E С A 
H L G С В 
H L E С В 
H L Ε Ρ A 
H S G С В 
H S E С С 
H S E С С 
H L E С А 
H L Ε Ρ В 
H S E С В 
H S E С В 
H L G С В 
С S E С С 
С S Ε Ρ D 
1 Η = hospital 
С = clinic 
2 S = small (less than 50.000 sick OPD consultations per year) 
L = large (more than 50.000 sick OPD consultations per year) 
3 G = Ghanaian doctor or nurse 
E = expatriate doctor or nurse 
4 С = Catholic 
Ρ = Presbyterian 
5 CHAG Category of size (see table 12) 
* see note page 51 
** estimate 
study period ended before drug donations arrived. In three cases stock administration 
had only started after the beginning of 1981 ; in one case a certain period of time only 
could be measured. In all, drug use was measured over 333 institution months with an 
average of 19.6 months per institution. 
Г .2.3 Measurement of drug use 
In fifteen institutions stock was administered by means of tally cards on which in 
and out going quantities and stock level were recorded. In nearly all cases drug move-
63 
ments were limited to receiving supplies from outside by purchase or donation and is-
suing them to the pharmacy. This is the reason that no differentiation could be made 
for in and out-patient use as these flows usually separate in the pharmacy only. For our 
study the tally cards were a very useful method of administration as also stock level was 
recorded which clearly indicated periods during which the drug had been out of stock. 
Outgoing quantities were measured. This is the total drug use being the sum of the 
amount of drugs received by the patient (called "drug consumption") and that of 
losses by wastage, pilfering and the like. 
In case the drug having been out of stock for a certain time, usually a number of 
months, it was recorded. When in a later stage drug use was paired with patient attend-
ance this could be corrected. For example: paracetamol had been out of stock in Ago-
go Hospital during two months in 1981 and 1982. The total druguse of 207.000 para-
cetamol in these 22 months can be paired with 22/24 of 322.286 total OPD consult-
ations over 1981-82. This method was used whenever the period of the drug being out 
of stock was not longer than one third of the study period. In the case of longer inter-
ruptions and in certain therapeutic groups it had to be assumed that alternatives had 
been used. For that reason all possible alternatives were measured as well. In the prev-
ious example it could safely be assumed that whenever paracetamol had been out of 
stock, aspirin or another analgesic had been used in stead. It would not be easy to mea-
sure this extra consumption separately. For this purpose separate recordings were 
made of "aspirin plus paracetamol" and "all oral analgesics". In these measurements 
this alternative use has been included. These extra calculations have been performed 
for all therapeutic groups were alternative use could be assumed during periods of 
shortages. As drugs with sometimes different dosage per day have to be added to each 
other, drug use in these cases has been expressed in Defined Daily Dose (DDD)109U4 
when necessary. The use of anthelmintics has been expressed in Defined Curative 
Dose (DCD) which is a necessary modification of the former as the length of the treat-
ment can be different. Whenever two dosages for the same drug had been used, e.g. 
125 mg and 250 mg penicillin tablets, the total quantity was calculated expressed in 
the most common dosage. 
In two cases, Koforidua hospital and Nsawam clinic, no tally cards were available to 
measure the flow of drugs. These institutions could be admitted to the study because a 
complete administrative record of all drugs purchased and received in 1981-82 was 
present. The two assumptions necessary to be made were that stock level at the be-
ginning of 1981 was roughly the same as by the end of 1982 and that no serious short-
ages had occurred in the mean time. Both assumptions seemed valid. 
In thirteen institutions data were collected from the stock administration by the au-
thor himself who by doing so could get an impression of the accuracy. In four cases in 
which accuracy of administration and staff had been assessed at previous visits data 
were accepted that had been compiled by the officer in charge. 
All data were coded and entered into the NAS computer of the Catholic University 
of Nijmegen, Netherlands. Most of the analyses have been performed by especially 
designed computer programmes, some others by available standard programmes. 
Drug use data were related to number of total OPD consultations over the periods 
studied. 
To express the average drug use per 10.000 total OPD consultations over all 17 insti-
tutions the "weighted mean" of the individual results per drug was taken. This 
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Table 22. Average drag use in 17 CHAG institutions over 1981-82, expressed per 10.000 
total OPD consultations, and differentiated for Ghanaian doctor and expatriate 
doctor hospitals. Number of institutions the data are based upon in brackets. Drugs 
not on the WHO list of essential drugs6 in brackets. 
1983 
WHO 
class. 
1.1 
1.2 
2.1 
2.2 
4.2 
5 
6.1 
6.2 
6.3.1 
Drug 
anaesthetic ether 500 ml 
thiopentone sodium inj. 5 g 
(ketamine inj. 200 mg/20 ml) 
lidocain inj. 1-2%, 50 ml 
lidocain inj. 5% heavy, 2 ml 
acetylsalicylic acid, tab. 300 mg 
paracetamol, tab. 500 mg 
paracetamol, syr., liter 
(ac.sal. plus paracet.tab.) 
(phenylbutazone, tab. 200 mg) 
indomethacin, tab. 25 mg 
(other analgesic tab.) 
(all analgesic tab.) 
injectable analgesic, non-opioid 
injectable analgesic, opioid 
atropine inj. 1 mg/ml 
diazepam, inj. 10 mg/2 ml 
phénobarbital, tab. 50-60 mg 
mebendazole, tab. 100 mg 
pipcrazine, tab. 500 mg 
piperazine, syr., liter 
tiabendazole, tab. 500 mg 
(levamisolc, tab. 40 mg) 
(bephenium, tab. 500 mg 
(all anthelmintics, DCDa 
metronidazole, tab. 250 mg 
ampicillin, cap. 250 mg 
ampicillin, inj. 500 mg 
ampicillin, syr. 125 mg/5 ml, 
60 ml 
benzathinebenzylpenicillin inj. 
benzylpenicillin, inj. 1 MU 
Phenoxymethylpenicillin 
tab. 250 mg 
phen.meth.penicillin syr., 60 ml 
procain penicillin, inj. 4 MU 
(benz.pen plus proc.pen inj., DDD)b 
Drug use 
per 10.000 
total OPD 
8 
33 
5 
19 
28 
27.000 
20.000 
13 
44.000 
4.500 
3.500 
5.600 
49.000 
210 
95 
110 
110 
2.800 
1.200 
1.500 
13 
510 
730 
870 
610 
2.500 
6.300 
180 
82 
44 
1.100 
4.000 
8 
390 
440 
Total OPD 
consultations 
(x 1000) and 
number of 
institutions 
the data are 
based upon 
1454 ( 9) 
1114 ( 6) 
894 ( 4) 
1181 (10) 
785 ( 6) 
2301 (16) 
2040 (14) 
354 ( 5) 
2141 (14) 
570 ( 5) 
493 ( 8) 
994 ( 8) 
2141 (14) 
1419 ( 8) 
935 ( 9) 
840 ( 4) 
1613 (10) 
1794 (13) 
760 ( 7) 
1375 (11) 
1379 (13) 
1238 ( 9) 
625 ( 5) 
345 ( 2) 
2380 (16) 
1958 (14) 
2280 (17) 
1504 (12) 
1470 (13) 
568 ( 5) 
2379 (17) 
1825 (16) 
140 ( 2) 
2303 (16) 
2269 (14) 
Ghanaian 
doctor 
hospitals 
10 
15 
0 
34 
36 
32.000 
29.000 
14 
58.000 
8.000 
6.400 
9.100 
66.000 
150 
140 
72 
130 
1.900c 
9.300 
1.900 
21 
1.100 
1.600 
0 
920 
2.500 
9.100 
380 
120 
22 
660 
4.600 
0 
510 
310 
Expatriate 
doctor 
hospitals 
8 
41 
5 
14 
25 
25.000 
16.000 
12 
38.000 
1.400 
2.600 
4.500 
41.000 
210 
79 
110 
110 
3.300 
840 
1.300 
10 
440 
480 
770 
510 
2.600 
5.400 
110 
81 
40 
1.400 
4.000 
8 
330 
510 
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1983 
WHO 
class. 
6.3 2 
6.3.4 
6.4 
6.5 
6.7 
6.8 
10.1 
10.2 
12.3 
12.4 
12.5 
16 
Drug 
chloramphenicol, cap. 250 mg 
chloramphenicol, inj. 1 g 
chloramphenicol, syr. 100 ml 
(sulfa, tab. 500 mg) 
(sulfathalazole, tab. 500 mg) 
(sulfameth.pyridazine, tab 500 mg) 
co-tnmoxazole, tab. 400/80 mg 
co-tnmoxazole, syr. 100 ml 
tetracycline, cap. 250 mg 
(tetracycline, inj. 250 mg) 
(tetracycline, syr. 60 ml) 
nitrofurantoin, tab. 100 mg 
(tetra + ampi + cotrim, tab , DDD) 
tetra + ampi + cotrim, syr., bil) 
(ampi + chloramph , inj., DDD) 
ethambutol, tab. 400 mg 
isoniazid, tab. 100 mg 
nfampicin, cap. 150 mg 
streptomycin, inj 1000 mg 
INH/Thiacetazone, tab. 
300/150 mg 
diethylcarbamazme, tab. 50 mg 
griseofulvin, tab. 125 mg 
chloroquine, tab. 150 mg base 
chloroquine, inj. 200 mg/5 mi 
chloroquine, syr., liter 
(pynmethamin, tab. 25 mg) 
metnfonatc, tab. 100 mg 
(mndazole, tab 500 mg) 
ferrous salt, tab. 200 mg 
folic acid, tab. 5 mg 
iron dextran, inj. 100 mg/2 ml 
Phytomenadione, inj. 10 mg/ml 
methyldopa, tab. 250 mg 
reserpine, tab. 0.25 mg 
(other antihypertens. tab.) 
(all antihypertensiva, DDD) 
digoxin, tab. 0.25 mg 
digoxin, inj. 0.25 mg/2 ml 
epinephrine, inj. 1 mg/ml 
furosemide, tab. 40 mg 
furosemide, inj. 20 mg/2 ml 
Drug use 
per 10 000 
total OPD 
3.800 
210 
65 
5.700 
2.500 
430 
1700 
19 
6.700 
24 
49 
3.000 
1.800 
97 
110 
1.300 
4.200 
360 
710 
4.100 
9.300 
920 
22.000 
640 
15 
6 100 
920 
480 
25.000 
12.000 
130 
54 
1.500 
1.900 
920 
800 
900 
39 
52 
1.300 
72 
Total OPD 
consultations 
(χ 1000) and 
number of 
institutions 
the data are 
based upon 
2158 
1705 
1228 
1799 { 
1159 
185 
1379 < 
221 | 
2239 ( 
601 ( 
624 ( 
1701 ( 
2289 ( 
1563 < 
2269 
401 
651 
401 | 
2170 
1636 
2036 | 
1312 ( 
2253 
2097 { 
1595 ( 
1593 
669 
1381 | 
2201 
1945 
1313 
814 
1502 
1097 
251 { 
1897 | 
1617 
861 
1634 
2034 
1550 
'16) 
[12) 
[11) 
'14) 
;i0) 
'
 2 ) 
И ) 
' 3) 
16) 
5) 
' 7 ) 
12) 
16) 
;i3) 
'14) 
: 2) 
' 4) 
' 2 ) 
,15) 
'12) 
'13) 
'11) 
'16) 
'15) 
'12) 
,11) 
' 5) 
' 8) 
116) 
:i5) 
'10) 
' 4) 
[12) 
I 9) 
i 3) 
[12) 
;io) 
: 6) 
[ 8 ) 
;i3) 
Ί 0 ) 
Ghanaian 
doctor 
hospitals 
5.000 
350 
54 
6.700 
6.400 
0 
1.900 
19 
12.000 
110 
88 
2.400 
2.500 
140 
170 
0 
1.500 
0 
770 
6.300 
8.700 
1.000 
34 000 
1.100 
27 
2.400 
0 
220 
26.000 
18.000 
120 
0 
2.400 
1.200 
930 
810 
2.000 
20 
32 
2.300 
120 
bxpatnate 
doctor 
hospitals 
3 400 
150 
72 
5.400 
1 100 
430 
1.700 
0 
4.900 
18 
9 
3.100 
1.500 
88 
81 
1300 
6 100 
360 
700 
3 400 
9.500 
890 
18.000 
460 
8 
6.600 
920 
510 
26.000 
11000 
140 
54 
1.000 
2 200 
900 
780 
640 
42 
55 
960 
62 
66 
1983 
WHO 
class. 
17.1 
17.2 
17.4 
17.5 
18 
21.1 
21.6 
22 
24 
25 
27 
Drug 
hydrochlorothiazide, tab. 25 mg 
(all diuretics, DDD) 
aluminium hydroxydc, tab. 500 mg 
promethazine, tab. 25 mg 
promethazine, inj. 50 mg/2 ml 
(all antihistaminics, tab.) 
atropine, tab. 1 mg 
(butylscopalamine, inj. 20 mg/ml) 
(laxative tab.) 
hydrocortisone, inj. 100 mg 
prednisolone, tab. 5 mg 
(tolbutamide, tab. 500 mg) 
(antibiotic eye-ointment, 5 g) 
acetazolamide, tab. 250 mg 
ergometrine, tab. 0.5 mg 
ergometrine, inj. 0.5 mg/ml 
oxytocin, inj. 10 lU/ml 
chlorpromazine, tab. 25 mg 
chlorpromazine, inj. 50 mg/2 ml 
diazepam, tab. 5 mg 
(all oral tranquillizers, tab.) 
aminophylline, tab. 200 mg 
aminophylline, inj. 250 mg/10 ml 
ascorbic acid, tab. 50 mg 
retinol, cap. 50.000 U 
(multivitamin, tab.) 
(multivitamin, syr., liter) 
(vit.B-Co, tab.) 
(vit.B-Co, inj. 10 ml) 
(multivit + vit.B-Co tab.) 
(all vitamin tab.) 
Drug use 
per 10.000 
total OPD 
2.200 
1.600 
2.400 
4.700 
67 
5.200 
2.000 
120 
1.500 
44 
4.200 
1.500 
69 
1.600 
1.100 
140 
65 
370 
49 
7.800 
10.000 
2.600 
32 
8.800 
690 
30.000 
13 
22.000 
180 
47.000 
52.000 
Total OPD 
consultations 
(x 1000) and 
number of 
institutions 
the data are 
based upon 
414 ( 2) 
2182 (13) 
831 ( 8) 
1745 (14) 
261 ( 2) 
2055 (15) 
59 ( 2) 
550 ( 2) 
979 ( 8) 
858 ( 6) 
1407 ( 9) 
1270 ( 8) 
526 ( 7) 
451 ( 3) 
1574 (10) 
1805 (14) 
1020 ( 8) 
271 ( 2) 
779 ( 5) 
2182 (14) 
2182 (14) 
947 ( 8) 
1536 ( 9) 
1412 (12) 
667 ( 3) 
2352 (16) 
56 ( 2) 
1823 (15) 
572 ( 2) 
2274 (15) 
2274 (15) 
Ghanaian 
doctor 
hospitals 
0 
1.900 
4.200 
11.000 
64 
11.000 
3.400c 
150 
1.300 
68 
2.800 
1.800 
100 
1.100 
540 
160 
100 
580 
59 
15.000 
16.000 
2.900 
57 
21.000 
0 
35.000 
15 
44.000 
0 
55.000 
64.000 
Expatriate 
doctor 
hospitals 
2.200c 
1.600 
1.900 
2.600 
75 
3.500 
920 
110 
1.600 
37 
4.700c 
1.400 
49 
1.700 
1.200 
140 
49 
300 
46 
5.000 
8.100 
2.500 
24 
5.600 
670 
29.000 
0 
18.000 
180 
45.000 
48.000 
a DCD = Defined Curative Dose 
b DDD = Defined Daily Dose 
с Based upon one or two hospitals only 
"weighted mean" was calculated by relating the total use in all 17 institutions to the to­
tal number of patients treated in the total number of periods in all institutions during 
which the drug had been available. As the result is calculated on the basis of total pa­
tient numbers, larger institutions contribute more to the result than smaller ones. 
Drug use was separately calculated for hospitals and clinics and also for hospitals 
with Ghanaian (GD) and with expatriate (ED) doctors. In all, drug use was measured 
of 94 drug dosage forms and 14 therapeutic groups. 
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IV.3 Results 
Mean use of 94 drugs and 14 therapeutic groups in 17 CHAG institutions over 
1981-82 is presented in table 22, expressed per 10.000 total OPD consultations. In 
view of the standard error of the mean the results are printed in two significant digits 
only. Drugs are listed according to the classification of the 198 3 WHO list of essential 
drugs6. The number of total OPD consultations and the number of institutions the re-
sults are based on, is given for each item. In the right half of the table mean drug use in 
Ghanaian doctor (GD) and expatriate doctor (ED) hospitals is given. 
It is not easy to interpret this table at first sight, yet possible differences in drug use 
between GD and ED hospitals can be analyzed by simply counting the number of 
times the mean use of a certain drug is higher for the one than for the other. Of 81 com-
parable drugs the use is higher in GD hospitals in 57 cases (70%) and in 24 in ED hos-
pitals (30%). Using the sign test this difference is significant (p<0.01). The prelimi-
nary conclusion is that according to this method mean drug use in hospitals with 
Ghanaian doctors is higher than in those with expatriate doctors. 
It is possible to indicate the size of this difference by adding up all different mean 
drug use data. The results can be expressed in monetary units. For this purpose the 
cost of drugs has been introduced, according to the IDA price indicator of February 
1984l78. The mean drug use per 10.000 total OPD consultations can be expressed in 
Dutch guilders (1 DF1 = US $ 0.33) and the total drug costs for all 94 drug dosage 
forms)* of table 22 can be calculated per 10.000 total OPD. Results are presented in 
table 23. 
Table 23. Total cost per 10.000 total OPD consultations of 94 drugs listed in table 22, differ-
entiated for hospitals and clinics and for Ghanaian doctor (GD) and expatriate 
doctor (ED) hospitals. Prices according to IDA price indicator, February 1984l78. 
CHAG institutions 
clinics 
hospitals 
GD hospitals 
ED hospitals 
Number 
17 
2 
15 
6 
9 
Cost per 10.000 total OPD 
DH. 6700.00 
2400.00 
7000.00 
9600.00 
4900.00 
Looking at the table it can be seen that clinics spent per consultation much less on 
drugs than hospitals. Furthermore it can be seen that in GD hospitals the amount 
spent is nearly twice that in ED hospitals. This confirms our preliminary conclusion 
that in GD hospitals more drugs are used than in ED hospitals. 
To analyze which drugs in particular were used in larger quantities in GD hospitals 
some data from table 22 have been combined in table 24 which shows drug use in ther-
)* Totals of therapeutic groups have of course been excluded 
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apeutic groups of which mean use in 6 GD hospitals grossly exceeds that in 9 ED hos­
pitals. It shows that for these therapeutic groups mean drug use perse is higher in 
GD hospitals than in ED hospitals, irrespective of drug choice within the therapeu­
tic groups and irrespective of cost. 
Table 24. Mean drug use per 10.000 total OPD consultations in therapeutic groups in which 
drug use in 6 Ghanaian doctor (GD) hospitals grossly exceeds use in 9 Expatriate 
doctor (ED) hospitals. Number of hospitals the data are based on in brackets. 
WHO 
class. 
2.1 
6.1 
6.3 
6.7 
17.2 
24 
27 
Therapeutic group 
all oral analgesics 
all anthelmintics 
antibioticsb oral 
antibioticsb syrups 
chloroquine 
all antihistaminics 
all tranquillizers 
all vitamins 
Unit 
tab. 
DCDa 
DDD' 
btl" 
tab. 
tab. 
tab. 
tab. 
GD hosp. 
66.000 (5) 
920 (5) 
2.500 (6) 
140 (4) 
34.000 (5) 
11.000 (5) 
16.000 (5) 
64.000 (5) 
ED hosp. 
41.000 (8) 
510 (9) 
1.500 (8) 
88(7) 
18.000 (9) 
3.500 (9) 
8.100 (8) 
48.000 (8) 
Factor 
1.6 
1.8 
1.6 
1.7 
1.9 
3.2 
2 
1.3 
a DCD = Defined Curative Dose 
b Excluding chloramphenicol 
с DDD = Defined Daily Dose 
d btl = botle 60 ml 
Table 25 lists the most striking examples of higher mean drug use with the number 
of hospitals the data are based on and the factor of difference. In the right half of the 
table drug use is expressed in DF1. It can be observed that higher use of ampicillin, 
tetracycline and chloroquine have enormous financial consequences. The total cost 
per 10.000 total OPD consentations for these 20 drugs is DF13700 which is 2.17 times 
the amount spent in ED hospitals. The absolute difference between the two, D R 2000 
per 10.000 total OPD, accounts for 4 3 % of the total difference between GD and ED 
hospitals (table 23). 
In some cases mean drug use is higher in ED hospitals than in GD hospitals. The 
most striking examples have been listed in table 26 with results expressed again in DFL 
As can be seen the total cost difference is D R 500 per 10.000 total OPD. As this is 
much less than the D R 2000 the other way around we can conclude that GD hospital 
preferences are more expensive than those from ED hospitals. 
Additional remarks have to be made on table 22. Some results that have to be inter­
preted with caution as they are based on recordings in one or two hospitals only have 
been marked in the table. Furthermore it can be seen that sometimes in ED hospitals 
other drugs are used as alternative for drugs used in GD hospitals. These alternatives 
are usually cheaper. Examples are: non-opioid analgesic injections compared with 
opioid, phenobarbitone versus diazepam and reserpine versus methyldopa. The latter 
especially is very expensive: per DDD forty times the price of reserpine178. 
For some drugs the mean drug use in GD and ED hospitals is very much the same. 
69 
Table 25. Drugs of which mean use in 6 Ghanaian doctor (GD) hospitals grossly exceeds 
mean use in 9 Expatriate doctor (ED) hospitals, with cost difference. 
Drug use expressed per 10.000 total OPD consultations. Number of hospitals the 
data are based on in brackets. 
WHO 
class. 
2.1 
6.1 
6.3.1 
6.3.2 
6.7 
12.3 
12.4 
16 
17.2 
24 
27 
Total 
Drug 
paracetamol tab. 
tiabendazole tab. 
levamisole tab. 
ampicillin cap. 
inj. 
sulfathalazole tab. 
tetracycline cap. 
inj. 
syr. (btl.) 
chloroquine tab. 
111]. 
syr. (1) 
methyldopa tab. 
digoxin tab. 
furosemide tab. 
promethazine tab. 
diazepam tab. 
ascorbic acid tab. 
multivitamin tab. 
vitamin BCo tab. 
Drug use 
GD hasp. 
29.000 (5) 
1.100 (3) 
1.600 (2) 
9.100 (6) 
380 (5) 
6.400 (4) 
12.000 (5) 
110 (1) 
88 (3) 
34.000 (5) 
1.100 (5) 
27 (5) 
2.400 (5) 
2.000 (3) 
2.300 (5) 
11.000 (5) 
15.000 (5) 
21.000 (4) 
35.000 (5) 
44.000 (4) 
ED hosp. 
16.000 (8) 
440 (5) 
480 (3) 
5.400 (9) 
110 (7) 
1.100 (5) 
4.900 (9) 
18 (4) 
9 (2) 
18.000 (9) 
460 (8) 
8 (5) 
1.000 (6) 
640 (7) 
960 (7) 
2.600 (8) 
5.000 (9) 
5.600 (6) 
29.000 (9) 
18.000 (9) 
Factor 
1.8 
2.3 
3.4 
1.7 
3.5 
5.7 
2.5 
6 
9.8 
1.9 
2.4 
3.4 
2.3 
3.3 
2.3 
4.3 
3 
4 
1.2 
2.4 
Dfl 
Cosí 
GD 
290.00 
87.00 
26.00 
650.00 
240.00 
100.00 
310.00 
70.00 
80.00 
740.00 
120.00 
110.00 
190.00 
16.00 
25.00 
98.00 
80.00 
210.00 
120.00 
150.00 
3700.00 
(Dfl) 
ED 
160.00 
38.00 
8.00 
380.00 
66.00 
18.00 
130.00 
12.00 
8.00 
390.00 
51.00 
33.00 
83.00 
5.00 
10.00 
23.00 
27.00 
56.00 
97.00 
61.00 
1700.00 
Table 26. Drugs of which mean use in 9 Expatriate doctor (ED) hospitals grossly exceeds 
mean use in 6 Ghanaian dortor (GD) hospitals, with cost difference. 
Drug use expressed per 10.000 total OPD consultations. Number of hospitals the 
data are based on in brackets. 
WHO 
class. 
6.3.1 
6.3.4 
6.7 
6.8 
22 
Total 
Drug 
benzylpenicil. inj. 
ethambutol tab. 
rifampicin cap. 
pyrimcthamin tab. 
metrifonate tab. 
ergometrin tab. 
Drug use 
GD hosp. 
660 (6) 
0 
0 
2.400 (3) 
0 
540 (2) 
ED hosp. 
1.400 (9) 
1.300 (2) 
360 (2) 
6.600 (7) 
920 (5) 
1.200 (8) 
Factor 
2.1 
2.8 
2.2 
Dfl 
Cost 
GD 
190.00 
11.00 
13.00 
210.00 
(Dfl) 
ED 
400.00 
91.00 
85.00 
30.00 
77.00 
27.00 
710.00 
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Perhaps the indications for use are so clear that personal preference or prescribing 
habits have no gross influence on total use. Examples are: diazepam injection, me­
tronidazole, streptomycin, diethylcarbamazine, ferrous salt, iron dextran injection, 
anti-hypertensiva, tolbutamide, ergometrine injections and aminophyllin. Tubercu­
lostatics are also used more or less to the same extent; there seems however to be some 
emphasis in ED hospitals on ethambutol and rifampicin. 
Г .4 Discussion and conclusion 
The fact that in clinics much less is spent on drugs than in hospitals, expressed in cost 
per 10.000 total OPD consultations, could have been caused by at least three reasons. 
The most important is that the patient population for clinics is different from that for 
hospitals. In section V.4 it will be shown that for clinics the percentage of "preventive" 
services like CWC and ANC is larger than for hospitals. As these groups require both 
less and cheaper drugs it is logical that drug costs per 10.000 total OPD consultations 
are lower. The second reason is that even in the group of sick OPD consultations pa­
tients visiting a clinic will require or receive less sophisticated and therefore often less 
expensive drugs than patients visiting a hospital and being treated by a doctor. A third 
possible reason is that in a clinic, being smaller and therefore perhaps better manag-
able than a hospital, losses by overprescribing, wastage, pilfering and the like might be 
less. The extent to which each of these factors contribute to the total result falls outside 
the scope of this study. 
The difference in drug use between Ghanaian doctor and expatriate doctor hospi­
tals is striking. It can have been caused by several factors. The first is that general pre­
scription patterns by Ghanaian doctors might be over-generous, drugs being pre­
scribed both in larger quantities and in more expensive dosage forms or alternatives, 
on less stringent indications. Secondly, in GD hospitals training and supervision of 
junior prescribing staff might be less extensive. Thirdly, management, administration 
and control of stock might be less effective in GD hospitals than in ED hospitals in 
which the doctor often is, or at least feels, responsible for drug supplies. A fourth rea­
son might be that the expatriate doctor is perhaps more influenced by thoughts of fu­
ture shortages and is therefore more careful in prescribing. Again, the relative contrib­
utions of each of these factors cannot further be assessed. 
The results of table 22 are the most reliable records currently available of drug 
utilization in Ghana. They record the actual drug use, that is the total drug use with­
in existing patterns of prescription and losses, in seventeen institutions over 2.5 mil­
lion patients contacts. These figures can be used to evaluate the 1981 CHAG drug 
need estimates (section V.3) and to estimate future drug needs. It cannot be proved 
that the figures could be a useful basis for drug need quantifications for other West Af­
rican or sub-Saharan countries, as no comparable studies from other countries are 
available. 
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Chapter Five 
EVALUATION OF CHAG DRUG COM-
MITTEE ACTIVITIES 
V.l Introduction 
In this chapter some of the activities of the CHAG Drug Committee are evaluated. 
The following aspects are discussed: the selection of drugs (V.2); the quantification of 
drug needs (V.3); and the system of allocation (V.4). Evaluation of results in each sec-
tion are followed by a discussion on the methodology. The chapter ends with a sum-
mary of the conclusions (V.5). 
V.2 Evaluation of the CHAG selection of drugs 
V.2.1 Introduction 
In this section the CHAG method of selecting essential drugs is evaluated by com-
paring it with the literature available in December 1983 on the subject of selecting es-
sential drugs (see the summary in section 1.3). The 1981 and 1983 CHAG lists of es-
sential drugs are compared with the list of drugs most frequently found on essential 
drugs lists (1.3.4) and with other lists of essential drugs that have been used as a basis 
for distribution in standard packages (1.6.2). 
V.2.2 Evaluation of results 
In table 27, the 29 "most essential" drugs from table 2 have been listed together 
with the number of times each has been included in 38 lists taken from the literature 
reviewal (1.3.4). Drugs from each of the lists mentioned in table 5 have been tabulated 
together with those from the 1981 and 1983 CHAG lists. As can be seen in the table, 
the 1981 CHAG standard list contains 14 (48%) of the 29 most essential drugs; these 
14 form 58% of the 24 items on the list. The 1981 CHAG total list (standard list plus 
extra hospital list) contains 16/29 (55%) which comprises 47% of the total list. 
These results are poor. Of the six items apparing on at least 75% of all essential 
drugs lists studied, two are missing on the CHAG list; of 18 drugs that appear on more 
than 60% of lists, seven are missing. 
The other lists from table 27 are much more comprehensive. The total lists of Ken-
ya7 and Tanzania8 contain 27 of the 29 most essential drugs, which comprise 71 % and 
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Table 27. 29 most essential drugs as they appear on essential drugs lists used for distribution 
by means of standard packages. 
29 most 
essential drugs 
Score on 
38 lists of 
essential 
drugs 
(nr) (%) 
>. 
e 
ω 
о 
о 
ST υ 
'•б J3 
с S3 
с 
а H 
OQ < 
•О Ό J= 
aspirin tab. 
chloroquine tab. 
iron tab. 
sulfa tab. 
tetracycline tab. 
antibiotic eye oint. 
broad anthelmintic 
oral rehydration salt 
antacid 
cough tab. 
benzyl benzoate 
piperazine 
procain penicillin inj. 
ergometrine 
phénobarbital tab. 
disinfectans 
chloroquine inj. 
vitamin (multi/BCo) 
phenoxymeth.penicil. 
tab. 
folic acid tab. 
lidocain 1-2% inj. 
metronidazole tab. 
benzath.benz.penicil. inj. 
chloroquine syr. 
laxans 
paracetamol tab. 
chloramphenicol tab. 
epinephrine inj. 
gentian violet paint 
38 
36 
34 
32 
30 
29 
28 
28 
27 
26 
25 
25 
25 
24 
24 
23 
23 
23 
22 
22 
20 
20 
20 
20 
20 
19 
19 
19 
19 
100% 
95 
89 
84 
79 
76 
74 
74 
71 
68 
66 
66 
66 
63 
63 
61 
61 
61 
58 
58 
53 
53 
53 
53 
53 
50 
50 
50 
50 
Score of most essential drugs (a) 
(a) as a percentage of 29 
Total number of items on the list (b) 
(a) as percentage of (b) 
15 
52 
15 
100 
21 
72 
21 
72 
34 
62 
22 
76 
51 
43 
24 
83 
73 
77% resp. of their lists. The lists from Southern Sudan54 are made up nearly exclus­
ively of top-scorers, but because they are rather short they contain only 52% and 69% 
resp. of them. The list of Simmonds and Walker107 is adequate. Of all lists, the 1981 
CHAG list has the least correlation with the literature consensus and thus, if literature 
consensus is taken as criterium, it is the least satisfactory. 
A few remarks may be made. Five of the 29 most essential drugs were considered as 
pharmaceutical preparations)* by the CHAG Drug Committee. These are: oral rehy­
dration salts, antacid, benzyl benzoate, disinfectantia and gentian violet. The CHAG 
supplied these items through a different channel and for that reason did not put them 
on the list of essential drugs. When these five are added to the score, the CHAG 1981 
list contains 21/29 (72%) of the most essential drugs. Furthermore, the committee 
improved the list in 1983 and after this review it contained 22/29 of the most essential 
drugs (76%) which comes to 24/29 (83%) when the pharmaceutical preparations are 
included. 
У.2.3 Evaluation of methods 
1) Introduction 
The 1981 CHAG list of essential drugs was compiled by the committee, based on 
the results of the 1980 drug inquiry (III.2.2), dicussions within the committee and 
feed-back with all hospital pharmacists. The CHAG list of essential drugs was revised 
in 1983. Each of these elements will be discussed separately. 
2) The 1980 inquiry 
In preparing the inquiry some mistakes were made. Some drugs were not included 
and could therefore not score. Asa result they were left out of the picture and were not 
considered for the list of essential drugs. These drugs are: antibiotic eye-ointment (lit­
erature score 76%), benzathine benzyl penicillin injection (53%) and laxans (53%). 
The conclusion has to be that wherever use is made of a drug inquiry and a choice is 
offered, this choice should include all possible alternatives. 
Some drugs scored very high in the 1980 inquiry although their literature score is 
low. Some of them were included in the CHAG list: ampicillin (inquiry: 72%, lit: 39% 
and even lower on short lists) and pethidine (inquiry: 69%, for hospital 96%, lit: 
37%). Others that were not included have been listed in table 11. These examples 
show that the results of an inquiry such as this can be different from the consensus in 
literature on essential drugs. The differences could of course express epidemiological 
variations in respect to the country concerned, but this is not confirmed by the kind of 
drugs that were preferred. It is more likely that the differences express a kind of collec­
tive prescribing practice which is not necessarily optimal. The many syrups that scored 
high in the inquiry can be taken as an example. The conclusion is that the results of a 
drug inquiry cannot be used indiscriminately as the basis for a drug programme. 
)* Pharmaceutical preparations are medical products that can easily be prepared locally from 
available and/or imported raw materials, e.g. syrups, ointments and mixtures. 
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3) Drug committee decisions and feed-back 
The committee, which had to make the final decisions on the list of essential drugs, 
made some mistakes. The first mistake was that some drugs that scored high in the in­
quiry were omitted from the list and it later came to light that these drugs scored high in 
the literature as well. These drugs are listed in table 28 with reasons for omission stat­
ed. In 1981, literature on other essential drugs lists was not available to the committee 
and could therefore not be considered while preparing the list. It is to be expected that 
these omissions would not have taken place if literature data had been available. It can 
therefore be concluded that literature on other essential drugs lists contains infor­
mation which is of importance when compiling a list of essential drugs. 
Table 28. Drugs that were omitted from the 1981 CHAG list despite high scores in the 1980 
inquiry and that later proved to have high literature scores. 
chloroquine syr. 
sulfa tablets 
paracetamol tablets 
CHAG 1980 
inquiry 
56% 
54% 
46% 
Literature 
53% 
84% 
50% 
Reasons why excluded in 1981 
expensive, bulky 
replaced by nitrofuration 
expensive 
Table 29. Drugs with low literature scores that were included in the 1981 CHAG list of es­
sential drugs, despite low score in the 1980 inquiry. 
diazepam tab. 
penicillin syr. 
diethylcarbamazine 
pyrimethamin tab. 
anti ТВ drugs 
anaesthetics 
CHAG 1980 
inquiry 
32% 
— 
34% 
— 
37-45% 
18-24% 
Literature 
28% 
28% 
26% 
26% 
21-36% 
28-36% 
Reasons why included 
pharmacists advise 
cheaper than ampicillin syr. 
for Northern Ghana 
pharmacists advise for clinics 
continuity 
essential for operations 
A second mistake was that the committee included in the 1981 list some drugs that 
scored low, both in the 1980 inquiry and in the literature. These drugs are listed in 
table 29. Inclusion of these drugs was based on discussions which took place within the 
committee and also during a meeting with the assembled hospital pharmacists. In part 
these inclusions were the result of this feed-back and were not based on a country­
wide consensus (e.g. in the case of diazepam and pyrimethamin). Diethylcarbamazine 
is the only drug included because of epidemiological variations within he country 
(heavy onchocerciasis in Northern Ghana). The remaining three drugs were included 
purely because of personal preference on the part of the committee. Penicillin syrup 
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was included because of being cheaper than ampicillin syrup, chloramphenicol syrup 
being already on the list. Anti-tuberculosis drugs were included because of a prefer­
ence on the part of the author; their non-inclusion would have hampered the continu­
ous treatment of the ТВ patient and, being in charge of a large ТВ clinic himself, he ex­
perienced marked feelings of compassion towards the ТВ sufferer. Anaesthetics were 
included because they were considered essential to the continued functioning of hos­
pital operating theatres. 
This mechanism of persone! preferences, channelled by the committee as a 
whole, is both necessary and inevitable. It is necessary as a means to adapt the list to 
national or even regional conditions; it is inevitable as a political concession, enabling 
the committee to function at all. In a consultative meeting e.g. with all hospital pharm­
acists, one simply cannot discard all suggestions as useless or as not having been con­
firmed by national consensus. 
4) Discussion 
In general the committee had been wavering between two different approaches. It 
had wanted a list that could be used for both clinics and hospitals, not realizing how 
different these two would be. The result was a list sufficient for use in clinics, although 
pharmaceutical preparations had not been included60. In a later stage these were sup­
plied through a different channel. For hospitals the list was too short. A more or less 
comprehensive list of hospital drugs should contain 60-80 drugs but for the original 
CH AG drug programme this was too expensive. For that reason only life-saving drugs 
could be selected, excluding, as mentioned, the pharmaceutical preparations. 
To summarise it can be said that the 1981 list was made as an essential drugs list, be­
ing a list of drugs considered essential irrespective of cost; yet, at the same time, it was 
to be the basis of a drug programme with budgetary limits. These two objectives had 
not been clearly differentiated from the beginning. The conclusion is that, before 
compiling a list of essential drugs, its objectives in regard to target group (clinic, ru­
ral health or hospital) and aim (restrictive, selective, or budget-limited) should be 
clearly defined. 
5) The 1983 revision of the CHA G list 
The 1983 revision of the CHAG list was based on the 1982 inquiry and on a limited 
literature review of some twelve essential drugs lists, together with the 1979 WHO 
list18. Of the 29 most essential drugs, 13 were not on the 1981 list. Of these 13, three 
had not been included in the 1980 inquiry at all. Only one of these three emerged from 
the 1982 inquiry: benzathine benzyl penicillin. Two others (antibiotic eye-ointment 
and laxans) were suggested only once by respondents and were therefore not included 
in the 1983 list. Of the remaining ten drugs, five were suggested three times or more by 
respondents and were included; two were not suggested at all and therefore not in­
cluded (chloroquine syrup and epinephrine injection) and the last three were pharma­
ceutical preparations, already taken care of through different channels. It should be 
remarked that oral rehydration salts and antacid, although previously separately con­
sidered as pharmaceutical preparations, were now included in the list, facilitating their 
availibility for clinics without a formulating pharmacy. 
After this review in total 22 of the 29 most essential drugs were now on the list 
(76%) which comes to 24/29 (83%) when the pharmaceutical preparations are in-
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eluded. Apart from this, other drugs that score high in inquiry and/or literature have 
been included (see table 16). In fact, some of the previous conclusions had already 
been put into practice and the goal of establishing a list of essential drugs was now 
clearly separated from that of any distribution plan within a limited budget. The final 
drug choice made, however, can still be considered as based insufficiently on literature 
and too much on the personal preferences of a small group. 
Y.3 Evaluation of the CHAG quantification of drug 
needs 
V.3.1 Introduction 
In this section the 1981 CHAG quantification of drug needs is evaluated by means 
of making a comparison with the available literature and also with the results of the 
1983 drug utilization study (section IV.3). 
V.3.2 Evaluation of results 
In table 5 four studies that describe eight essential drugs lists that are being used as a 
basis for distribution of essential drugs by means of standard packages have been sum­
marised. These were the only publications available up to 1984 in which drug needs 
have been quantified for a certain type of health institutions per unit of time and/or 
per number of new patients. The unpublished material of Southern Sudan54, regret­
tably, does not state the number of new patients or consultations for which the estimat­
ed quantities are intended and can therefore not be used. All other quantifications can 
be recalculated into drug quantities per 10.000 "Treatment Episodes", which is the 
unit of comparison proposed by a recent WHO working group on the quantification of 
drug needs (see section V,4,3,5)74. To create a more or less comparable group of lists 
the list for B-dispensaries from Tanzania8, being too short, had to be excluded. The 
five lists that have been used have been indicated in table 5. 
In table 30 estimated quantities of 21 drugs or therapeutic groups that appear on 
most of the lists are presented. To these five lists the 1981 CHAG estimates, including 
those for some pharmaceutial preparations (Appendix 4) and relevant results of the 
1983 drug utilization study (IV.3), have been added. All original figures have been re­
calculated into quantities per 10.000 "Treatment Episodes" which is the same as "to­
tal OPD consultations" in the CHAG concept and "new patients'" in the Kenya and 
Tanzania plans, so that figures are comparable. 
1) Correlation 
The linear relationship between each two columns of the table can be expressed by 
the correlation coefficient r which in case of a positive correlation has a value between 
О (no correlation) and 1 (maximal correlation). The advantage to be gained by mak­
ing use of the correlation coefficient is that it is independent of the scale on which the 
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Table 30. Comparison of estimated drug needs per 10.000 Treatment Episodes between five 
essential drugs lists that have been used f or distribution by means of standard pack-
ages, the 19 81 CHAG drug need estimates used for the CHAG drug programmes, 
and the 1983 drug utilization study. 
Number of consultations 
in original publication 
Multiplying factor 
lidocain 1-2% inj. 50 ml 
aspir. + paracet. tab.D 
antihistaminic tab. 
broad anthelm. 
DCD** D 
piperazin tab. D 
penicill. tab. D 
proc.pen.inj. 
3-4 MU D 
sulfa tab. D 
tetracyclin cap. 
chloroquine tab. D 
iron tab. D 
folic acid tab. D 
bcnz.ac.comp.oint.gram 
gentian violet pow.gr. 
antacid tab. D 
laxans tab. 
antibiotic eye oint. 
tube 5 g. D 
tranquillizer tab. 
antiasthmatic tab. 
oral rehydr.salt.ltr 
vitamin (multi+BCo) tab. 
Simm. & 
Walker 
107 
10000 
1 
22000 
292 
2500 
5000 
300 
6000 
9000 
2000 
9000 
9000 
2500 
200 
5000 
500 
400 
5500 
Moore7·46 
Kenya 
disp. A.c. 
2000 3000 
5 3.33 
10 
17500 23333 
2500 1667 
125 167 
5000 3333 
5000 6667 
500 333 
5000 6667 
5000 
15000 16667 
20000 46667 
10000 16667 
2500 3333 
50 33 
10000 10000 
2500 1667 
250 333 
6000 8333 
5000 5000 
750 667 
5000 10000 
Tanzania8 
disp. A h.c. 
1000 2000 
10 5 
100 100 
12000 17000 
1000 1500 
250 375 
1000 1000 
10000 10000 
500 750 
10000 5000 
10000 5000 
20000 20000 
20000 15000 
10000 5000 
10000 5000 
250 125 
5000 5000 
1000 500 
250 375 
2000 2500 
2000 2000 
2500 2500 
10000 10000 
CHAG 
1981 
estim. 
10000* 
.61 
30 
48800 
1220 
203 
406 
2440 
488 
3050 
3660 
18300 
24400 
12200 
1286 
64 
3050 
1474 
183 
8540 
610 
386 
61000 
CHAG 
drugut. 
study 
10000 
1 
20 
46000 
5200 
200 
1500 
4000 
390 
5700 
6700 
22000 
25000 
12000 
2400 
69 
11000 
2600 
52000 
D Drugs that have been used for comparison in absolute figures (see Table 32) 
* CHAG 1981 estimates were calculated per 10.000 si'cfcOPD consultations. In 1981-82 
61 % of the total OPD consultations were for sick OPD consultations, therefore the multi-
plying factor is 0.61 
** DCD = Defined Curative Dose 
table is presented. Thus, the figures of the original publications could have been main-
tained and the correlation would have been the same. The figures, however, have been 
reduced to the same denominator for ease of general scrutiny and for comparison in 
magnitude. This is discussed later in this section. 
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Table 31 presents the results of the analysis of the correlation between the several 
columns of table 30. In the first line correlation is expressed between the 1981CHAG 
estimates and both available literature and the 1983 drug utilization study (the "ob­
served reality"); in the second line the literature is compared with the drug utilization 
study. 
Tabel 31. Correlation between five essential drugs lists used for distribution by means of 
standard packages, CHAG 1981 estimates and 1983 drug utilization study. 
r = Pearson Coefficient of Correlation. 
CHAG 1981 
estimates 
1983 drug 
util, study 
Simm. & 
Walker107 
r = 0.8480 
г = 0.8401 
Moore 
Kenya7 
disp. A.c. 
r = 0.5564 
г = 0.5864 
г = 0.5554 
r = 0.5822 
Tanzania8 
disp. A A.c. 
г = 0.5409 
r = 0.6045 
r = 0.6819 
r = 0.7314 
1983 
drug util. 
study 
г = 0.9891 
All correlations are highly significant (all p<0.01). The highest degree of correla­
tion is observed between the CHAG 1981 estimates and the 1983 drug utilization 
study (r=0.9891, p=0.000). This proves that the ratio of figures within the CHAG 
estimate shows maximum correlation with that of the observed reality. As men­
tioned above this does not prove anything about the absolute magnitude of the figures. 
Of the five literature studies the 1981 estimates have the highest degree of correlation 
with that of Simmonds and Walker U)7. There is a very high degree of correlation be­
tween the lists of Moore (r=0.9223, not in the table), and these lists correlate very well 
with the lists from Tanzania (r=0.7918, not in the table) which between themselves 
have the highest degree of correlation (r=0.9139, not in the table). Of the five studies, 
Simmonds' and Walker's is the best related to the drug utilization study, followed by 
the one for Tanzanian health centres. 
2) Comparison in absolute figures 
To compare the absolute figures of these series is not easy, as not all drugs appear on 
all lists. However, data from all seven series are available on eleven drugs. These have 
been marked in table 30. For each list the average value of the figures on these eleven 
drugs can be calculated and these averages give some idea of the general level of drug 
quantities used. Results are presented in table 32, in which the result of the 1983 utili­
zation study has been put at 100% for purposes of comparison. 
These figures show that in regard to the average level of drug quantities the CHAG 
estimates are higher than most figures from the available literature. The quantities 
from Tanzania and Simmonds and Walker are generally lower and the health centre 
quantities from Kenya are a bit higher. Very good correlation in average level exists 
between the 1981 estimates and the 1983 drug utilization study; the estimates (and 
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Table 32. Average value of eleven figures indicated in table 30 showing relative level of drug 
quantities in five essential drugs lists used for the purpose of distribution by means 
of standard packages, in the 1981CHAG estimates and in the 1983 drug utiliza-
tion study which is put at 100% for purposes of comparison. 
Simmonds and Walker107 
Moore, Kenya7 disp. 
h.c. 
Tanzania8 disp. A 
h.c. 
CHAG 1981 estimates 
1983 drug utilization study 
A verage value 
5.590 
8.034 
11.894 
8.091 
7.227 
10.322 
10.912 
% 
51% 
74% 
109% 
74% 
66% 
95% 
100% 
the subsequent drug distribution programmes) seem to be around 95% of the ob-
served usage. 
The conclusion is that correlation between the 1981 CHAG drug need estimates 
and five of the available lists from the literature is significant (p<0.01) and is mostly so 
with the study of Simmonds and Walker '()7. The average level of the estimates seems 
to be higher than that given in most of the available literature. 
3) Comparison between 1981 estimates and 1983 drug utilization study 
There is more material available in order to determine whether the correlation level 
in general between the 1981 estimates and the 1983 drug utilization study is really so 
good as suggested by the previous rough comparison. For all 1981 drug needs esti-
mates as listed in table 14, comparable data from the 1983 drug utilization study, 
based on data over 1981-82, are available. As has been mentioned before, the reason 
to perform that study at all was to check the 1981 estimates and the combination of the 
two could even be regarded as a prospective study (section IV. 1). 
The complete comparison is presented in table 33. In a way similar to that in tables 
30 and 32 the average values can be compared. Results are presented in table 34 for 
three groups of figures: the figures for 14 drugs of which the figures are below 1000,28 
drugs with figures below 10.000, and the total group of 33 drugs. This division is desir-
able as otherwise the result would be influenced mainly by the high figures. 
As can be seen the overall correlation in average level is striking. None of the differ-
ences is significant. According to this method the 1981 estimates are similar to the ob-
served usage over 1981 and 1982. In the group of 14 drugs of which smaller quantities 
only are necessary the estimates have been generous. What should be realized is that in 
this group of drugs one often has to work with minimum packing quantities (e.g. for 
ether, thiopentone sodium and furosemide injections). 
The conclusion that the 1981 CHAG estimates show optimal correlation with 
the observations over 1981 and 1982 both in ratio between the values as in average 
level of them is therefore justified. 
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Table 33. Comparison between CHAG 1981 drug need estimates and the 1983 drug utiliza-
tion study concerning 1981-82. 
Drug 
chloroquine tab. 150 mg base 
proc.pen.inj. 4 MU 
ampicillin cap. 250 mg 
ergometrine inj. 0.5 mg/ml 
tetracycline cap. 250 mg 
nitrofurantoin tab. 50 mg 
phénobarbital tab. 100 mg 
folic acid tab. 5 mg 
ferrous sulphate tab. 200 mg 
multivitamin or BCo tab. 
aspirin tab. 300 mg 
metrifonate tab. 100 mg 
promethazine tab. 25 mg 
chloroquine inj. 200 mg/5 ml 
novaminsulphone inj. 
antibiotic syr. 
mebendazole tab. 100 mg 
metronidazole tab. 250 mg 
penicillin tab. 250 mg 
piperazine syr. Itr 
diazepam tab. 5 mg 
diethylcarbamazine tab. 100 mg 
pyrimethamine tab. 25 mg 
pethidine inj. 100 mg/2 ml 
benzyl penicillin inj. 1 MU 
chloramphenicol cap. 250 mg 
diazepam inj. 10 mg/2 ml 
streptomycin inj. 1 g 
anaesthetic ether 500 ml 
furosemide inj. 20 mg/2 ml 
thiopentone sodium inj. l g 
INH/Thiacetazone 300/150 mg 
lidocain inj. 2% 50 ml 
CHAG 1981 
estimates 
unit 
per 6 m 
15.000 
400 
2.000 
200 
3.000 
5.000 
3.000 
10.000 
20.000 
50.000 
40.000 
1.000 
1.000 
300 
500 
200 
1.000 
1.000 
2.000 
10 
4.000 
10.000 
10.000 
200 
500 
4.000 
200 
800 
20 
100 
100 
6.000 
25 
per 10.000 
total OPD" 
18.300 
488 
2.440 
244 
3.660 
6.100 
3.660 
12.200 
24.400 
61.000 
48.800 
1.220 
1.220 
366 
610 
244 
203h 
1.220 
2.440 
12 
4.880 
12.200 
12.200 
244 
610 
4.880 
244 
976 
24 
122 
122 
7.320 
30 
1983 drug util. 
study per 
10.000 treatm. 
episodes 
22.000 
390 
6.300 
140 
6.700 
5.700' 
2.800 
12.000 
25.000 
52.000 
44.000d 
920 
5.200 
640 
210 
170e 
200b 
2.500 
4.000 
17r 
7.800 
9.300 
6.100 
210 
1.100 
3.800 
110 
710 
8 
72 
33 
4.100 
19 
a CHAG 1981 estimates were calculated per unit per six months. Two units per year equates 
10.000 sick OPD consultations per year, so to calculate quantities per 10.000 sick OPD 
they have to be multiplied by 2. Sick OPD was 61% of the total OPD during 1981-82 for 
all CHAG institutions, so to calculate quantities per 10.000 total OPD consultations (= 
Treatment Episodes) they have to be multiplied by 0.61 as well 
b Expressed in DCD (Defined Curative Dose) 
с For sulfa plus nitrofurantion 
d Aspirin plus paracetamol 
e Penicillin, chloramphenicol, ampicillin, tetracyclin and cotrimoxazole 
f Tablets plus syrup recalculated in litres 
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Table 34. Comparison between 1981 estimates and 1983 drug utilization study of averages 
within three groupes of figures from table 33. All differences are not significant 
(p>0.05). 
14 drugs <1.000 
28 drugs <10.000 
33 drugs (total) 
A verage value in 
1981 estimates 
281 (128%) 
2428 ( 93%) 
7050 (101%) 
Average value in 
1983 drug utiistudy 
219 (100%) 
2608 (100%) 
6988 (100%) 
V.3.3 Evaluation of methods 
I) Evaluation of the "consumption-based" method 
The 1981 CHAG drug need quantification has been performed according to the 
"consumption-based" method (1.4.3) measured at central store level. A proper com­
parison with results obtained through the alternatives, the "population-based" and 
the "service-based" or "demand-morbidity" methods is not possible as in Ghana no 
studies of drug need quantification have been carried out in accordance with these 
methods. Moreover, results could not possibly have been obtained as insufficient reli­
able data on quantified epidemiology of diseases and on the coverage of existing 
health facilities are available, and as morbidity statistics from health institutions were 
too fragmentary to be of any use and also as no standard therapy regimens were in gen­
eral use. Because of these factors the use of the epidemiological method in calculating 
drug needs for CHAG institutions has never been a realistic alternative. 
Because of the lack of comparable results the only evaluation that can be made is 
that the results of the 1981 drug need quantification with the "consumption-based" 
method have been excellent as has been proved in the previous section. Yet it is advis­
able to review some of the possible disadvantages of this method and the inaccuracies 
which could occur in its use. 
An initial objection to the use of the "consumption-based" method is that measur­
ing drug use is not the same as measuring drug needs, especially in view of the fact that 
only a fraction of all sick people in a certain area have access to health facilities. This 
"coverage" for Ghana has been estimated at 15-30% івбдэідвв.ім j^g ¿rug needs of 
people not able to attend health facilities have not been measured and as a consequ-
ence total drug needs for the area have been underestimated. 
The answer to this initial objection is two-fold. In the first place, knowing the total 
drug needs for a certain area in the case of a theoretical 100% coverage is not really 
relevant if no facilities are available to treat the patients and to prescribe and dispense 
the drugs. Secondly, the actual coverage is the result of several factors, including not 
only the accessibilitybut also the acceptability of health facilities. It is illusory to think 
that with western style hospitals, clinics, dispensaries and even with village health 
workers a 100% coverage of all potential patients will ever be achieved. Part of the 
population will always choose for alternative forms of medicine. For these two rea-
sons, allocating the total drug supply to meet the needs of a certain area to institutions 
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that have a less than 100% coverage is useless. A proper measurement of drug con-
sumption in well-run health institutions that do not suffer from considerable shortages 
furnishes a good working estimate of projected drug needs for the immediate future 
within the existing coverage of the area. Quantified total drug needs for the area as a 
whole are only useful for long term planning purposes. 
A second objection to the use of the "consumption-based" method is that time var-
iation might occur. In other words, patient numbers and coverage might change so 
that historical measurements of drug use could result in insufficient insight into future 
needs. 
The answer to this second objection is again two-fold. In the first place every predic-
tion of the future is based on the analysis of data from the past, and so are the "popula-
tion-based" method and the "service-based" method. This is, therefore, no particular 
shortcoming in the "consumption-based" method. Secondly, drug use has not been 
expressed as an absolute figure but as related to the number of patients treated. In 
other words, in the case of an increase in coverage or in the event of a marked increase 
in patient attendance an adjustment in drug allocation could follow.)* The rate of drug 
use per patient will not have changed much. In practice, such changes in patient at-
tendance figures would always be relatively slow except in the case of major emergen-
cies such as war or natural disasters. Usually, these slow changes would be covered by 
in-built reserves in the allocated quantities. Examples of such changes are the slowly 
developing resistance of P. falciparum to chloroquine and an increasing incidence of 
schistosomiasis around the Volta Lake. 
A third objection to the use of the consumption based method is that epidemiologi-
cal variations might occur. Drug needs or drug use in one area might not be the same as 
in other areas because of variations in disease pattern and epidemiological data. 
The answer to this objection can be given by asking a counter question: "so the alt-
ernative is to measure the epidemiological incidence of all diseases in all areas?" Al-
though this is the back-bone of the "population-based" and the "service-based" meth-
od, the question is a rhetorical one as this is, of course, impossible in practice. Even if 
national drug needs had been calculated using one of these methods, either these epi-
demiological data would have been collected in a specific study area and would, there-
fore, not be representative of all other patient populations, or the data would repre-
sent a kind of national average in which no provision would have been made for var-
iations between different regions. The ideal of using epidemiological data from all 
areas, resulting in an adapted supply of drugs to each specific patient population might 
be justified but is unattainable in tropical countries. A second point to be made is that 
it remains to be seen whether epidemiological data really differ so greatly in respect to 
area. Although no such data are available to prove this, it is unlikely to be the case con-
cerning the majority of the common "diseases of poverty" against which most of the 
essential drugs are used. Perhaps in some countries some rough differences could be 
observed in different climatological zones e.g. humid lowlands, dry savanna or cooler 
mountain areas. In the Ghana setting the committee could only think of two drugs: 
diethyl carbamazine, because there is much onchocerciasis in the North (this is only a 
)* The additional allocation of drugs in the emergency situation of Ghanaians expelled from 
Nigeria back to their home-country is a good example of such an adjustment (see section 
III.5). 
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quantitative difference as it is also common in the South and as patients frequently tra-
vel to far-away hospitals) and retinol (vitamin A), which is lacking in the common 
food in the North while sufficiently present in the forest area (palm-oil). So even while 
the committee was aware of possible epidemiological variations in drug needs, on the 
final 1983 version of the CHAG list, of 51 drugs only these two were included because 
ofthat reason. It remains to be proved that the necessary range and quantity of essen-
tial drugs to treat the diseases of poverty would be different for other areas of the coun-
try or other West African or even sub-Saharan countries, and in particular that these 
differences would be of a different order than those variations caused by prescription 
habits or by inadequate administration, stock control or supervision. 
A fourth objection to the "consumption-based" method could be that, by measur-
ing drug use, current prescription habits are accepted, while all over Africa these are 
usually sub-optimal3·48·186·200-206. 
The answer is that even when a kind of general prescription level is measured (in 
IV. 3 this has been tried) and if this level is considered to be wrong, the way to change it 
would be by adapting professional and postbasic training to that effect139 and not by 
cutting the drug supply, as this would simply result in the stock being exhausted earli-
er. 
In the African world of thought which does not really care about dead things such as 
drugs or statistics, quantification is a difficult concept: something is, or is not. This is re-
lated to the fact that the African concept of time is different. In Western cultures the 
concept of time is prospective, in non-western cultures it is usually retrospective or cir-
cular. Planning recognizes the concept of there being a future and that one even has a 
grip on it. This type of thought is typically western. The African however is not so con-
vinced that he can influence the future; it does not interest him and he is therefore less 
interested in planning. In practice this means that, in general, the level of consumption 
is hardly ever influenced by the level of stock on hand and that a certain consumption 
pattern will continue until suddenly the shelf is empty. For this reason the level of drug 
allocation will hardly have any corrective effect on prescription patterns. Of course 
some influence is possible, in particular when a limited quantity of selected drugs is 
distributed and at the same time careful re-training on indications for use and standard 
therapy is given. Moreover, in the selection and allocation of drugs some influence can 
be exerted. The committee did so by omitting some drugs from the list although the re-
sults of the inquiry suggested that many institutions preferred to use them (see table 
11). Other drugs were purposely under-allocated e.g. chloroquine injection, ampicil-
lin and various syrups. Still there is sufficient reason to doubt whether the few chloro-
quine injections that were allocated really have been reserved for the vomiting coma-
tose child for which they were meant. 
A fifth objection to using the "consumption-based" method for estimating future 
drug needs is that the figures do not differentiate between consumption by the patient 
and losses due to wastage and theft. 
The answer here runs parallel to that of the previous objection. First, losses and 
theft are very difficult to measure117 while measuring drug use at pharmacy, ward or 
patient level is unpractical if not impossible. Secondly, it is unrealistic to assume that 
allocating quantities exactly sufficient for patient needs would reduce pilfering! In 
view of what was mentioned above these two bear no relation to each other and the re-
sult would only be that stocks would be exhausted earlier. Even within an institution a 
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reduction in or the exact allocation of drug supplies to wards or pharmacy would have 
only a limited effect on pilfering as then the patient would probably receive less than 
prescribed. Corruption and theft are complicated problems117"119 that are not solved 
by simply reducing the supply. This means that it is a realistic approach to estimate 
drug needs based on measurements of drug consumption plus losses (together then 
called "drug use"). 
A sixth and last point has to be discussed here. For both the 1981 estimates and the 
1983 drug utilization study, drug use has been measured at stock level and has been re­
lated to number of patients treated (Ш.З and IV.3). For the CHAG distribution pro­
grammes drug use has been related to number of sick OPD consultations (III.3), in the 
literature to new patients (V.3.2) and in the drug utilization study, in principle, to 
both. As far as measurement of drug use is concerned this makes no real difference. 
The measurement is the same, only the presentation of the results is different. 
Summarising, one can say that for the CHAG the "consumption-based" method 
was the only realistic possibility and that it has given good results. The method as­
sumes negligible epidemiological variations and variations in time; it measures ac­
tual drug use which is the total drug use within existing patterns of coverage, pre­
scription and losses. 
2) Evaluation of the choice of the sample 
We have seen that the results of the drug utilization measurement in the two hospi­
tals used as a basis forthel981 CHAG drug need estimates were more or less identical 
with those from the drug utilization study in seventeen institutions. The question has 
to be discussed as to why this result was so good and whether this could have been an 
effect of pure chance. In other words, could Agogo and Dormaa hospitals have been 
predicted to be representative for the total? 
The criteria for selecting the two hospitals were: a strong hospital management re­
sulting in a sound administration of stores and drug supplies, reliable patient statistics, 
a rational and supervised pattern of prescription by screening nurses, medical assis­
tants and junior doctors, a continuous stock of essential drugs and a reduced risk of ex­
cessive losses. 
As in the drug programmes hospitals were to receive more than three quarters of all 
supplies (table 13) it was logical to concentrate on hospitals when estimating drug 
needs; moreover, as has been mentioned, administration is often less reliable in clinics 
(table 19). For these two reasons the decision to take hospitals as a sample is justified. 
It is not possible to compare the patient populations in the two hospitals with the 
CHAG average, for two reasons: for Dormaa hospital no separate patient attendance 
data for sick OPD consultations and the child welfare clinic are available and in Agogo 
the picture is not clear as big ophthalmological and surgical clinics form part of the 
hospital. Given these limitations some data on patient populations have been summa­
rised in table 35. 
As can be seen from the table, in some respects Agogo and Dormaa hospitals are on 
opposite sides of the CHAG average and the combination could be respresentative of 
the total. 
The next question to be answered is whether the level of drug use in the sample of 
two could have been predicted to be representative for the seventeen. The answer to 
this question presents a problem, because drug use in Ghanaian doctor hospitals has 
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Table 35. Comparison of patient population of Agogo and Dormaa hospitals with averages 
of 22 CHAG hospitals and 44 CHAG institutions from which reliable data are 
available, in percentage of total OPD consultations, over 1981-82. 
Agogo* 
Dormaa 
22 CHAG hosp. 
44 CHAG inst.** 
Stdfc 
OPD % CWC % 
67.7 25.6 
83.1 
64.5 22.9 
61.0 25.7 
ANC % 
6.7 
16.9 
12.6 
13.3 
Total 
OPD % 
100 
100 
100 
100 
Adm. % 
2.5 
6.6 
4.5 
* excluding eye patients 
** hospitals and clinics 
OPD out-patients department 
CWC child welfare clinic / under fives clinic 
ANC ante natal controls 
Adm. admissions 
proved different from that in expatriate doctor hospitals (Г .З) whilst both hospitals in 
the sample belong to the latter group. To what extent this difference is due to a differ­
ent pattern of prescription alone or to a more general difference in management, as 
other factors like store control and theft are also involved, does not fall within the 
scope of this study. Not all the six GD hospitals from the study show signs of overcon-
sumption and some of them are well managed. For this reason the effect on the results 
of a limited number of hospitals with overconsumption in general, be it because of 
overprescription or through other causes, got lost in the material from many more in­
stitutions with rational prescribing practices and reasonable consumption rates. The 
conclusion is that the sample of two has been representative of the seventeen because 
the number of institutions with a deviating pattern is limited; the fact that the institu­
tions with a deviating pattern are to be found mainly within the group of Ghanaian-
doctor hospitals has been sufficient to distinguish this group as being markedly differ­
ent. 
Another bias which might make it likely that the results obtained in two institutions 
would be identificai with those obtained from seventeen is that the first observations 
could have been made within the same selection parameters as the second, i.e. a selec­
ted group of well-run institutions. As has been mentioned in section IV.2.1 this is not 
the case insofar as size, origin of doctors and/or relation to church is concerned. Yet it 
can be expected that the control of drugs and perhaps even the prescription habits are 
less careful in the less well-administered hospitals and that, for that reason, losses and 
overall drug use might be higher. No procedure exists to measure this as the reliable 
administration necessary to check it is the very thing that is lacking. When the total 
functioning of these institutions is considered to be sub-optimal, it is défendable to 
omit them from the survey and concentrate on data collected from well-administered 
and better functioning institutions. In using the data from these institutions as a basis 
for estimating future drug needs the criteria established to select these institutions 
have set something of a "standard". In the process of actually choosing the sample it 
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is difficult to separate the two objectives, "representativity" and "desirability", and 
in practice the latter will also be of influence. 
3) Conclusion 
Data from a carefully chosen sample of two hospitals, selected on a basis of good 
management, sound administration of stores and drugs, reliable statistics on pa­
tient attendance, continuous supply of essential drugs and limited chance of exces­
sive losses, were found to correspond closely with the data from a group of fifteen 
hospitals and two clinics over the following two year period; this group of seventeen 
institutions can be considered as representative for the total of the 66 CHA G insti­
tutions. 
Y.4 Evaluation of the CHAG allocation system 
V.4.1 Introduction 
In this section the results of the CHAG system of allocation are evaluated by com­
paring quantities actually allocated with actual average drug consumption in each of 
seventeen CHAG institutions. The method of allocation will be evaluated by discuss­
ing the parameters used for dividing institutions into four categories of size. 
У.4.2 Evaluation of results 
/J Results 
For each of the seventeen institutions for which the average drug use was known 
from the drug utilization study (IV.3), six month quantities to be allocated had been 
calculated by multiplying drug quantities from the distribution unit (table 14) by one, 
three, six of ten according to category of size (tables 12 and 21). Combining these fig­
ures of allocated drug quantities with the individual average drug use per 10.000 total 
OPD consultations as known from the drug utilizations study and with the average 
number of patients over 1981-82 made it possible to calculate for each of the institu­
tions and for each drug the number of months for which the allocated quantity would 
be sufficient, assuming that the rate of drug use after receiving the drugs would be the 
same as the rate measured in the drug utilization study over 1981-82. 
For each institutions these results have been expressed in number of drugs sufficient 
for at least four, six, nine or eighteen months. In table 36 these data have been present­
ed. As can be seen, 430 drug use data are available from seventeen institutions with an 
average of 25.3 per institution. 
Of these 430 drug use data, 344 (80%) show that the quantity was sufficient for 
four months. 282 (66%) drug quantities were sufficient for six months and 194 (45%) 
for more than nine months. The margins of acceptability around the target of six 
months could be set at four and nine months. In this case the difference between 80% 
and 45 %, that is 3 5 %, is the percentage which can be considered to have hit the target. 
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Table 36. Number of months that drugs allocated to last for six months would actually be suf­
ficient, based on drug use and patient attendance statistics over 1981 -82 for 17 in­
stitutions. 
CHAG 
Cat. 
A 
В 
С 
D 
Institution 
Akwatia 
Nkawkaw 
Agogo 
Berekum 
Kpandu 
Koforidua 
Asikuma 
Maase-Ofinso 
Dormaa-Ahenkro 
Duayaw-Nkwanta 
Hwidiem 
Techiman 
Adidome 
Nsawam 
Agroyesum 
Pramso 
Bolgatanga 
total 
% 
Number of 
drug data 
available 
7 
24 
32 
30 
28 
24 
29 
30 
32 
23 
27 
30 
24 
18 
31 
28 
13 
430 
100% 
4 m 
6 
17 
30 
23 
16 
19 
28 
23 
27 
19 
25 
23 
14 
17 
21 
23 
13 
344 
80% 
Drugs to last 
6 m 
4 
11 
23 
22 
10 
17 
25 
17 
24 
15 
23 
18 
9 
16 
19 
19 
10 
282 
66% 
9m 
2 
6 
10 
15 
7 
13 
16 
11 
17 
14 
19 
13 
9 
13 
15 
11 
8 
194 
45% 
18 m 
3 
4 
10 
5 
4 
7 
6 
8 
6 
9 
6 
— 
4 
9 
7 
5 
93 
22% 
(%) 
atom 
57% 
46% 
72% 
73% 
36% 
71% 
86% 
57% 
75% 
65% 
85% 
60% 
39% 
89% 
61% 
68% 
77% 
For 93 allocations (22%) the ball went far over the goal with allocated drug quantit­
ies lasting for over eighteen months. 
Within the existing variation of drug use in all the institutions these results are very 
acceptable. Twothirds of the drugs have been allocated in sufficient quantities. 
In general a slight tendency to over-allocate can be observed: only 20% of drugs 
have been under-allocated while 45% lasted for over nine months. However, only 
22% were really overallocated in such a way that expiry dates might start to play a role. 
Both under and over-allocating will be discussed separately. 
2) Under-allocating 
In three hospitals less than half of the allocated quantities of drugs could be expect­
ed to be sufficient for six months (see table 36). These are: Nkawkaw, Adidome and 
Kpandu hospitals. Nkawkaw is a very large and busy expatriate doctor hospital with 
an average of 133.170 sick OPD consultations per year recorded over 1981-82, which 
is the highest number of all the CHAG hospitals. Although receiving the maximum 
(ten unit) allocation of drugs this apparently has not been enough. Overprescribing 
might constitute an aggrevating factor. Kpandu and Adidome are both Ghanaian-
doctor Ghanaian management hospitals with extremely high levels of drug use. Adi-
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dome with an average of 26.062 sick OPD per year over 1981-82 is rightly placed in 
distribution category С but Kpandu with an average of 46.700 received the benefit of 
the doubt and has been placed in category В meant for 50-100.000 sick OPD per year 
(table 12). The observation that these two have been rather under-allocated is of 
course related to the observation that their drug use was extremely high)*. Apart from 
these two there is a third Ghanaian doctor hospital with a high level of drug use. This 
hospital, Maase-Ofinso, ended up with only 57% of the allocated drugs being suffi­
cient for six months. However, with an average of 35.516 sick OPD per year recorded 
over 1981-82 it is extremely well off in category В so that in this case we have to con­
clude that over-allocation has partly compensated for severe over-consumption. 
Summarising one can say that of three hospitals with high consumption levels, two 
have been put into higher categories than their number of annual sick OPD patients 
would have justified thus allocating to them relatively generous quantities of drugs. 
Even then for one of these two and also for the one that was not "up-graded" actual al­
location was not enough within the existing rate of drug use. Apart from these and the 
one extremely big hospital that was already receiving the maximum allocation, for all 
hospitals allocation has been sufficient for most drugs. In general, the CHAG system 
of allocation of drugs has achieved the result that two thirds of the drug allocations 
have reached the original objective of a six months supply, with a tendency to over-
allocating. 
3) Over-allocating 
It is advisable to have a closer look at the group of drugs that, in practice, were great­
ly over-allocated. For this purpose, for each drug the number of times it appeared in 
the group of "over eighteen months" in table 36 was counted. Drugs that appeared 
five times or more are listed in table 37. Of each of these the ratio between the quantity 
allocatedper 10.000 total OPD consultations (second column in table 33) and the av­
erage use per 10.000 total OPD for all seventeen institutions over 1981-82 (third 
column of table 33) is given. This ratio is called "over-allocation ratio" and drugs are 
listed in descending order of this ratio. 
Before commenting on individual examples some general observations can be 
made. 
There is of course a parallel between drugs having been over-allocated as listed in 
table 37 and the ratio of over-allocation as derived from the comparison between the 
1981 drug allocation and the 1983 drug utilization study (table 33). Of six drugs in 
which the ratio between allocation and average use is more than 2.0, five appear again 
in table 37 as having been overallocated in at least five institutions. While this could 
have been expected, the fact is striking that, of six drugs or therapeutic groups that 
have been mentioned in table 29 as drugs selected by personal preference or commit­
tee decisions rather than being supported by results of the 1980 inquiry, four re-ap­
pear in table 37 as drugs having been greatly over-allocated! This shows that drugs for 
which no general needs emerged from the inquiry were, indeed, hardly used outside a 
few institutions. This shows that there is a relation between the rate of drug use and the 
selection of drugs because extreme below-average drug use may indicate low priority. 
)* This observation was made during the drug utilization study. Specified data on drug use in in­
dividual hospitals could not be included in this book. 
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Table 37. Drugs that were greatly over-allocated to at least five of seventeen CH AG institu­
tions with ratio of average over-allocation and analysis of underlying decision. 
Drug 
antibiotic eye-ointment 
thiopentone sodium inj. 
novamin sulphone inj. 
anaesthetic ether 
pyrimethamin tab. 
ergometrin inj. 
antibiotic syr. 
diethylcarbamazine lab. 
pethidin inj. 
D 
D 
D 
D 
D 
Over-
alloc 
ratio* 
5.32 
3.69 
2.86 
2.67 
2.01 
1.74 
1.43 
1.31 
1.14 
Decision 
influenced by 
comm**/CBM*** 
comm. 
46% inq. '80 
comm. 
comm/phar 
69% inq. '80 
comm.choice 
comm./pharm. 
96% inq. '80 
Comment on decision 
CBM advise; no data available 
by then to estimate the needs. 
allocation (and choice?) 
based on Agogo consumption 
pattern (surgery?). 
; 
apparently use in Agogo and 
Dormaa is not representative 
for other institutions. 
pen.syrup: 10-15 χ too much 
chl.phen. 1.9 χ too much 
epidemiological variation. 
no reliable data available; 
variation in consumption rate? 
D Drugs that were mentioned in table 29 as being selected without support from the 1980 
inquiry 
* Over-allocation ratio is the ratio between the actual allocation and the average use per 
10.000 total OPD consultations (see table 33) 
** comm. = drug committee decision not supported by results from the 1980 inquiry 
** CBM = Christoffel Blind Mission who donated essential drugs valued at DM 500.000 on 
the condition that antibiotic eye ointment should be included 
The two drugs that were included in the 1981 list of essential drugs with low scores 
both in the 1980 inquiry and in the literature, that did лог reappear as being greatly 
over-allocated, are diazepam, which was under-allocated and tuberculostatics that 
were mildy over-allocated. In all other cases the selection of drugs from table 29 was 
not justified, or at least not in the quantities that were finally allotted. 
Coming back to table 37 some of the items will now be discussed separately. The 
case of the antibiotic eye-ointment seems clear: the committee made the mistake of 
not including it in the 1981 list, after having forgotten to include it in the 1980 inquiry; 
this mistake was corrected by CBM when donating a large quantity of essential drugs 
on the condition that antibiotic and atropine eye-ointments would be included; the 
necessary quantities were only roughly estimated as by then no reliable data were 
available, and too much was put into the basic distribution unit. However, there is an­
other side to this mistake: the author, who was by then the only medical officer on the 
committee, hardly ever saw an eye-patient, as attached to the Agogo hospital there is a 
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big eye department with two ophthamlologists in attendance. This explains in part 
why the need for the selection of an antibiotic eye-ointment could have escaped the at-
tention of the committee; moreover, as the operation of the eye department is com-
pletely independant from the general hospital, no consumption data on eye-ointments 
appeared in the general Agogo store records and this is an additional reason as to why 
they might have been lost sight of. 
A somewhat similar thing happened in regard to the anaesthetics. Perhaps the au-
thor had unconsciously in mind the role anaesthetics and novamin sulphone injection 
play in Agogo with its big specialist surgical department, and this might have been an 
extra reason to include these borderline drugs in the 1981 CHAG list. Certainly the 
higher rate of consumption in Agogo pushed up the quantity that was chosen for the 
basic unit, although the existence of fixed, rather large minimum packing quantities 
was also a factor. 
These examples show that a hospital with specialist departments constitutes a bias 
when measuring drug utilization with the intention to estimate drug needs for a group 
of non-specialist institutions. 
The case of the antibiotic syrups also needs some explanation. For economy's sake 
penicillin and chloramphenicol syrup were chosen for the 1981 list; this was based on 
the assumption that, in many cases, ampicillin syrup could be replaced by the much 
cheaper penicillin with the chloramphenicol syrup on hand for serious cases. How-
ever, the use of penicillin proved to be extremely low and informal contacts with mem-
ber institutions revealed that prescribers were not happy with it. This is an example 
which illustrates that changing prescribing patterns from above is not easy. The deci-
sion to exchange the two syrups for ampicillin on the 1983 list seems to have been justi-
fied. 
To summarise, the committee's personal choices as shown in table 29 have been 
of limited value. A specialist hospital is not an optimal basis on which to estimate 
the drug needs of a group of non-specialist institutions. 
Y.4.3 Evaluation of methods 
1) Introduction 
Discussing the results of the CHAG system of allocation we have already slipped 
into discussing some of the methods used. 
In general one can say that the results have been acceptable, with at least two thirds 
of the drug quantities being sufficient in view of the objectives set. Though the results 
as they stand are acceptable one may still attempt to evaluate the methods used and see 
whether any lessons can be learned from them. It might even be the case that satisfac-
tory results were achieved despite serious errors in the methodology. The issue to be 
discussed can be summarised as follows: effectivity being established, how was the ef-
ficiency? In other words, could we have done better or could we have arrived at the 
same results with less effort? 
The main elements of the method of allocation, it will be recalled, where the distrib-
ution of supplies in standard packages and in specified quantities according to catego-
ries of size. These categories have been defined within three parameters: number of 
beds; annual number of sick OPD consultations; annual number of deliveries (table 
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12). The reasons for choosing these parameters have been given in section III.3. We 
will first try to evaluate the use of these categories by discussing the selection of par­
ameters for hospitals and clinics. Secondly, the use of only four categories of size will 
be evaluated. 
2) The selection of parameters for hospitals 
Each parameter used should ideally express a clearly defined separate factor in the 
rate of drug use. To evaluate the parameters to this criterium would require more 
specified data on drug consumption as related to various categories of patients (e.g. 
out-patients, in-patients, preventive services etc) than the drug utilization study can 
offer. The reason for these data not being available, as has been mentioned before, is 
that drug use was measured at the central drug store level of which drug flow to differ­
ent categories of patients cannot be measured separately. 
Table 38. Statistical data for 14 CHAG hospitals for which complete and reliable data over 
1981 and 1982 are available. For comparison data on 19 CHAG clinics over 1982 
have been added. 
Total OPD consultations 
χ 1000 
Av.number of beds per 
institution 
Av.number of total OPD consultations 
per year 
% Sick OPD 
Beds per 10.000 total OPD 
Beds per 10.000 sick OPD 
Av.number of admissions per year 
% Admissions per total OPD 
% Admissions per sick OPD 
Admissions per bed per year 
Av.number of deliveries per year 
% Deliveries per total OPD 
% Deliveries per sick OPD 
8 large 
hospitals 
2 044 
151 
128 000 
71%* 
12 
17 
5 000 
3.9%·· 
5.5%··' 
33 
1360 
1.5% 
1.1% 
6 small 
hospitals 
725 
101 
58 000 
58%' 
17 
30 
3 700 
6.5%·* 
11.0%··· 
37 
620 
1.8% 
1.1% 
19 
clinics 
1170 
15 
62 000 
59% 
2.4 
4.1 
525 
1.5% 
1.1% 
* significant (p<0.02), Students t-test: t=2.728 
** significant (p<0.01), Students t-test: t=5.183 
*** significant (p<0.01), Students t-test: t=3.518 
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Another procedure which could be used to establish the effectivity of the parame­
ters is to analyze whether the figures in some categories of patients might be related to 
each other. The method of evaluation used here will be to survey all categories of pa­
tients insofar as they have been differentiated in CHAG statistics and to see whether 
their effect on drug use has been sufficiently expressed in the choice of parameters. 
The first question to be answered here is whether it was justified to omit the parame­
ter "in-patients" or "admissions", the reasons for which were that the recorded figures 
were unreliable because its definition is subject to variation and that the actual number 
of admissions, when strictly defined, would be a more or less constant fraction of the 
number of out-patients (III.3). 
To check on the veracity this assumption the hospital statistics of 14 CHAG hospi­
tals that were both reliable and complete over 1981 and 1982 have been combined. 
The group has been divided into smaller and larger hospitals with 50.000 sick OPD 
consultations per year as the limit between the two groups (table 38). 
Three main differences can be observed. The first difference is that smaller hospi­
tals show a lower percentage of sick out-patients than larger hospitals (58% versus 
71%). This difference is significant (p<0.02). In other words, in smaller hospitals a 
larger proportion of the total out-patient numbers is accounted for by "preventive" 
services such as child welfare clinic and ante natal controls. A second observable dif­
ference is that in smaller hospitals the bed/OPD ratio is higher than in large hospitals 
(17 versus 12). This means that in smaller hospitals more beds are available in relation 
to fewer OPD patients. The third observation to be made, which is related to the sec­
ond, is that in smaller hospitals the number of admissions is 11 % of the sick OPD num­
ber as compared to 5.5% for larger hospitals. This difference is also significant 
(p<0.01). This means that in smaller hospitals a larger proportion of the sick out-pa­
tients is indeed admitted. 
The result of these differences between smaller and larger hospitals is that smaller 
hospitals have per number of sick OPD both relatively more preventive services and 
more admissions. The choice of taking sick OPD as a measure for drug consumption 
seems therefore not a fair one as it puts smaller hospitals in a disadvantageous posi­
tion. 
To reflect in brief on the practice of the CHAG system, the effect has not been dra­
matic as in many small hospitals the relatively high number of beds (when compared to 
OPD) has resulted in the up-grading of the hospital to a higher category, especially in 
upgradings from В to C. This shows that the number of beds has been a more import­
ant factor than the committee ever realized. 
The conclusion is that sick OPD is not a fair criterium for estimating drug needs 
as it puts smaller hospitals in a disadvantageous position. This effect can be comp­
ensated for by taking as well the number of beds as a criterium. 
We can ask ourselves whether the total number of OPD consultations would be a 
better parameter than the number of sick OPD consultations. The smaller hospitals 
have a lower percentage of sick OPD (58%) and a higher percentage of admissions 
(6.5%) while the larger ones have a higher proportion of sick OPD (71%) and relat­
ively fewer admissions (3.9%). If categories of size and therefore drug allocation 
would be related to total OPD the smaller hospitals would have proportionately more 
admissions and the larger ones would have proportionately more sick OPD. As both 
admissions and sick out-patients are likely to need more drugs than the average "total 
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OPD" patients these extra claims on supplies could at least compensate each other. In 
other words, an imaginary extra reserve would then, in smaller hospitals, be used for 
the extra proportion of admissions while in larger hospitals it would be necessary to 
meet the needs of the extra proportion of sick OPD consultations. 
An attempt can be made to estimate the degree to which these two effects could 
compensate each other. Per 100 total OPD consultations the difference in drug use of 
(71-58) patients, being the extra number of sick out-patients in larger hospitals, 
should ideally be compensated for by that of (6.5-3.9) extra patients being admitted in 
smaller hospitals. This would be the case when an admitted patient would need 13/ 
2.6 = 5 times as many drugs as an out-patient. This is not an unreasonable assumption, 
so we can state that whenever total drug needs are related to the total number of out-
patient consultations the effects of proportionately more admissions in smaller hospi-
tals are more or less compensated for by those of proportionately more sick out-pa-
tients in the larger hospitals. 
The conclusion is that when no other parameters are used the total number of 
out-patients ("total OPD") is a better parameter for estimating drug needs than the 
number of sick out-patients ("sick OPD"). 
We will now concentrate on the question whether the number of admissions would 
not be a better parameter to express in-patient care than the number of beds. It should 
again be stressed that the data on the number of admissions have to be used with cau-
tion. 
We have seen that in smaller hospitals a larger proportion of sick out-patients is ad-
mitted than in larger hospitals. This difference was significant (p<0.01). This means 
that the number of admissions is insufficiently expressed by taking the number of sick 
out-patients as a parameter. Therefore, in one way or another, in-patient care has to 
be translated into a separate parameter. 
The CHAG has done this by taking the number of beds into account. As the num-
ber of admissions per bed is more or less the same for smaller and for larger hospitals 
(see table 38) this seems to be not a bad approach. The lack of reliable data on admis-
sion numbers prevents any further conclusions on the question as to whether this was 
the best possible decision. No hard evidence is available to prove that one of the two is 
better. The observation that the number of admissions is an unreliable figure, as no 
straight definition of "admission" exists, remains valid although it cannot be further 
tested. As for smaller hospitals both number of admissions and number of beds are 
higher per number of out-patients, it probably does not make much difference which 
of the two is considered as a parameter. In this situation secondary criteria start to play 
a role. As the number of beds is the more uniform, the more stable and the better 
verificable it seems a more easy and reliable parameter to use to estimate the role of 
in-patient care in quantifying drug needs than the number of admissions. 
There remains a brief discussion on the remaining categories of patients. The num-
ber of child welfare clinic attendances is badly correlated to any other category of pa-
tients. In a group of 41 CHAG institutions with reliable relevant statistics over 1982 
no significant correlation with any other category of care could be established. A rea-
son for this might be that the term child welfare clinic or under-fives clinic is not very 
well defined. Are these only healthy children under five or simply all consultations in-
volving children under five, including the sick? The CHAG system considered their 
collective drug use in the case of the former as negligible and in case of the latter as a 
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proportionate spin-off of the sick out-patients. Because we are confronted with a 
vague definition it might be better to use the total number of out-patients, so that all 
consultations are counted. 
The number of ante natal controls shows a very high correlation with the number of 
deliveries in 28 CHAG institutions on which reliable data are available over 1982 
(r=0.86, p=0.000). In the CHAG system the number of deliveries was used as a par-
ameter so that this category of care has been expressed sufficiently. 
The number of deliveries itself shows a high correlation with the number of sick out-
patients in 32 CHAG institutions over 1982 (r=0.72, p=0.000). This means that in-
formation according to this parameter has a tendency to follow that on the number of 
sick out-patients. Correlation between the number of deliveries and the total number 
of out-patients is, regrettably, not known but the fact that the number of deliveries is 
around 1.1% of total out-patient numbers in both large and small hospitals and in clin-
ics (see table 38) suggests that the number of deliveries is probably also correlated with 
the total number of out-patients. For this reason one could consider leaving out the 
number of deliveries as a separate parameter. 
The number of major operations show high correlation with the number of beds in 
16 CHAG hospitals for which data were available over 1982 (r=0.71, p=0.0001). As 
such, it was expressed within the CHAG system of allocation although the committee 
did not realize this and had discarded the data as being badly defined and strongly de-
pendent on motivation and the skill of available manpower. 
In summarizing we can say that the parameter "number of beds" expressed both the 
number of admissions and the number of major operations, and that the parameter 
"deliveries" expressed both the number of deliveries and ante natal controls and fol-
lowed the parameter "sick out-patients". The number of under-five consultations is 
not very accurately expressed by any of the parameters, yet its drug requirements are 
not specific enough to make the introduction of a separate parameter necessary, espe-
cially if the parameter "total number of out-patients" is used. 
The conclusion reached is that the three parameters used, the number of beds, 
the annual number of deliveries, and the annual number of sick out-patient consult-
ations, sufficiently represent the various categories of patients, although using the 
total number of out-patient consultations instead of the number of sick out-patient 
consultations should be considered. 
3) The use of parameters 
Something has to be said on the use of the parameters in relation to clinics. Within 
the CHAG system there was no clinic with more than 50 beds, so that the parameter 
"beds" was never of any use. This is of course related to the fact that in clinics no em-
phasis is placed on in-patient care apart from emergency and maternity cases. 
As the number of deliveries (and the number of ante natal controls) seems strongly 
related to the number of out-patients, one could ask oneself whether this parameter 
could not be left out as well. Much is to be said in favor of using a single parameter in 
the case of clinics, dispensaries and rural health programmes. Because the percent-
age of preventive services can safely be assumed higher in these institutions than in 
hospitals and because differentiation between sick out-patients, ante natal controls 
and under-fives both in practice and in statistical recording will be less, it is more logi-
cal to take the total number of out-patient consultations as a parameter to express the 
use of and the need for drugs and medical materials. 
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This has in fact been done in the essential drugs programme in Kenya7 and Tanza­
nia8 and in the publications by Walker1"71". As mentioned before, a recent WHO 
working group on the estimation of drug requirements74 advised that drug needs 
should be expressed per 1000 Treatment Episodes. The working definition was put at: 
"each patient contact for an episode of illness, requiring a new course of treatment". 
Patient contacts for ante natal controls and under-fives requiring treatment are in­
cluded. Although it remains unclear how healthy under-fives are counted, the CHAG 
description of "total number of out-patients" comes very close to this new concept, the 
application of which seems very useful in respect to basic out-patient care. It is advis­
able to use "total number of out-patient consultations" or "treatment episodes" as 
a single parameter both for hospitals and clinics and rural health programmes. For 
institutions with in-patient care "number of beds" can be used as a supplementory 
parameter. 
4) The use of four categories of size 
The committee decided to establish four categories of size for allocating drugs and 
medical materials. The question as to whether this was optimal has to be answered. 
Going from one category to the next implied an enormous difference in allocated 
quantities (from D to С meant a three-fold and from С to В a two-fold increase). The 
alternative could be to establish more than four categories, e.g. ten. The problem 
arises that in such a system one could hardly use more than one quantitative parameter 
without running into serious trouble in indicating the relative value of, perhaps, con­
tradictory parameters. Such a system could, in fact, only work with one parameter and 
that could then only be the total number of out-patients, as we have seen in the previ­
ous section. That would imply that categorisation would run parallel to total number 
of out-patients, e.g. one unit per 10.000 total out-patient consultations or so. This sys­
tem was considered but has been decided against for the time being, for two reasons. 
The most important reason is that it would become very attractive to make annual sta­
tistics a bit more favourable in order to receive one or two units more. Secondly, it 
would have made the categorization rather unstable and would require yearly adjust­
ments. In general it would give rise to continuing discussions and negotiations. 
The disadvantage of big jumps in allocated quantities has been accepted by the 
committee because it was never claimed that the method of calculating and distribut­
ing drug quantities would be accurate. In fact a variation of at least ± one third was as­
sumed. In general the idea was to calculate minimum quantities and to create a reserve 
capacity by using the inaccuracies of rounding up figures for the quantities per distrib­
ution unit and categorization in four categories. For this reason any rounding up and 
any doubtful categorization has received the benefit of the doubt. It is very well possi­
ble that, more than anyhing else, this decision has compensated for all possible short­
comings. It might also explain why more drugs have been over-allocated than under-
allocated. 
The conclusion reached is that the use of four only categories for distribution has 
here been acceptable as long as the accuracy of the rest of the allocation system was 
not known and as long as borderline cases received the benefit of the doubt. 
For this reason few complaints have been received. The system was considered ac­
curate enough and nearly all the institutions accepted it readily. Being rather stable it 
was very useful, not least for the staff in the CHAG warehouse who could use the sys­
tem any time materials had to be allocated (see section III.5). 
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5) Conclusion 
Concluding the evaluation of results and methods of the CHAG system of allocat-
ion we can say that two thirds of all drug allocations have reached the set objective with 
a slight tendency towards over-allocating. Under-allocating was mainly observed in 
hospitals with extremely high levels of drug use. Over-allocating was partly due to the 
lack of information in the case of some particular drugs, to selection of drugs of low 
priority, and to the fact that the selection and the quantification of drug needs were in 
some cases based on data from a specialist hospital. A more general reason was that, 
purposely, a certain reserve was created by rounding figures up in case of doubt. 
Regarding the choice of the parameters to define the four categories of size we can 
say that these parameters have sufficiently expressed the various categories of patient 
care within hospitals. It is preferable to use the parameter "total number of out-patient 
consultations" instead of "number of sick out-patients consultations". This is the case 
in particular for clinics, dispensaries and rural health programmes in which the total 
number of out-patient consultations can be used as a single parameter. For institutions 
with in-patient care the number of beds can be used as a supplementary parameter. 
The use of "total number of out-patient consultations" comes very near the recent 
WHO advise to relate basic drug needs to the number of "treatment episodes". 
The use of only four categories of size for allocation purposes has made the system 
stable and easy to use and was acceptable as long as borderline cases received the ben-
efit of the doubt. It gave rise to a certain degree of over-allocation. 
Y.5 Summary of the conclusions 
V.5.1 Selection of drugs 
Whenever use is made of an inquiry to select drugs, this inquiry should be well-
prepared. Whenever a choice is offered, this choice should include all possible alt-
ernatives. The results of such a drug inquiry cannot be used indiscriminately as the 
basis for a drug programme as it is an expression of general prescription patterns 
which are not necessarily optimal (V.2.3.2). 
Literature on essential drugs lists contains important information when compil-
ing or checking a list of essential drugs (V.2.3.3). 
Before compiling a list of essential drugs, its objectives in regard to target group 
(clinic, health centre, hospital) and aim (restrictive, selective or budget-bound) 
should be clearly defined (V.2.3.4). 
The 1981 CHAG list of essential drugs was influenced too much by existing pref-
erences and budgetary limits and was insufficiently based on literature on the selec-
tion of essential drugs (V.2.3). 
V.5.2 Quantification of drug needs 
The 1981 CHAG drug need estimates show optimal correlation with the results 
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of the 1981-82 drug utilization study, both in ratio between the values and in their 
average level (V.3.2). 
In obtaining these results, the use of the "consumption-based" method has been 
the only realistic alternative. This method assumes negligible epidemiological var-
iations and variations in time; it measures actual drug use which is the drug use 
within existing patterns of coverage, prescription and losses (V.3.3. /). 
The carefully chosen sample of two hospitals has been representative for the to-
tal group of seventeen institutions; this group can be considered as representative 
for the total of 66 institutions (V.3.3. J). In chosing the sample a standard is set in 
which the two elements, representativity and desirability, can not always be sepa-
rated (V.3.3.2). 
V.5.3 Allocation of drugs 
The CHA G system of allocation has achieved that in two thirds of cases allocated 
quantities of drugs have been sufficient, with a slight tendency to over-allocation 
(V.4.2). 
The parameters used to define categories of size have sufficiently expressed the 
various types of patient care (V.4.3.2). The system could be simplified by introduc-
ing "total out-patient consultations" or "total treatment episodes" as single par-
ameter for all types of health institutions, to be supplied with the parameter "num-
ber of beds" for hospitals (V.4.3.3). 
The system of allocation according to four categories of size has been effective as 
long as borderline cases have received the benefit of the doubt (\.4.3.4). 
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Chapter Six 
DISCUSSION 
Of the many essential drugs lists that have been published it is hardly ever known on 
what grounds they have been constituted. The list of Simmonds and Walker107 in 
which the selection of drugs is based on the demand-morbidity method, is the best and 
very nearly the only example. 
The analysis of the decisions leading to the 1981 list of the CHAG and its 1983 revi-
sion is instructive. We have concluded that the results of drug inquiries have to be used 
with caution as they tend to express a collective pattern of prescription that is not ne-
cessarily optimal. A second conclusion was that personal preferences of the drug com-
mittee and the feedback from representatives from the institutions which were in-
tended to adapt the results of the inquiry into a workable set of essential drugs did not 
produce an optimal effect either. Knowledge of available literature is an essential ele-
ment in checking whether proposed essential drugs lists are complete and whether all 
proposed drugs are really necessary. 
The summary of essential drugs lists for use in Africa as given in section 1.3 can be a 
very useful instrument to any person or group of persons involved in preparing a list of 
essential drugs. It seems likely that, for the common range of diseases of poverty that 
constitute such a big proportion of the health problems in Africa, a core list of essential 
drugs could be applicable to the needs of nearly all sub-Saharan countries. Epidemio-
logical variation is likely to occur in respect to some specific tropical infections only, of 
which schistosomiasis and onchocerciasis are typical examples. It should however be 
realized that drugs against these conditions are usually not regarded as "core" drugs 
but as drugs "just outside" ; the decision as to their inclusion should be made on the ba-
sis of local conditions. The core list of 29 "most essential drugs" (table 2) is to be used 
as a starting point. It is interesting to note that both the Kenyan7 and the Tanzanian8 
list contain 27 of the 29 core drugs and very few others (table 27). 
The first six items on the core list, being drugs found on more than 75 % of all avail-
able lists, can be considered as the "kernel in the core". This might be illustrated by the 
fact that recently a small range of drugs has been selected for village health workers in 
Yemen which includes exactly these six drugs plus piperazine and multivitamin74. 
The core list can be used to check in how far a given drug list corresponds with other 
lists from Africa. If this process of checking would have been possible for the CHAG 
Drug Committee, the 1981 list would have been much better insofar as the choice of 
drugs was concerned. 
The three methods discussed of quantification of drug needs are not always equally 
useful or easy to carry out. To calculate future drug needs for a country as a whole irre-
spective of the coverage by existing health services, the population-based method is to 
be preferred. It assumes that reliable epidemiological data are available and the results 
produced are useful in long-term planning. 
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For developing countries the service-based or demand-morbidity method is to be 
preferred, mainly because it produces results that can be used immediately and are al-
so preferable, as an optimal pattern of prescription and losses is assumed. It is an ideal-
istic method because it implies taking action against overprescribing and pilfering and 
because it has as its ultimate objective the responsible use of scarce resources. An ex-
tensive programma of training and re-training of first-line health workers in the use of 
a limited range of essential drugs in reasonable quantities is essential to optimal effec-
tivity. Experience with such a programme has been gained in Kenya7·45,46,207 and a 
similar programme has been planned for Tanzania8''9,143. The source of the morbidity 
data which are used as basis for the drug need quantification is the Achilles heel of the 
method. It is very difficult to obtain reliable and comparable data from a large number 
of health institutions and, in particular, from a whole region or country. The main 
problem is that at primary health care level usually symptoms instead of diseases are 
treated. The lack of a strict diagnoses and, in most cases, the recording of symptoms 
alone make morbidity records fragmentary and can even be misleading in the event 
that recorded symptoms are, in a later stage, translated into diagnoses. 
This situation leaves only two possible procedures of data collecting open for the 
demand-morbidiy method. The first method is to study a carefully chosen sample of a 
few institutions in which recording is optimal. This has usually been the method used. 
A second, more long-term possibility is to devise a simple record form listing a set of 
symptoms/diseases running parallel with a standard treatment regime that in its turn 
runs parallel with a set of essential drugs. This close combination of drugs, standard 
therapy manual and record form, together with a forth element in the form of a wall-
chart160 listing all essential drugs, indications for use, necessary precautions and 
standard dosage as standardized information both for health workers and the general 
public, is probably the better and is at present being tested in the Tanzanian pro-
gramme. 
The demand-morbidity method cannot always be used, e.g. in the case of lack of re-
liable epidemiological data or lack of morbidity records from health institutions, or 
when no possibility exists of inducing a rationalization of the existing prescription pat-
tern, because without this rationalization drug supplies will run short. For the CHAG 
both these elements presented problems. In our case-study reliable morbidity data 
were not available and, even more important, the CHAG is not a governmental body 
with legislative power but a voluntary association of church related hospitals and clin-
ics. As has been shown, the prescription pattern between the institutions varied. In ac-
cepting the assignment to plan and coordinate drug supplies for its member institu-
tions it was neither possible nor acceptable for the CHAG to express a strong opinion 
on overprescribing. The CHAG is a Ghanaian organisation of Ghanaian health insti-
tutions serving the Ghanaian population. Therefore the expatriate advisers on the 
drug committee had to be careful in gainsaying a Ghanaian manner of prescribing 
when the need to change it was not felt. We have indeed seen that both in selection and 
in quantity of essential drugs the CHAG not only had a tendency but, to a degree, also 
had the duty to accept more or less the existing situation. 
A final point to be considered in weighing the service-based method against the 
consumption-based method is to be found in the nature of the health institutions to be 
served. The East African programmes concentrate solely on dispensaries and health 
centres. The consumption-based method would probably not have been possible, as 
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stock administration is usually lacking in these institutions and shortages frequently 
occur. Some form of morbidity records is more likely to be present and can serve as a 
basis for calculating drug requirements. The CHAG drug programme on the other 
hand has mainly concentrated on hospitals. Estimating future drug needs by means of 
the demand-morbidity method might very well be increasingly difficult in the case of 
an increased number of diagnoses and necessary drugs. It remains to be proved that 
the method is applicable at all to hospital care involving a range of 60-80 drugs. Up till 
now (1984) no example has been recorded. In Ghana we preferred to use the con-
sumption-based method and this study indicates that it can work. It would be interest-
ing to have for comparison an example of drug need estimates for hospitals obtained 
through the demand-morbidity method. 
Distinguishing between the two levels of drug use has been very useful and this may 
give insight into the order of difference between the prescribing by Ghanaian and by 
expatriate doctors, and its financial consequences. It also preserves the option to 
choose which of the two prescription levels to accept as a standard for the allocation of 
drugs. This is information useful to both health planners within the country and to 
donor agencies be they governmental or voluntary. 
Just as it seems likely that the core list of essential drugs will be useful to other sub-
Saharan countries, it might very well be that the drug requirements per number of 
treatment episodes for these core drugs are also more or less the same for countries in a 
situation comparable to Ghana's. This hypothesis can however not be tested with the 
data presently available. Some difference in the general level of drug need estimates 
exists between the demand-morbidity calculations from Tanzania and Kenya and the 
consumption-based results from Ghana, but these differences are not impressive. The 
CHAG drug use for the lower prescription level as observed in expatriate doctor hos-
pitals has to be put at about 70% of the average CHAG figure for hospitals in general 
(see table 23) and this 70% level comes very close to the level calculated in the studies 
made in East Africa (table 32). 
We can conclude that a service-based calculation of drug needs which assumes an 
acceptable pattern of prescription and losses, comes very close to the observed low-
level variation in observed drug use in Ghana. 
An interesting conclusion to be drawn from this study is that the carefully chosen 
sample of two hospitals made it possible to predict fairly accurately the drug use in sev-
enteen institutions over the two years following. We cannot draw a definitive conclu-
sion and state that this will always be the case in other sub-Saharan countries, but the 
fact that it has been possible in Ghana can lead to the indicative conclusion that it 
might very well be possible elsewhere. Assuming it is possible would make measuring 
drug use in other countries an easy and hardly labor-intensive exercise. 
It would be very interesting to perform drug use measurements according to the 
method described in this study in some selected health institutions in other sub-Sahar-
an countries. If the use of essential drugs in several other countries was found to be of 
the same order as that indicated by the results from Ghana it would constitute a strong 
argument in favour of the hypothesis that requirements of the most essential drugs are 
more or less uniform in sub-Saharan Africa. 
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The last word has not been spoken on the subject of allocation and distribution of 
essential drugs. It is only since 1981 that a hesitant start has been made in establishing 
systems of distribution based on standard packages. The eighties will probably see 
more use made of it as it seems at present the most promising procedure to supply rural 
health institutions in an easy and practical way. Probably the most substantial advan-
tages of the system are that it recognises that rural health facilities have a right to their 
own fair share of health resources, and the complete separation from the supply of dis-
trict hospitals. 
Allocation using standard packages will nearly always generate a certain surplus of 
some drugs. This "loss" is inherent in the method and is even so readily acceptable as 
the advantages of the system carry much more weight. Nevertheless these losses will 
increase as the system is perfected and as interruptions to the flow of supply diminish. 
The better the system works the more the need will arise to incorporate a mechanism 
of correction to compensate for these losses. This would most likely lead to a system of 
returning surplusses or of exchanging surplus drugs for other drugs. This would com-
plicate the system extremely. Moreover, it would only work whenever the drugs from 
the standard package have had to be paid for and the exchange also takes place on a 
monetary basis. With drugs distributed free of charge it is unlikely that surplusses will 
ever be returned. 
For the CHAG the drug needs were so urgent and reserve stocks in the institutions 
so low that this point of returning surplusses hardly ever came up. Moreover, the drugs 
were either donated or sold to the CHAG institutions at low prices. If a permanent 
drug supply for hospitals would be established using these standard packages a me-
chanism for the returning of surplusses would have to be established. This would imply 
the need for qualified personnel in the CHAG office and warehouses. 
No other experience with the system of allocating a number of distribution units de-
pendent on size of the receiving institution, as has been practised in Ghana, has been 
reported. In most studies the quantities of drugs have been related to a fixed average 
size of institution, e.g. dispensaries of 2000 and health centres of 3000 treatment epi-
sodes per month in Kenya46. The CHAG system, with its four categories of size, was 
rough but satisfactory as it deliberately created certain reserves. If it were to be used on 
a long term basis it would certainly need a system to enable its adjustment or for the ex-
change of surplusses as has been mentioned above. 
As the supply of essential drugs using standard packages will probably be practised 
more and more, the need will arise to refine the system. The drug needs of an individu-
al health station can for this purpose best be expressed by calculations based on the 
number of treatment episodes. In the case of the presence of in-patient care as well 
(e.g. hospitals), the number of beds can be used as a second parameter. 
The difference between the CHAG system and the East Afrian programmes can be 
summarized as follows: the CHAG system has concentrated more on hospitals, while 
the East African programmes concentrate exclusively on dispensaries and rural health 
centres. The CHAG system worked with a four-tier system of allocation based on size 
of the institution while the East African system worked with fixed quantities per type 
of health station. 
The question as to whether drug use in the CHAG institutions has changed, or more 
precisely, has increased after having received essential drugs in sufficient or even gen-
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erous quantities is a subject of interest and worthy of future study. Such a study would 
give a final insight in the effectivity of the essential drugs programme. It is to be hoped 
that the six-months quantities that have been distributed have not induced a higher 
rate of prescription and of losses. If this should prove to be the case the conclusion 
would have to be made that drugs should be distributed in smaller, e.g. one-month 
quantities with all the consequent management problems. 
Africa is in confusion. Colonial powers have left but their influence has been strong 
enough to destabilize most of the traditional values208. What is left is not a harmonious 
new entity but a mixture of old African traditions and incohesive pieces of western civ-
ilization from which the Africans are still engaged in selecting the elements they like. 
Drugs are an important factor in speeding up the process of the disappearance of 
diseases, the incidence of which is already decreasing because of social and hygienic 
improvements63·209. In Africa the antibiotic bullet is still very effective in reducing 
morbidity and mortality. As a consequence the "pills for all ills" have not failed to 
make their impression. It is however necessary to realize that the African has, in fact, 
little reason to appreciate the form western medicine has taken in most of his villages. 
"Why should I waste time going to the clinic while I have something to do. You spend 
hours waiting to see the doctor and when you finally see him he may not even look at your 
face let alone examine you. He simply writes something and tells you to go and collect 
some medicine which almost always turns out to be APC or codeine". 
This quotation from a patient who treated himself at home instead of going to a clin-
ic was made by Gabriel Fosu210 from Ghana. The scant ritual associated with western 
medical treatment211 and the formal and mechanistic approach to disease without 
connection to its cause210, in addition to the sometimes rude treatment in general are 
frequent complaints and are often the reason that patients consult a doctor only in a 
later stage of the disease, if at all. Even then patients often do so only for symptom re-
lief while they trust the traditional healer to effect the actual spiritual cure210·211. In this 
way the function of western medicine has been reduced to treatment of symptoms and 
the observation seems true that confidence in western drugs is greater than confidence 
in doctors211. The doctor is a necessary adjunct to the distribution of medicines. 
This can give us a better understanding of what Van der Geest '19 called the "third 
field of medical behavior" (besides traditional and western medicine): modem self-
care, over the counter medicine, injection doctors etc. This behavior constitutes an ex-
ample of the confused African balancing between traditional and western values. The 
advantages of this "third field" are many: its services are omnipresent, quick, and not 
stressful as usually no social distance exists119'212·213. 
It should be realized that this third form of medicine could very well be a typically 
African answer to meeting health needs, bom of the unhappy marriage of Africa and 
the western world. The general concept of this third form of medicine should not be 
discarded too quickly as it has already been considered as a possible way to improve 
drug supply to rural areas. Morley2H mentioned the possibility of re-training pharma-
ceutical retailers to treat some basic diseases, Van der Geest in another publication118 
mentions this as a viable possibility in view of present drug shortages, the logical pref-
erence for self care and the unavailability of qualified medical services, and Mozam-
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bique seems to have started with licensed shops selling subsidized essential drugs over 
the counter36. Experience with "pro-pharmacies" in Cameroon has lead to the recom-
mendation that these should be private enterprises with a reasonable profit margin215. 
It was necessary to mention all this in order to make us aware of the relative value 
and limited impact of our western medical system in Africa. This study has described 
and evaluated the activities of the CHAG in trying to supply its member institutions 
with sufficient essential drugs. Whenever one accepts the presence and value of mis-
sion hospitals with their external resources, partly expatriate staff and western influ-
ences, it is also understandable and acceptable that these institutions try to function 
optimally according to technological concepts of efficiency and effectivity. Therefore 
the activities of the CHAG drug committee were a consequence of the presence of 
mission hospitals and church related health care. The justification for the CHAG 
activities and also for this study is subject to the justification of the role that churches, 
with their overseas connections, play in Africa. 
Church related health institutions have existed in Ghana for nearly a hundred and 
fifty years189·190'216. They contribute about one third of all public health care193 and are 
generally well-accepted217·218, both by the general public and by the government. 
They have the duty to be pioneers219, to be wherever the local government cannot 
(yet) be86. They should translate love for one's neighbour into health terms and should 
pursue justice in health157. In a paper from the Christian Medical Commission of the 
World Council of Churches their activities have been summarised as: "supportive ac-
tion in favor of those who are socially, economically or geographically marginal, and 
action to stimulate a government to a policy of a spirit of justice and equity"157. In 
practice church related health care should offer a limited range of cost-effective medi-
cal approaches, should offer possibilities for adapted locally applicable training and 
should always keep an eye open for social injustices218. 
The relations between the western and the Ghanaian churches or, in general, be-
tween the western and the African countries should be characterized by what Soete-
man220 called a "critical dialogue", a third stage after a first historical phase of patro-
nage and a second phase of keeping silent at a distance. This critical dialogue is possi-
ble as part of an open relationship not confused by feelings of superiority or inferiority 
and without false modesty. As part of such a dialogue between equal partners this 
study can be justified. It can offer some information which could serve as a tool for the 
use of health planners in African countries that have chosen to meet the basic needs of 
the majority of the population. 
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SUMMARY 
The concept of a selection of essential drugs to satisfy the health needs of the major-
ity of the population developed in the seventies and is being taken up by more and 
more developing countries. Many lists of essential drugs have been published. The 
number of publications on the quantities of essential drugs that are necessary is how-
ever very limited. 
The Christian Health Association of Ghana Drug Committee studied the essential 
drug needs for 66 church related hospitals and clinics in Ghana which constitute more 
than one third of all public health care available in the country. It concentrated on 
three main questions: which drugs should be considered essential, how much of each 
would be necesary, and how could they be distributed using the existing logistic 
means? 
To find out which drugs were essential an inquiry was held to which 75 % of all insti-
tutions responded. Based on the results and on feed-back from all pharmacists from 
the institutions the committee drew up a list of essential drugs. 
To define the quantities of these drugs that would be necessary, drug use in a chosen 
sample of two hospitals, Agogo and Dormaa, was measured. This measurement was 
performed using the consumption-based method, by adding up all drug quantities is-
sued by the central hospital store and linking these drug use data with the number of 
out-patient consultations in the same period. Selection criteria for the sample were: 
sound management resulting in an effective administration of stores and drug sup-
plies, reliable patient statistics, a rational and supervised pattern of prescription by 
screening nurses, medical assistants and junior doctors, a continuous stock of essential 
drugs and a limited risk of exessive losses. 
All drugs for the relief programmes were obtained through overseas suppliers. It 
was decided to have them prepacked in standard units. Each unit contained calculated 
quantities or different essential drugs. Health institutions were divided into four cate-
gories of size receiving 1, 3, 6 or 10 basic units. Every unit was calculated as being 
enough for 10.000 out-patient consultations which should be sufficient for about six 
months. Certain reserves were built in. During 1982-83 several drug conseignments 
were distributed to all CHAG institutions according to this system. 
To check whether the allocated quantities had been correctly estimated a drug utili-
zation study was performed over two administrative years (1981-82) involving 2.5 
million patient contacts. These data were also collected by the consumption-based 
method in fifteen hospitals and two clinics. The results have been studied by computer 
analysis. The statistics on average drug use (drug consumption by the patient plus 
losses by bad prescription habits, pilfering and wastage) in these seventeen institutions 
is the most reliable recorded information currently available on drug utilization in 
Ghana. It could be proved that the average drug use in Ghanaian doctor hospitals had 
been about twice as high as the drug use in expatriate (mostly western) doctor hospi-
tals. 
The selection of CHAG essential drugs has been evaluated by means of comparison 
with a quantified consensus of 38 available essential drugs lists made in or for African 
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countries. The number of times a certain drug was included in each of these lists was 
counted. Drugs that appeared on more than 50% of these lists were considered "core-
drugs" and called "most essential drugs". 
The CHAG list contained at first only 14 of the 29 most essential drugs. After a la-
ter revision of the list this was increased to 24. An analysis of the decisions involved in 
selecting essential drugs for the first CHAG list revealed that the results of the drug in-
quiry had reflected the existing prescription patterns to a degree that would restrict its 
overall usage, and that the feed-back from hospital pharmacists and also the inclusion 
of personal preferences within the committee had not produced optimal results. The 
conclusion is that knowledge of the existing literature on essential drugs is essential in 
checking whether proposed essential drugs lists are complete and whether all pro-
posed drugs are really necesary. If this information had been available to the CHAG 
Drug Committee the list of essential drugs would have been more inclusive. 
The list of 29 most essential drugs can be used as a starting point for essential drugs 
lists in other sub-Saharan countries, to be made up, when necessary, by drugs against 
specific infections prevalent in the region. 
Besides the consumption-based method, two other ways of estimating drug needs 
are mentioned in the literature. The population-based method, used to calculate drug 
needs for a whole country, irrespective of the coverage of the existing health services, 
assumes a basis of reliable epidemiological data and produces results that are useful in 
long-term planning only. The service-based ox demand-morbidity method estimates 
drug requirements by multiplying recorded morbidity patterns among patients at-
tending health institutions with a proposed standard therapy. It is an idealistic method 
as it implies taking action against overprescribing and pilfering. An extensive pro-
gramme of re-training first-line health workers is a precondition for satisfactory effec-
tivity. It is difficult to obtain reliable and comparable data on morbidity pattern of pa-
tients in a large number of health institutions. These are usually obtained from a small 
selected sample. 
In Ghana the demand-morbidity method could not be used as no reliable records 
on morbidity were available and as the CHAG was not in a position to change patterns 
of prescription. Moreover, it remains to be proved that the demand-morbidity method 
can be used in hospitals with their many diagnoses and different treatment regimes as, 
up till now ( 1984), it has only been practised in the case of drug supply to in dispensa-
ries and health centres. 
The 1981 CHAG drug needs estimates have been compared with the three avail-
able studies from the literature and with the results of the drug utilization study con-
cerning the years 1981-82. This comparison revealed that the estimates show a very 
close correlation with the drug use as measured through the drug utilization study both 
in the ratio between the figures and in absolute size. The general level of the CHAG es-
timates is a bit higher than that of the results shown in the studies from East Africa, 
which have all been calculated through the demand-morbidity method. This differ-
ence can be partly attributed to the sub-optimal prescribing and the losses that are in-
cluded in the CHAG consumption-based drug use measurements. It is however inter-
esting to see that the general level of drug use in the "low-level" variety of drug use in 
Ghana, as observed in expatriate doctor hospitals in the drug utilization study, ap-
proaches the level given in the studies from East Africa. This seems to indicate that the 
required quantities of essential drugs are more or less the same for many sub-Saharan 
countries, as is the core-list of most essential drugs. 
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In the studies from East Africa, drugs have been allocated in fixed quantities per 
type of health institution. In the CHAG system, a four-tier level of allocation was used 
with a standard selection of 24 essential drugs for all institutions and an extra 10 for 
hospitals only. To express drug needs as dependent on the size of the institutions three 
parameters had been used. Analysis of each of these parameters showed that the total 
number of out-patient consultations is the most useful. It can be used as a single par-
ameter for all types of health institutions. In the case of drug use for in-patient care 
having to be expressed as well, the number of beds is a simple and reliable second par-
ameter. The parameter "total out-patient consultations" is nearly identical to "treat-
ment episodes", the unit of expressing drug needs proposed by the WHO. 
The drug use in seventeen CHAG institutions which can be considered as represen-
tative of all the institutions has been predicted by a study in a carefully chosen sample 
of two hospitals. This indicates that drug use in an entire country could be measured by 
this method. As very little information is available on the essential drug requirements 
in other sub-Saharan countries it would be both useful and interesing to collect materi-
al from these countries for comparison. 
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SAMENVATTING 
Het concept van een lijst van essentiële geneesmiddelen voor de basisbehoeften van 
de meerderheid van een bevolking stamt uit de zeventiger jaren en wordt door steeds 
meer ontwikkelingslanden overgenomen. Hoewel er inmiddels zeer veel verschillen-
de lijsten van essentiële geneesmiddelen zijn gepubliceerd is er weinig bekend over de 
hoeveelheden waarin deze essentiële geneesmiddelen nodig zijn. 
De Medicijnen Commissie van de Christian Health Association of Ghana (CHAG) 
heeft in 1980-81 de vraag bestudeerd welke geneesmiddelen essentieel zijn voor de 66 
kerk-gebonden gezondheidsinstellingen in Ghana, welke tezamen meer dan een der-
de deel van alle publieke gezondheidsvoorzieningen uitmaken. De commissie heeft 
zich op drie hoofdvragen geconcentreerd: welke medicijnen moeten als essentieel 
worden beschouwd, in welke hoeveelheden zijn deze medicijnen nodig en hoe zouden 
zij gedistribueerd kunnen worden binnen de bestaande logistieke voorzieningen. 
Om de eerste vraag te beantwoorden werd er in 1980 een schriftelijke enquête ge-
houden waarop 75 % van alle CHAG instellingen heeft geantwoord. Gebaseerd op de 
resultaten ervan en in overleg met hoofden van apotheken van CHAG instellingen 
stelde de commissie een CHAG lijst van essentiële geneesmiddelen op. 
De hoeveelheden waarin die geneesmiddelen nodig zouden zijn werden bepaald 
door het medicijngebruik te meten in twee ziekenhuizen, Agogo en Dormaa Hospital. 
De meting werd verricht met de zgn. consumptie-methode, door alle hoeveelheden 
medicijnen op te tellen welke gedurende een bepaalde periode door het centrale zie-
kenhuis magazijn aan de ziekenhuis apotheek uitgegeven waren. Deze hoeveelheden 
werden gerelateerd aan het aantal polikliniek consulten over dezelfde periode. Selec-
tiecriteria voor de keus van de twee ziekenhuizen waren: een sterke ziekenhuisleiding 
met daardoor een goede administratie van magazijnen en medicijnvoorraden, be-
trouwbare patiënten statistieken, een rationeel en goed gecontroleerd voorschrijfpa-
troon door "screening nurses", "medical assistants" en junior doktoren, een ononder-
broken medicijn voorziening en een beperkt risico van diefstal. 
Alle medicijnen voor de noodhulpprogramma's in Ghana werden geleverd door 
overzeese bedrijven. De medicijnen werden voorverpakt in standaardeenheden. Elke 
eenheid bevatte bepaalde hoeveelheden van verschillende medicijnen. Gezondheids-
instellingen werden verdeeld in vier grootte-categorieën die 1, 3, 6 of 10 eenheden 
ontvingen. Elke eenheid bevatte voldoende essentiële geneesmiddelen voor 10.000 
polikliniekconsulten en de bijbehorende opnames, voor een periode van ongeveer zes 
maanden. Zekere reserves werden ingebouwd. In 1982 en 1983 werd een aantal me-
dicijnzendingen op deze manier aan alle CHAG instellingen gedistribueerd. 
Teneinde na te gaan of de toegewezen hoeveelheden medicijnen goed geschat wa-
ren werd achteraf een studie verricht naar het medicijngebruik in CHAG instellingen 
over de administratieve jaren 1981 en 1982 (2.5 miljoen consulten). Deze gegevens 
werden in vijftien ziekenhuizen en twee klinieken verzameld volgens de consumptie-
methode. De resultaten werden per computer geanalyseerd. Het gemiddeld medicijn-
gebruik (medicijnconsumptie van de patiënten plus verliezen door teveel voorschrij-
ven, diefstal en bederf) in deze zeventien instellingen is de nauwkeurigste meting van 
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medicijngebruik in Ghana die op dit moment beschikbaar is. Er kon worden bewezen 
dat het gemiddeld medicijngebruik in ziekenhuizen met Ghanese doktoren ongeveer 
twee maal zo hoog was als in ziekenhuizen met westerse doktoren. 
De CHAG lijst van essentiële geneesmiddelen werd geëvalueerd door een vergelij-
king met een "kern"lijst van 29 "meest essentiële geneesmiddelen"; dit zijn genees-
middelen die voorkomen op meer dan 50% van een groep van 38 lijsten van essentiële 
geneesmiddelen die gepubliceerd zijn in of voor Afrika. De CHAG lijst bevatte aan-
vankelijk slechts 14 van deze 29 meest essentiële medicijnen, maar na een latere revi-
sie steeg dit aantal tot 24. Een analyse van de beslissingen die ten grondslag lagen aan 
de eerste CHAG lijst bracht aan het licht dat de resultaten van de medicijnen enquête 
teveel een uitdrukking waren van de bestaande voorschrijfpatronen om zonder meer 
te kunnen worden gebruikt, en dat overleg met hoofden van ziekenhuisapotheken en 
persoonlijke inzichten van commissieleden zelf de resultaten niet hadden verbeterd. 
De bestaande literatuur over essentiële medicijnen blijkt een zeer noodzakelijk gege-
ven om te controleren of een bepaalde lijst van essentiële medicijnen werkelijk volle-
dig is en of alle voorgestelde geneesmiddelen inderdaad essentieel zijn. Als deze infor-
matie beschikbaar was geweest voor de CHAG commissie zou de CHAG lijst comple-
ter zijn geweest. 
De kernlijst van de 29 meest essentiële medicijnen kan gebruikt worden als uit-
gangspunt voor lijsten voor andere landen bezuiden de Sahara. Waar nodig moet deze 
kern-lijst worden uitgebreid met enkele medicijnen tegen infecties specifiek voor de 
betreffende regio. 
Naast de consumptiemethode worden in de literatuur nog twee andere methodes 
beschreven om de benodigde hoeveelheden essentiële geneesmiddelen te schatten. 
De populatie-methode wordt gebruikt om hoeveelheden te schatten voor een heel 
land, onafhankelijk van het percentage van de bevolking dat bereikt wordt door de be-
staande gezondheidsinstellingen. De methode gaat uit van de aanwezigheid van be-
trouwbare epidemiologische gegevens en geeft resultaten die bruikbaar zijn voor 
planning op lange termijn. De morbiditeits-methode schat de benodigde hoeveelhe-
den door een vastgesteld gemiddeld morbiditeitspatroon van een patientenpopulatie 
te vermenigvuldigen met een voorgestelde standaard behandeling. Dit is een idealisti-
sche methode aangezien uitgegaan wordt van actie tegen slechte voorschrijfpatronen 
en diefstal. Voorwaarde voor goede effectiviteit is daarom een veelomvattend pro-
gramma van omscholing van eerste-lijns gezondheidswerkers. Het is daarbij moeilijk 
om betrouwbare en vergelijkbare gegevens te verzamelen over het morbiditeitspa-
troon van patiënten in een groot aantal gezondheidsinstellingen. Gewoonlijk zijn de 
gegevens afkomstig van een kleine steekproef. 
In Ghana kon de morbiditeitsmethode niet gebruikt worden omdat er geen be-
trouwbare morbiditeitsstatistieken beschikbaar waren en omdat de CHAG niet in de 
positie was om het voorschrijfpatroon te veranderen. Bovendien is nog niet bewezen 
dat de morbiditeitsmethode gebruikt kan worden voor ziekenhuizen met hun grotere 
aantallen diagnoses en verschillende behandelingsschema's. Tot nu toe (1984) zijn al-
leen voorbeelden bekend van de morbiditeitsmethode waar deze gebruikt is om de 
medicijnbehoefte voor plattelandsklinieken te schatten. 
De CHAG schattingen van de benodigde hoeveelheden medicijnen werden verge-
leken met drie gepubliceerde studies uit Oost Afrika en met de resultaten van de stu-
die naar medicijngebruik in Ghana. De CHAG schattingen bleken een zeer goede 
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correlatie te vertonen met het gemeten medicijngebruik in de twee navolgende jaren 
zowel in verhouding tussen de getallen als in de absolute waarden ervan. Het gemid-
deld niveau van de CHAG schattingen bleek iets hoger te liggen dan de getallen uit 
Oost Afrika, die overigens alle berekend waren met de morbiditeitsmethode. Dit ver-
schil moet gedeeltelijk worden toegeschreven aan de verliezen door sub-optimaal 
voorschrijfpatroon, diefstal en bederf die in de door de CHAG gebruikte consumptie-
methode worden meegeteld. Het is daarbij interessant om op te merken dat het ge-
middeld niveau in de "lage" variant van medicijngebruik in Ghana, zoals die gemeten 
is in de ziekenhuizen met westerse doktoren, dicht in de buurt komt van het niveau van 
de schattingen uit Oost Afrika. Dit maakt het aannemelijk dat de benodigde hoeveel-
heden essentiële medicijnen min of meer identiek zijn voor veel landen bezuiden de 
Sahara, net zoals dat het geval lijkt voor de kern-lijst van meest essentiële geneesmid-
delen. 
In de studies uit Oost Afrika werden de medicijnen gedistribueerd in vaste hoeveel-
heden per type gezondheidsinstelling. De CHAG gebruikte een vier categorieën sys-
teem met een standaard lijst van 24 essentiële geneesmiddelen voor alle instellingen 
en 10 extra medicijnen voor ziekenhuizen alleen. Om de medicijnbehoefte te relate-
ren aan de grootte van de instellingen werden drie parameters gebruikt. Analyse van 
elk van deze parameters toonde aan dat het totaal aantal polikliniekconsulten de beste 
is. Deze grootheid kan gebruikt worden als enige parameter voor alle types gezond-
heidsinstellingen. Wanneer de medicijnbehoefte van intramurale zorg ook moet wor-
den uitgedrukt is het aantal bedden een simpele en betrouwbare tweede parameter. 
De parameter "totaal aantal polikliniekconsulten" is vrijwel identiek met "treatment 
episodes", de eenheid voorgesteld door de WHO. 
Het is mogelijk gebleken het medicijngebruik in 17 CHAG instellingen, die repre-
sentatief zijn voor alle 66 CHAG instellingen, goed te voorspellen door een zorgvul-
dig uitgekozen sample van twee ziekenhuizen te bestuderen. Dit maakt het aanneme-
lijk dat medicijngebruik in een ontwikkelingsland als geheel op deze manier eenvou-
dig kan worden gemeten. Aangezien er zeer weinig informatie beschikbaar is over de 
hoeveelheden medicijnen nodig voor andere landen bezuiden de Sahara is het aan te 
bevelen materiaal uit deze landen te verzamelen ter vergelijking. 
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APPENDIX I 
Quantitative analysis of consensus in 38 essential drugs lists made in or for sub-Saharan African 
countries, divided for short (0-50 items), medium (51-100 items) and long (over 100 items) lists, 
presented in order of 1983 WHO classification. 
Number of lists the drug is included in expressed as percentage of the maximum possible. Drugs 
not on 1983 WHO list of essential drugs6 in brackets. 
WHO 
class. 
1.1 
1.2 
2.1 
2.2 
3 
4 
5 
6.1 
6.2 
6.3.1 
6.3.2 
Drug 
ether 
thiopentone inj. 
lidocain 1-2% inj. 
ас. salicylic acid 
paracetamol 
phenybutazone 
morfia or pethidine 
nalaxone inj. 
chlorophenamine 
atropine inj. 
diazepam inj. 
phénobarbital 
Phenytoin 
mebendazole 
piperazine 
niclosamide 
tiabendazole 
(TCE) 
(levamisole) 
(broad anthelmintic) 
metronidazole 
emetine inj. 
ampicillin cap. 
syr. 
benz.benz.pen.inj. 
benz.cryst.pen.inj. 
phenoxymeth.pen. tab. 
proc.pen.inj. 
chloramphenicol cap. 
syr. 
inj. 
erythromycin 
sulfadimidin 
(other sulfa) 
(all sulfa) 
co-trimoxazole 
tetracycline 
nitrofurantoin 
Total score 
in 38 lists 
nr 
7 
9 
20 
38 
19 
8 
14 
7 
11 
15 
14 
24 
6 
14 
25 
17 
13 
9 
8 
28 
20 
10 
15 
9 
20 
18 
22 
25 
19 
9 
10 
7 
27 
6 
32 
11 
30 
10 
(%) 
(18) 
(24) 
(53) 
(100) 
(50) 
(21) 
(37) 
(18) 
(29) 
(39) 
(37) 
(63) 
(16) 
(37) 
(66) 
(45) 
(34) 
(24) 
(21) 
(74) 
(53) 
(26) 
(39) 
(24) 
(53) 
(47) 
(58) 
(66) 
(50) 
(24) 
(26) 
(18) 
(71) 
(16) 
(84) 
(29) 
(79) 
(26) 
22 short 
lists 
nr 
0 
1 
6 
22 
10 
2 
3 
2 
3 
4 
4 
8 
0 
7 
13 
5 
5 
2 
4 
15 
10 
3 
7 
3 
7 
7 
12 
12 
6 
2 
3 
2 
15 
2 
17 
3 
16 
2 
(%) 
(0) 
(5) 
(27) 
(100) 
(45) 
(9) 
(14) 
(9) 
(14) 
(18) 
(18) 
(36) 
(0) 
(32) 
(59) 
(23) 
(23) 
(9) 
(18) 
(68) 
(45) 
(14) 
(32) 
(14) 
(32) 
(32) 
(55) 
(55) 
(27) 
(9) 
(14) 
(9) 
(68) 
(9) 
(77) 
(14) 
(73) 
(9) 
9 medium 
lists 
nr 
1 
2 
7 
9 
4 
3 
5 
0 
3 
5 
5 
9 
2 
3 
5 
6 
3 
3 
2 
7 
5 
1 
3 
1 
6 
4 
5 
6 
6 
2 
3 
1 
5 
3 
8 
4 
7 
4 
(%) 
(П) 
(22) 
(78) 
(100) 
(44) 
(33) 
(56) 
(0) 
(33) 
(56) 
(56) 
(100) 
(22) 
(33) 
(56) 
(67) 
(33) 
(33) 
(22) 
(78) 
(56) 
(И) 
(33) 
(H) 
(67) 
(44) 
(56) 
(67) 
(67) 
(22) 
(33) 
(И) 
(56) 
(33) 
(89) 
(44) 
(78) 
(44) 
7 long 
lists 
nr 
6 
6 
7 
7 
5 
3 
6 
5 
5 
6 
5 
7 
4 
4 
7 
6 
5 
4 
2 
6 
5 
6 
5 
5 
7 
7 
5 
7 
7 
5 
4 
4 
7 
1 
7 
4 
7 
4 
r%; 
(86) 
(86) 
(100) 
(100) 
(71) 
(43) 
(86) 
(71) 
(71) 
(86) 
(71) 
(100) 
(57) 
(57) 
(100) 
(86) 
(71) 
(57) 
(29) 
(86) 
(71) 
(86) 
(71) 
(71) 
(100) 
(100) 
(71) 
(100) 
(100) 
(71) 
(57) 
(57) 
(100) 
(14) 
(100) 
(57) 
(100) 
(57) 
WHO 
class. 
6.3.4 
6.4 
6.5 
6.6 
6.7 
6.8 
10.1 
10.2 
11.1 
12.3 
12.4 
12.5 
13.1 
13.2 
13.6 
15 
16 
17.1 
17.2 
Drug 
ethambutol 
isoniazid 
streptomycin inj. 
INH/thiacetazone 
diethylcarbamazine 
griseofulvine 
sod.stib.gluc.inj. 
chloroquine tab. 
syr. 
(inj·) 
quinine inj. 
amodiaquine 
metrifonate 
(niridazole) 
(either) 
ferrous sulphate 
(fumarate) 
(either) 
folic acid 
hydro.cobal.inj. 
iron dextran inj. 
vitamin К inj. 
dextran 70 inf. 
reserpine 
(all antihypert.) 
digoxin tab. 
inj. 
epinephrine inj. 
benzoic ac.comp. oint. 
neomyc.bacitr.oint. 
(gentian violet) 
benzyl bezoatc 
lindane 
Chlorhexidine 
iodine 
(either) 
furosemide tab. 
inj. 
hydr.chl.thiazide 
(either diur. lab.) 
alum.hydr. 
magn.hydr.mix 
(either) 
promethazine tab. 
syr. 
Total score 
in 38 lists 
nr 
8 
10 
17 
14 
13 
7 
4 
39 
20 
23 
11 
7 
6 
13 
17 
32 
5 
34 
22 
8 
10 
11 
8 
9 
11 
11 
11 
19 
16 
8 
19 
25 
11 
15 
19 
23 
10 
10 
10 
16 
17 
18 
27 
16 
9 
(%) 
(21) 
(26) 
(45) 
(37) 
(34) 
(18) 
(И) 
(95) 
(53) 
(61) 
(29) 
(18) 
(16) 
(34) 
(45) 
(84) 
(13) 
(89) 
(58) 
(21) 
(26) 
(29) 
(21) 
(24) 
(29) 
(29) 
(29) 
(50) 
(42) 
(21) 
(50) 
(66) 
(29) 
(39) 
(50) 
(61) 
(26) 
(26) 
(26) 
(42) 
(45) 
(47) 
(71) 
(42) 
(24) 
22 short 
lists 
nr 
3 
3 
6 
4 
5 
0 
1 
22 
8 
10 
0 
1 
2 
5 
7 
17 
2 
18 
11 
3 
3 
4 
1 
3 
3 
3 
1 
8 
6 
4 
9 
13 
3 
5 
8 
11 
4 
1 
2 
5 
7 
7 
12 
5 
2 
(%) 
(14) 
(14) 
(27) 
(18) 
(23) 
(0) 
(5) 
(100) 
(36) 
(45) 
(0) 
(5) 
(9) 
(23) 
(32) 
(77) 
(9) 
(82) 
(50) 
(14) 
(14) 
(18) 
(5) 
(14) 
(14) 
(14) 
(5) 
(36) 
(27) 
(18) 
(41) 
(59) 
(14) 
(23) 
(36) 
(50) 
(18) 
(5) 
(9) 
(23) 
(32) 
(32) 
(55) 
(23) 
(9) 
9 medium 
lists 
nr 
1 
2 
4 
3 
3 
2 
1 
8 
7 
7 
5 
3 
1 
4 
5 
8 
1 
9 
4 
1 
1 
2 
2 
2 
3 
2 
4 
5 
5 
1 
6 
7 
3 
5 
5 
6 
1 
4 
4 
6 
6 
4 
8 
5 
1 
(%) 
(И) 
(22) 
(44) 
(33) 
(33) 
(22) 
(И) 
(89) 
(78) 
(78) 
(56) 
(33) 
(И) 
(44) 
(56) 
(89) 
(И) 
(100) 
(44) 
(И) 
(И) 
(22) 
(22) 
(22) 
(33) 
(22) 
(44) 
(56) 
(56) 
(И) 
(67) 
(78) 
(33) 
(56) 
(56) 
(67) 
(И) 
(44) 
(44) 
(67) 
(67) 
(44) 
(89) 
(56) 
(И) 
7 long 
lists 
nr 
4 
5 
7 
7 
5 
5 
2 
6 
5 
6 
6 
3 
3 
4 
5 
7 
2 
7 
7 
5 
6 
5 
5 
4 
5 
6 
6 
6 
5 
3 
4 
5 
5 
5 
6 
6 
5 
5 
4 
5 
4 
7 
7 
6 
6 
(%) 
(57) 
(71) 
(100) 
(100) 
(71) 
(71) 
(29) 
(86) 
(71) 
(86) 
(86) 
(43) 
(43) 
(57) 
(71) 
(100) 
(29) 
(100) 
(100) 
(71) 
(86) 
(71) 
(71) 
(57) 
(71) 
(86) 
(86) 
(86) 
(71) 
(43) 
(57) 
(71) 
(71) 
(71) 
(86) 
(86) 
(71) 
(71) 
(57) 
(71) 
(57) 
(100) 
(100) 
(86) 
(86) 
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WHO 
class 
17.5 
18.1 
18 4 
19 1 
19 2 1 
21 1 
21.4 
21.5 
22 
24 
25 1 
25 2 
26.1 
26 2 
27 
Drug 
either tab Ayr 
(papaver bellad ) 
senna 
other laxans 
(either) 
hydrocortisone inj 
prednisolone 
insulin comp.zinc inj. 
insulin inj. 
antivenom serum 
tetanus antitoxine 
BCG vaccine 
DPT vaccine 
measles vaccine 
poliomyelitis vaccine 
tetanus vaccine 
sulfacetimide eye oint. 
tetracycline eye oint 
(other AB eye oint ) 
(either) 
pilocarpine eyedr. 
(hom)atropine eyedr. 
ergometnne tab 
inj. 
either 
oxytocin inj. 
chlorpromazine tab. 
inj. 
diazepam tab. 
aminophyllin tab 
inj. 
salbutamol 
ephednne 
(either) 
codein 
(other) 
(either) 
oral rehydr.salts 
glucose 5% inf 
sod chi 0.9% mf. 
water for inj. 
ascorbic acid 
rctinol 
(multivitamin) 
(vitamin B-Co) 
(either) 
Total score 
in 38 lists 
nr 
18 
11 
13 
10 
20 
11 
10 
5 
8 
7 
9 
9 
10 
8 
9 
11 
7 
17 
15 
29 
7 
7 
14 
20 
24 
10 
17 
15 
12 
14 
15 
8 
16 
26 
10 
9 
17 
28 
10 
11 
17 
11 
18 
18 
15 
23 
(%) 
(47) 
(29) 
(34) 
(26) 
(53) 
(29) 
(26) 
(13) 
(21) 
(18) 
(24) 
(24) 
(26) 
(21) 
(24) 
(29) 
(18) 
(45) 
(39) 
(76) 
(18) 
(18) 
(37) 
(53) 
(63) 
(26) 
(45) 
(39) 
(32) 
(37) 
(39) 
(21) 
(42) 
(68) 
(26) 
(24) 
(45) 
(74) 
(26) 
(29) 
(45) 
(29) 
(47) 
(47) 
(39) 
(61) 
22 short 
lists 
nr 
6 
2 
6 
2 
8 
1 
2 
0 
1 
0 
0 
1 
2 
1 
2 
3 
3 
6 
9 
14 
0 
0 
6 
7 
11 
0 
5 
5 
4 
4 
2 
0 
7 
10 
1 
4 
5 
15 
2 
3 
7 
4 
7 
6 
6 
10 
(%) 
(27) 
(9) 
(27) 
(9) 
(36) 
(5) 
(9) 
(0) 
(5) 
(0) 
(0) 
(5) 
(9) 
(5) 
(9) 
(14) 
(14) 
(27) 
(41) 
(64) 
(0) 
(0) 
(27) 
(32) 
(50) 
(0) 
(23) 
(23) 
(18) 
(18) 
(9) 
(0) 
(32) 
(45) 
(5) 
(18) 
(23) 
(68) 
(9) 
(14) 
(32) 
(18) 
(32) 
(27) 
(27) 
(45) 
9 medium 
lists 
nr 
6 
6 
3 
3 
5 
3 
2 
0 
1 
1 
3 
3 
3 
3 
3 
4 
1 
7 
2 
8 
2 
2 
2 
7 
7 
4 
5 
4 
3 
4 
6 
3 
3 
9 
4 
3 
6 
8 
2 
2 
5 
2 
5 
6 
5 
7 
(%) 
(67) 
(67) 
(33) 
(33) 
(56) 
(33) 
(22) 
(0) 
(11) 
( И ) 
(33) 
(33) 
(33) 
(33) 
(33) 
(44) 
( И ) 
(78) 
(22) 
(89) 
(22) 
(22) 
(22) 
(78) 
(78) 
(44) 
(56) 
(44) 
(33) 
(44) 
(67) 
(33) 
(33) 
(100) 
(44) 
(33) 
(67) 
(89) 
(22) 
(22) 
(56) 
(22) 
(56) 
(67) 
(56) 
(78) 
7 long 
lists 
nr 
6 
3 
4 
5 
7 
7 
6 
5 
6 
6 
6 
5 
5 
4 
4 
5 
3 
4 
4 
7 
5 
5 
6 
6 
6 
6 
7 
6 
5 
6 
7 
5 
6 
7 
5 
2 
6 
5 
6 
6 
5 
5 
6 
6 
4 
6 
(%) 
(86) 
(43) 
(57) 
(71) 
(100) 
(100) 
(86) 
(71) 
(86) 
(86) 
(86) 
(71) 
(71) 
(57) 
(57) 
(57) 
(43) 
(57) 
(57) 
(100) 
(71) 
(71) 
(86) 
(86) 
(86) 
(86) 
(100) 
(86) 
(71) 
(86) 
(100) 
(71) 
(86) 
(100) 
(71) 
(29) 
(86) 
(71) 
(86) 
(86) 
(71) 
(71) 
(86) 
(86) 
(57) 
(86) 
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APPENDIX 2 
List of CHAG Member Institutions and annual statistics over 1982. Figures between brackets are estimates. 
VR 
ER 
CR 
WR 
Ash 
name 
Battor 
Kpandu 
Adidome 
Dodi Papase 
Dzodze 
Abor Werne 
Nkwanta 
Anfocga 
Ho 
Vane 
Akwatia 
Nkawkaw 
Kofondua 
Kwahu 'I afo 
Agomanya 
Anum 
Begoro 
Nsawam MC 
A. Ofoase 
A. Swedru 
Boso 
Nsawam Orth 
Ntronang 
Wenchi 
A si к urna 
Asin Foso 
Apam 
Duakwa 
Ba 
Dunkwa 
Eikwe 
S. Asafo 
S Bodi 
Sec. Takoradi 
Agogo 
Maase-Ofinso 
Agroyesum 
Pramso 
Agogo R.H. 
Wiamuasi 
Abira 
Bosumtwi 
Donyina 
Essienempong 
Mampong 
rel 
Cath 
Cath 
EPC 
Cath 
Cath 
Cath 
Cath 
Cath 
hPC 
EPC 
Cath 
Cath 
Cath 
Cath 
Cath 
S.A. 
S.A. 
Caih 
Cath 
Cath 
S.A. 
Cath 
Cath 
S.A. 
Cath 
Cath 
Cath 
S.A. 
S.A. 
Pent 
Cath 
Cath 
Angl 
Cath 
Pres 
Cath 
Cath 
Cath 
Pres 
S.A. 
Cath 
Meth 
Cath 
Cath 
Angl 
kind 
hosp 
hosp 
hosp 
hosp 
hosp 
elm 
clin 
clin 
clin 
clin 
hosp 
hosp 
hosp 
clin 
clin 
clin 
clin 
M.cl 
clin 
clin 
clin 
clin 
clin 
clin 
hosp 
hosp 
hosp 
clin 
clin 
clin 
hosp 
hosp 
clin 
clin 
hosp 
hosp 
hosp 
hosp 
R.H. 
clin 
clin 
clin 
clin 
clin 
babyh 
cat 
В 
В 
С 
С 
С 
В 
В 
С 
D 
D 
А 
А 
В 
В 
С 
С 
С 
С 
С 
С 
D 
D 
D 
D 
В 
В 
С 
В 
D 
D 
В 
В 
D 
D 
А 
В 
С 
С 
В 
С 
D 
D 
D 
D 
D 
Beds 
130 
213 
133 
127 
150 
49 
37 
93 
(6) 
291 
166 
130 
30 
26 
9 
10 
8 
8 
6 
(30) 
6 
6 
96 
85 
105 
12 
6 
6 
95 
84 
6 
6 
185 
160 
92 
75 
38 
10 
2 
10 
6 
6 
20 
OPD 
83 739 
52.800 
18.838 
20.170 
(32.000) 
63.077 
76.832 
(46.000) 
(6.000) 
126.413 
143.545 
89.104 
104 144 
49.156 
20.756 
36 600 
22.981 
41.076 
37.068 
3.983 
4.094 
20.205 
(61 726) 
(49.265) 
(10 000) 
54.095 
12.724 
(6.000) 
72.169 
89.482 
(6 000) 
(6.000) 
112.605 
36.193 
16.610 
44.076 
88.070 
45.452 
10.836 
(18.500) 
(6.000) 
(6.000) 
cwc 
8.632 
(15.000) 
7.133 
7.628 
(5 500) 
26.416 
(6 500) 
(13.000) 
2.599 
(6.000) 
(8.084) 
29.745 
25.242 
14.557 
5.201 
13.577 
15.520 
5.330 
500 
933 
6.244 
6.389 
3.987 
(20.575) 
(16.422) 
(13.000) 
18.274 
13.303 
(6.000) 
3.515 
33.738 
(6.000) 
(6.000) 
40.182 
5.589 
25.479 
21.068 
12.200 
24 856 
7.015 
(14.500) 
(6.000) 
(6.000) 
ANC 
14.888 
2.600 
4 092 
5.020 
(3 800) 
12.315 
13.318 
(6.000) 
(2.000) 
21.149 
27.738 
16.743 
20.590 
3.628 
6.453 
(6.000) 
2.146 
750 
968 
2.197 
1.483 
19377 
14 314 
(4.500) 
20.070 
3.630 
(2.000) 
9.500 
(5.000) 
(2.000) 
(2.000) 
10.417 
5.976 
7.435 
8.443 
10.715 
7.902 
2.283 
(3.000) 
(2.000) 
(2.000) 
Deliv. 
1011 
824 
320 
427 
(600) 
1228 
411 
800 
(200) 
1686 
2656 
1866 
1230 
384 
687 
134 
1023 
818 
(200) 
716 
1 
(200) 
600 
403 
(200) 
(200) 
1193 
1234 
421 
630 
1130 
582 
195 
(160) 
(200) 
(200) 
Surg. 
708 
527 
237 
173 
(500) 
952 
624 
453 
371 
441 
205 
511 
1451 
411 
85 
233 
Xray 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Phar 
HPh 
HPh 
HPh 
HPh 
HPh 
(CPh) 
(CPh) 
CPh 
HPh 
HPh 
HPh 
CPh 
HPh 
HPh 
HPh 
HPh 
DHP 
DHP 
DHP 
DHP 
DHP 
DHP 
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BA 
NR 
UR 
name 
Berekum 
Dormaa-Ahcnkro 
Duayaw-Nkwanla 
Hwidiem 
Techiman 
Nkoranzaman 
Wcnchi 
Dormaa R H 
New Drobo 
Abease 
Damongo 
Nalcrugu 
Wapuli 
Bawku 
Jirapa 
Nandom 
Bawku R H 
Bolgatanga 
Lawra 
WaR H 
Wiaga 
lotal 
rel 
Cath 
Pres 
Cath 
Cath 
Cath 
Cath 
Meth 
Pres 
Cath 
Cath 
Cath 
Bapt 
EPC 
Pres 
Cath 
Cath 
Pres 
Pres 
Melh 
Calh 
Cath 
66 
kind 
hosp 
hosp 
hosp 
hosp 
hosp 
hosp 
hosp 
R H 
clin 
clin 
hosp 
hosp 
clin 
hosp 
hosp 
hosp 
R H 
R H 
clin 
R H 
clin 
instit 
cat 
A 
В 
В 
В 
В 
С 
С 
С 
С 
D 
С 
С 
D 
А 
В 
В 
В 
D 
D 
D 
D 
Beds 
155 
140 
142 
106 
88 
40 
74 
26 
6 
131 
75 
3 
229 
20 
130 
40 
12 
4386 
OPD 
95 245 
(48 000) 
41731 
39 082 
55812 
(21 000) 
(32 540) 
(34 000) 
27 543 
(6 000) 
29 052 
(20 000) 
(4 000) 
(55 000) 
(15 000) 
(30 000) 
63 837 
4 398 
(3 000) 
(6 000) 
(14 000) 
2 495 633 
cwc 
25 528 
(16 000) 
17 349 
22 761 
25 173 
(9 000) 
(10 850) 
16 736 
17 080 
(6 000) 
20 167 
(10 000) 
(1 400) 
(90 000) 
(13 500) 
(15 000) 
106 192 
22 555 
(3 000) 
(10 000) 
(14 000) 
1 005 724 
ANC 
15 025 
12 629 
10 349 
13 828 
15 286 
(4 500) 
5 693 
3 585 
12 034 
(2 000) 
(6 000) 
(5 000) 
184 
(13 000) 
(12 000) 
(9 000) 
37 983 
3 829 
(1000) 
(5 000) 
2 794 
493 841 
Dehv 
2047 
1081 
688 
719 
1401 
(170) 
550 
1182 
(200) 
396 
(400) 
(1300) 
(1300) 
(1000) 
484 
37 688 
Surg 
796 
326 
396 
460 
219 
(150) 
85 
553 
(300) 
(350) 
(600) 
(150) 
12 267 
Xray 
X 
X 
X 
X 
X 
X 
X 
Phar 
HPh 
HPh 
DHP 
DHP 
HPh 
DHP 
DHP 
DHP 
HPh 
HPh 
HPh 
DHP 
DHP 
DHP 
OPD All sick patients (adults and children above 5 years) 
CWC Under Five Clinic/Child Welfare Clinic 
ANC Ante Natal Controls 
Surg Major Surgery only 
X-ray Functioning X-ray present 
Phar HPh hospital-pharmacy, CPh Clinic pharmacy, DHP Diocesan Hospital Pharmacy 
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APPENDIX 3 
CHAG list of essential drugs, 1983 
standard extra 
anaesthetics (1) 
licocain 2% inj. 50 ml 
licodain 5% inj. heavy 
ether 500 ml 
thiopentone sodium inj. 
ketamine (ketalar) 
analgesics (2,3) 
aspirin 
paracetamol 
inj. analgesic 
pethidine inj. 
anthelmintic (7) 
piperazine tab. 
metronidazole (flagyl) 
mebendazole (vermox) 
melrifonate 
diethylcarbamazin (banocide) 
antibacterial (7) 
penicillin tab. 
procain penicillin inj. 
benzath. benzylpenicillin (penadur) 
pen. G. inj. (cryst.) 
tetracycline cap. 
ampicillin caps. 
ampicillin syr. (60 ml) 
chloramphenicol caps. 
cloramphenicol inj. 
sulfadimidine 
nitrofurantoin 
antimalarial (7) 
chloroquine tab. 
chloroquine inj. 
pyremethamin (daraprim) 
antituberculosis (7) 
streptomycin inj. 
INH/Thiacetazone 
vitamins, minerals (11, 28) 
folic acid 
ferrous sulphate 
multivitamin 
vitamin A cap. 
unit per 
10.000 patients 
50 V 
50 V 
20 b 
50 V 
25 V 
60.000 
30.000 
300 A 
200 A 
5.000 
5.000 
2.000 
2.000 
10.000 
5.000 
800 V 
100 V 
1.500 V 
15.000 
10.000 
200 b 
8.000 
500 A 
10.000 
6.000 
50.000 
500 A 
10.000 
1.200 V 
6.000 
40.000 
50.000 
100.000 
1.000 
CHAG 
total annual 
consumption 
15.000 V 
10.000 V 
4.000 b 
10.000 V 
5.000 V 
18.000.000 
9.000.000 
90.000 A 
40.000 A 
1.500.000 
1.500.000 
600.000 
600.000 
3.000.000 
1.500.000 
240.000 V 
30.000 V 
300.000 V 
4.500.000 
3.000.000 
60.000 b 
1.600.000 
100.000 A 
3.000.000 
1.800.000 
15.000.000 
150.000 A 
3.000.000 
240.000 V 
1.200.000 
12.000.000 
15.000.000 
30.000.000 
300.000 
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standard extra 
cardiovascular, diuretics (13, 16) 
hydrochlorthiazidc 
furosemidc inj. 
reserpin 
digoxin tab. 
gastrointestinal (Π) 
aluminiumhydroxyde tab. 
oral rehydration salts (for 1 Itr) 
atropin inj. 
oxytocics (22) 
ergometrine tab. 
ergometrine inj. 
oxytocin inj. 
psychotherapeutics (24) 
diazepam tab. 
diazepam inj. 
chlorpromazine inj. 
various (Π, 25) 
promethazine tab.(phenergan) 
prednisolone tab. 
aminophylline tab. 
aminophylline inj. 
unit per 
10.000 patients 
5.000 
100 A 
5.000 
2.000 
5.000 
500 
100 A 
2.000 
300 A 
100 A 
15.000 
200 
200 
10.000 
5.000 
1.000 
100 
CHAG 
total annual 
consumption 
1.500.000 
20.000 A 
1.500.000 
400.000 
1.500.000 
150.000 
20.000 A 
600.000 
90.000 A 
20.000 A 
4.500.000 
60.000 
40.000 
3.000.000 
1.000.000 
300.000 
20.000 
The standard-drugs are for all CHAG-institutions (hospitals and clinics). The extra-
drugs are for hospitals only. 
Infusions, mixtures and topical preparations are not included in the list. The list is ba­
sed on CHAG-questionaires of 1981 and 1983, the WHO list of essential drugs, and 
literature-references. 
Numbers in brackets refer to categories of drugs in the WHO list of essential drugs. 
The total annual consumption is calculated on the basis of 300 standard-units and 200 
extra-units per year. 
The total annual costs, including transport and insurance, are estimated at DFl 
2,200.000.- (prices 1983, IDA). 
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APPENDIX 4 
CHAG hst of essential pharmaceutical preparations, 1983 
The total is based on 300 units. 
Preparation 
Ointments: 
Applic/lotions 
Mixtures: 
Various: 
Sulphur 
Whitfield 
Ichtammol 
Liniment 
Gammexane 
Calamine 
Gentian Violet 
Pot. perm. 
Eusol 
lodin tict. 
Kaolin 
Antacid 
Cough 
Iron tonic 
Antispasmodic 
Oral Rehydration 
Eye drops B. Ac. 
Nosedrops Ephedr 
Eardrops B. Ac. 
Lysol cone, for 
Chloralhydrate 
Quantity 
per 10.000 patients 
25 kg 
25 kg 
10 kg 
50 kg 
25 kg 
501tr 
25 1tr 
251tr 
100 Itr 
251tr 
150 Itr 
250 Itr 
250 Itr 
50 Itr 
50 Itr 
750 Itr 
10 Itr 
5 Itr 
10 Itr 
1000 Itr 
1kg 
CHAG 
per year 
7 500 kg 
7 500 kg 
3 000 kg 
15 000 kg 
7 500 kg 
15 000 Itr 
7 500 Itr 
7 500 Itr 
30 000 Itr 
7 500 Itr 
45 000 Itr 
75 000 Itr 
75 000 Itr 
15 000 Itr 
15 000 Itr 
225 000 Itr 
3 000 Itr 
1 500 Itr 
3 000 Itr 
300 000 Itr 
300 kg 
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STELLINGEN 
I 
Het is zeer waarschijnlijk dat de behoefte aan die medicijnen welke essentieel zijn bij 
de voorkoming en behandeling van de meest voorkomende armoede ziekten, voor 
veel landen in Afrika gelijk is. 
II 
Om medicijngebruik te vergelijken is de "Defined Daily Dose" (DDD) een goede 
maateenheid. Voor bepaalde therapeutische groepen, zoals anthelmintica, is het ge-
bruik van "Defined Curative Dose" (DCD) te prefereren. 
Ill 
De beste en meest simpele parameter om de medicijnbehoefte van een gezondheids-
instelling uit te drukken is het totaal aantal geregistreerde consulten. In geval ook in-
tramurale zorg aanwezig is kan het aantal beschikbare bedden als tweede parameter 
gebruikt worden. 
IV 
Het vestigen van een geneesmiddelenindustrie in een ontwikkelingsland verschuift 
de afhankelijkheid van geneesmiddelen naar een afhankelijkheid van grondstoffen, 
reserveonderdelen en technische hulp. De geneesmiddelenvoorziening wordt hier-
door niet goedkoper. 
V 
De World Health Organization is als geen andere organisatie in staat en verplicht 
internationale normen voor medisch gedrag vast te stellen. 
VI 
Hoewel antilichamen tegen Leptospira soorten bij volwassenen veelvuldig kunnen 
worden aangetoond wordt icterus in Ghana slechts zelden door leptospirose veroor-
zaakt. 
VII 
In ontwikkelingslanden is bij een patiënte met een matige bekkenvemauwing en een 
obstetrische toekomst symphysiotomie te verkiezen boven Sectio caesarea. 
Vili 
Een dieet zonder rode peper draagt niet bij tot de genezing van een ulcus duodeni. 
(Kumar N et al. Br Med J 1984; 288:1803-4) 
IX 
Aangezien patiënten met vier of meer okselklier metastasen vaak ook reeds op af-
stand zijn gemetastaseerd draagt routinematige bestraling van regionale klieren na 
mamma-amputatie in deze gevallen weinig bij tot vergroting van de overlevingskans. 
De indicatie voor deze bestraling dient derhalve opnieuw te worden bezien. 
X 
Er gaat meer troost uit van een acceptatie van het verdriet van een patiënt dan van een 
ontkennen van de reden ervan. 
(Leer JWH. In: Begeleiding van patiënten met 
kanker. Stafleu, 1982) 
XI 
Trommelvliesbuisjes bij de behandeling van otitis media met effusie ("glue ear") 
verbeteren de uiteindelijke kwaliteit van het gehoor niet. 
(Brown MJKM. J R Soc Med 1978; 71:353-6) 
XII 
De term "stethoscoop" is onjuist aangezien niet gekeken maar geluisterd wordt. 
XIII 
"MUSIC MINUS ONE" grammofoonplaten geven de orchestrale begeleiding van 
bekende concertstukken weer. Het hoge tempo waarin de ontbrekende solo-partij 
moet worden meegespeeld is niet in overeenstemming met de te verwachten capaci-
teiten van de doelgroep. 
H.V. Hogerzeil 
12 december 1984 


